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Introduction
Cardiovascular diseases (CVDs) remain the number one cause of death
worldwide, with yearly deaths expected to increase from 17.3 to 23.6 million by
20301. Medical expenses associated with the treatment of CVD place a
significant burden on the United States healthcare system. In 2010, CVD
medication costs totaled $14.6 billion2. Poor compliance with CVD medication
has gained attention as a driving factor of increased medical costs and
preventable CVD-related deaths. Adherence to long-term prescribed CVD
medications is as low as 50%3-5. Statin drugs, a group of lipid-lowering
medication, are the most commonly prescribed CVD medication worldwide.
Approximately 71% of individuals with CVD and 48% of individuals with
hypercholesterolemia use cholesterol-lowering medication, with 93% of these
medications being statins6. The monthly cost of statins can range from $4 to
$600, depending on type, dose, and if a generic version is available7. Further,
statin use can pose significant dose-dependent side effects. These include
myalgia, as the most common side effect, as well as acute liver injury, hepatic
steatosis, increased risk for development of Type II Diabetes, and cognitive
impairments8. Side effects associated with statins are among the most common
reasons for patients ceasing drug therapy9.
Currently, there is no optimal set of guidelines for prescribing statin drug
therapy. The 2013 American College of Cardiology/American Heart Association
(ACC/AHA) recommends initiation of statin treatment in patients with a 10-year
global CVD-risk of 10% or greater, which 10-year risk being based on age,
gender, ethnicity, blood pressure, current treatment with antihypertensive
medication, and presence of diabetes or smoking behaviors10. The 2016 United
States Prevention Services Task Force (USPSTF) guidelines also recommend a
1

10-year global CVD-risk of 10% or greater, as well as patients having one or
more CVD risk factor (hypertension, dyslipidemia, smoking, diabetes). The gap in
these conflicting guidelines could leave 9.3 million Americans untreated if one
was fully adopted over the other11. Thus, current pharmacological therapies used
for the prevention and treatment of CVD are costly, burdensome, have
associated health risks, and current guidelines could leave patients untreated.
Implementing lifestyle therapies, including dietary modification, could
improve CVD-outcomes, possibly reduce burden associated with medication
adherence,

and

contribute

to

a

healthier

aging

population.

Current

recommendations for treatment and prevention of CVD include statin therapy and
adoption of a low-fat diet, such as the National Cholesterol Education
Program/American Heart Association Step I or Step II diets. These dietary
patterns recommend a reduction of total fat (<30% of calories), saturated fat
(10% and <7% total calories), and dietary cholesterol (300 and 200mg daily).
This recommendation is consistent with evidence that a reduction in exogenous
fatty acids will, in turn, reduce the need to clear chylomicrons during lipoprotein
metabolism, since higher chylomicron levels may promote atherogenesis12.
Therefore, low-fat diets work by controlling exogenous sources of fats, and are
often paired with statin drugs, which control cholesterol at an endogenous level.
Statin drugs, also known as HMG-CoA reductase inhibitors, gained
popularity in the 1990’s, as knowledge of “good” and “bad” cholesterol became
more widespread. Statin drugs became standard treatment for high dyslipidemia
following publication of the Scandinavian Simvastatin Survival Study (4S study)
in 1994. This secondary prevention, randomized, double blind, placebo-control
trial investigated long-term use of simvastatin to reduce total mortality and
coronary events in 4444 post-myocardial infraction (MI) and angina pectoris
2

patients with total cholesterol levels between 212 and 309mg/dL. The trial found
a 42% reduction in cardiac mortality, as well as 38% reduction in LDL and 28%
reduction in total cholesterol over the 6-year follow-up period13. This landmark
trial contributed a great body of support for statins in preventing cardiovascular
death through lowering total and LDL cholesterol levels.
In the same year, French cardiologist Dr. Michel de Lorgeril published his
findings of the Lyon Diet Heart Study. Similarly to the 4S Study, the Lyon Diet
Heart Study was a randomized, secondary prevention trial in 605 post-MI
patients. The study compared the effects of an alpha-linolenic acid-rich
Mediterranean diet (n=302) to a typical French diet (n=303), which is similar to
Western diets in fat quality and content. The study evaluated differences in
primary, secondary and tertiary endpoints, such as cardiac deaths, non-fatal MI,
and overall mentality over a planned 5-year study period. The trial was halted
after 27 months due to the Mediterranean diet group having a 50 to 70% lower
risk of recurrent cardiac events compared to the control. This study was the first
to provide evidence that questioned the lipid hypothesis due to finding no
difference in serum lipids from baseline in the Mediterranean diet group14.
The developing body of literature on the Mediterranean diet over the past
60 years has challenged the low-fat diet, showing more favorable reductions in
serum lipids, as well as mortality risk, with the adoption of a Mediterranean diet.
The Mediterranean Diet was first recognized for its cardioprotective benefits by
Minnesota physiologist Ancel Keys in the Seven Countries Study. Keys found
significantly lower rates of cardiovascular disease in countries surrounding the
Mediterranean Sea15. The Mediterranean Diet emphasizes the following: high
consumption of locally sourced plant-based foods, such as fruits, vegetables,
whole grain breads, nuts, and legumes; olive oil as the main source of dietary fat;
3

moderate red wine consumption (one drink each day for women, two drinks each
day for men); twice weekly fish consumption; low to moderate intake of dairy; and
up to seven eggs per week; limited consumption of red and processed meats to
once or twice per month.
Since it’s discovery, the beneficial role of the Mediterranean Diet has
been largely studied. Both short- and long-term benefits of the diet have been
established. One of the most notable studies to date is the Prevención con la
Dieta Mediterránea (PREDIMED) trial, which investigated the role of the
Mediterranean diet in primary prevention of Cardiovascular Disease. The study
evaluated the effects in subjects randomized to a Mediterranean diet
supplemented with olive oil or mixed nuts, or a low-fat diet. The PREDIMED trial
found an energy-unrestricted Mediterranean diet, supplemented with nuts or
extra-virgin olive oil, resulted in a 30% risk-reduction in major CVD events in
subjects at high-risk for CVD compared to the low-fat diet control. The study also
found decreased markers of inflammation (CRP, IL-6, IL-7), total serum
cholesterol, body weight, plasma glucose, insulin resistance, development of
type 2 diabetes, and an improvement in endothelial function16.
Although Mediterranean diet intervention trials continue to show the
beneficial effects of the dietary pattern, statin drugs and low-fat diets continue to
be most commonly prescribed regimen for the prevention and treatment of CVD.
Recent meta-analyses on the Mediterranean diet have found significantly
lowered triglycerides, LDL, and total cholesterol compared to low-fat diet control
groups, as well as a positive association between length of intervention and
improvement in HDL-cholesterol17.
There is sufficient literature examining the lipid-lowering ability of the
Mediterranean diet, with many of these studies noting participants taking statin
4

drugs. No meta-analysis has evaluated the moderating effects of statin drug
therapy in the relationship between the Mediterranean diet and serum lipids. A
meta-analysis of existing randomized control studies would provide evidence on
whether statin drugs provide additional beneficial effects in improving blood
lipids, or if the changes observed are a result of the Mediterranean diet alone.
Further, no meta-analysis has compared the effects of the Mediterranean diet to
a low-fat diet with statins on serum lipids. This can allow for reduced CVD
mortality, reduced individual prescription and health care costs, more
individualized nutrition recommendations for individuals with dyslipidemia, and
clarification on the role of diet in the lipid hypothesis.
Thus, research questions for the meta-analysis include: 1) Are the lipidlowering effects of the Mediterranean diet moderated by statin drug therapy in
adults who are at high-risk or with existing Cardiovascular Disease (CVD)? 2)
Does the Mediterranean diet produce greater improvements in serum lipid levels
than a low-fat diet in adults at-risk and with existing cardiovascular disease? 3) Is
the Mediterranean diet as effective as a low-fat diet with statin drugs in improving
serum lipids in adults? The purpose of this thesis was to conduct a high-quality
meta-analysis to evaluate the effects on statin drugs in the relationship between
the Mediterranean diet and serum lipids, compare the effects of the
Mediterranean diet to those of a low-fat diet on serum lipids, and to compare the
effects of the Mediterranean diet to those of a low-fat diet with statin drugs. The
specific aims are: 1) To evaluate the impact of the Mediterranean diet on serum
lipids (total cholesterol, LDL-cholesterol, HDL-cholesterol, triglycerides) in adults
at high-risk and with existing CVD, 2) to evaluate the moderating effect of statin
drug therapy on the relationship between the Mediterranean diet and serum
lipids, 3) compare the effects of a Mediterranean diet to those of a low-fat diet on
5

serum lipids, and 4) compare the effects of the Mediterranean diet to the low-fat
diet with statins on serum lipids in adults at-risk and with existing CVD. The
primary hypothesis is statin drugs will not be a significant moderator in the
relationship between the Mediterranean diet and serum lipid levels. The null
hypothesis states that the addition of statin drugs will have an effect on the
relationship between the Mediterranean diet and improvement in serum lipids.
The secondary hypothesis is the Mediterranean diet will provide greater
improvements in serum lipid levels than a low-fat diet, with the null hypothesis
stating there would be no difference in improvements observed among serum
lipids between the low-fat and Mediterranean diet low-fat diet. Our third
hypothesis is the Mediterranean diet will be equally effective in improving serum
lipids compared to the traditionally prescribed low-fat diet and statin drug therapy
combination. The null hypothesis for this hypothesis is the Mediterranean diet will
not be equally effective as the low-fat diet and statins in their abilities to lower
serum lipids in adults who are at-risk and with existing CVD.

Methods
Literature Search
To adequately compare the Mediterranean and low-fat diets, two
separate literature searches were performed. Peer-reviewed literature articles
were obtained following the Preferred Reporting Items for Systematic Reviews
and Meta-Analyses: The PRISMA Statement guidelines18. Comprehensive
literature searches were conducted using seven computer databases: PubMed
(MEDLINE), EMBASE via Scopus, CINAHL, PsycINFO, Academic Search
Premier, Agricola, and CAB Direct. The University of Connecticut Health
Sciences Librarian (JL) assisted in the search. No language or date restriction
6

was used. For the Mediterranean diet, original research articles published until
September 22, 2016 were included. A combination of key words and Medical
Subject Headings related to the study were used. Examples of search terms
included: “Mediterranean diet,” “Mediterranean-style diet,” “cardiovascular
disease,” “hyperlipidemia,” “dyslipidemia,” “hydroxymethylglutaryl-coa reductase
inhibitors”, “antihyperlipidemic medication,” “statin*,” and “Simvastatin.” The
comprehensive search, with all terms, can be found in Appendix 1. The low-fat
diet search also had no language or date restriction, and included published
articles through October 7, 2016. The search terms differed in that instead of
using Mediterranean diet-related words, examples include: “low fat,” “reduced
fat,” “American Heart Association AND diet,” “therapeutic lifestyle changes AND
diet,” “DASH,” “hypolipidemic,” and other related terms and phrases. These
search terms can be found in Appendix 2.
Inclusion criteria stated the Mediterranean diet, as a whole dietary
pattern, must have been at least one of the interventions in the study. The study
must have pre-test and post-test data for at least one of the outcome variables of
interest: triglycerides, low-density lipoprotein (LDL) cholesterol, high-density
lipoprotein (HDL) cholesterol, or total cholesterol. Due to this being a new area of
research, an inadequate number of studies have analyzed the Mediterranean
diet with statin drugs as part of an intervention. Therefore, the studies did not
need statin medication as part of an intervention, but did need to report the
percentage or number of subjects taking statin drugs in-text or in a table, such as
one for demographic information. No minimum or maximum percentage of
participants on statin drugs was placed for the study to be included. If a study
met all criteria, but did not report statins in demographic information, one
researcher (MC) contacted the provided study correspondence to inquire if the
7

data were available. Participants needed to be high-risk or with existing
cardiovascular disease. High-risk subjects were defined as individuals with Type
2 Diabetes Mellitus, or with at least 3 cardiovascular disease risk factors,
including:

elevated

LDL-cholesterol

(>160mg/dL),

low

HDL-cholesterol

(<40mg/dL), Hypertension (>140mmHG/>90mmHG), overweight/obesity (BMI
>25kg/m2), current smoking behaviors, or a family history of premature coronary
heart disease. If studies were secondary analyses of other trials (i.e. PREDIMED
substudies), they needed to have different sample sizes and be conducted at
different locations to ensure the same data was not being accounted for twice. All
studies needed to be experimental or Quasi-experimental in design. Exclusion
criteria included studies with only pre-test or only post-test data, studies using
statin drugs that were not/pending approval by the United States Food and Drug
Administration, trials that allowed use of dietary supplements, interventions that
only examined one component of the Mediterranean diet (only red wine, only
olive oil, etc.), and non-intervention trials, trials with exercise as part of the
intervention. Studies on subjects with Renal Disease or HIV/AIDS were also
excluded due to the disease state requiring very restricted dietary guidelines and
the disease-associated lipodystrophy.
For the low-fat diet search, inclusion criteria only differed in that one of
the interventions must have been a low-fat diet, defined as <30% of total calories
from fat, with statin drug therapy, at any dosage, with the low-fat diet as at least
one of the interventions. All systematic reviews and meta-analyses found through
the literature search were hand-searched to ensure all relevant articles were
included.
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Data Extraction
A 5-page, 330-item coding form, along with coding manual, created by a
team of 3 Registered Dietitians, and physician, and biostatistician, was used to
extract information from each included study. Examples of items coded for
included: study information, such as study publication year, year of data
collection, and journal name; population risk characteristics, such as age,
disease state, and medication use; methods and design, including experimental
conditions, and diet intervention characteristics. Two researchers (MC and JS)
independently coded each article. A third part expert (TBHM) was consulted to
settle disagreements and discrepancies between the independent researchers.
Appendix 3 contains the coding form used for data extraction in this metaanalysis.
Risk of Bias
The Cochrane Collaboration’s tool was used to assess bias within
individual studies. This tool uses a minus sign (“-“) to indicate a high risk of bias,
a plus sign (“+”) to indicate moderate risk of bias, and two plus signs (“++”) to
indicate low risk of bias for the parameter being evaluated. Various parameters
were used to assess risk of the individual studies, such as subject level of
randomization, subject and researcher blinding to intervention, report of attrition,
and selective reporting. Methodological quality (MQ) has been identified as an
under-reported element in the results of meta-analyses19. Methodological quality
score was calculated using a 17-question, 22-point methodological quality control
form, created from combining methodological quality rating scales published by
Miller20 and Jadad21. This form can be found in Appendix 4. This meta-analysis
used MQ ratings as a possible moderator in mixed-effects regressions.
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Statistical Analysis
All descriptive statistics of the study populations were calculated using
SAS version 9.422. These included total number of participants, percentage of
male and female participants, mean age of subjects, and range and mean year of
publication, among others. All code for the analysis can be found in Appendix 5.
Inter-rater reliability (IRR) 23, which assesses the rate of agreement between the
two coders as a proportion, was calculated using IBM SPSS Statistics Version
2224. Categorical variables were calculated using Kappa coefficient25, and
continuous variables were calculated using Pearson’s R23.
A standard mean effect size was calculated for each variable of interest in
each study using an Excel coding calculator that uses a factor to control for small
sample size26. The standard mean change, d, is the difference between the pretest and post-test means for a variable in a sample, divided by the pre-test
standard deviation27. This allows for results of different study designs to be
compared, regardless of the unit of measurement used in the individual studies.
The standard mean difference follows a normal distribution, with zero as the null
value. The effect is assessed using Cohen’s Classification, which interprets 0.25
as a small effect, 0.5 s a medium effect, and 0.8 or higher as a large effect28.
The remaining statistical analysis was conducted in R version 3.3.1.

29

using the ‘metafor’ package30, which is the package for meta-analysis in the R
program. Weighted means were calculated using random-effects and fixedeffects models, because they allow some studies to carry more weight in the
analysis than others. Random-effects and fixed-effects models are used because
they make different assumptions about the nature of the studies. Random-effects
models control for sample size and variance, and assume all the data come from
different populations. Fixed-effects models assume the data come from the same
10

population, and do not account for variance between studies31. Heterogeneity
was assessed to consider the extent of consistency among the results27, and was
evaluated with Cochran’s Q and I2. Two tests are used for heterogeneity because
the Q statistic has low power in meta-analyses with few included studies or small
sample size, or may carry too much power if there are many studies included.
The Q statistic tests for significance of heterogeneity32, and I2 tests for magnitude
of heterogeneity with a range of 0-100%31. An I2 value of 0 to 40% suggests
heterogeneity observed may not be important, 30 to 60% represents there may
be moderate heterogeneity, 50 to 90% represents there may be substantial
heterogeneity, and 75 to 100% means there is considerable heterogeneity
observed33. Publication bias was computed, which is used to evaluate how
representative the samples in the studies are of the population by regressing the
standard errors with the estimated models. This was measured with four
statistical tests: two inferential tests, Begg34 and Egger35 and two graphical tests,
trim-and-fill36 and a funnel plot37.
Moderator analysis was used to explain the significant amount of
heterogeneity observed among the studies. A moderator is a third variable that
alters the relationship of the independent and dependent variables. If the
moderator variable is significant, it can strengthen or weaken the relationship
between the independent and dependent variables. Moderators can be
categorical or continuous variables. In this analysis, proportion of participants
using statin drugs was used as a moderator to evaluate if the drug provided a
significant improvement in any of the variables of interest (LDL-cholesterol, HDLcholesterol, triglycerides, total cholesterol) when used in combination with a
Mediterranean diet. Other variables that at least 5 studies reported information
on were evaluated as moderators to explain heterogeneity observed among the
11

studies. Variables evaluated as possible moderators included: a diagnosis of
CVD or having cardiovascular risk factors, such as Hypertension, Dyslipidemia,
or Type 2 Diabetes Mellitus, current smoking behaviors, being female, and
weight status. Differences in study characteristics, such as intervention group
size, sample size, level of supervision in trials, number of follow-ups, and length
of study intervention, as well as region in which the study was conducted were
also tested as moderator variables according to justification in the scientific
literature17.

Dietary

intervention

characteristics,

such

as

recommended

macronutrient distribution, intake of dietary cholesterol and saturated fats, dietary
fiber, and sodium intake were also evaluated. The Moving Constant Technique38
was used to create estimates and confidence intervals at multiple levels of the
moderators, as well as confidence bands around the entire meta-regression line,
to evaluate the effects of the dietary pattern further. All syntax for statistical
analysis conducted in R can be found in Appendix 6 for the Mediterranean diet
studies, and Appendix 7 for the low-fat diet studies.
Results
Literature Search
Inter-rater reliability resulted in a kappa coefficient of 0.93, with 96%
agreement between coders for the Mediterranean diet studies, and 0.96 with
96% agreement for coding of low-fat diet studies. A Pearson’s coefficient of r=1.0
was obtained for continuous variables for both the Mediterranean diet and low-fat
diet studies. The initial Mediterranean diet literature search provided 1,265
articles, after removal of duplicate publications. Additionally, all systematic
reviews and meta-analyses found through the literature search were handsearched to verify all relevant publications were included39-47, resulting in two
additional articles being accepted for inclusion in the study that were not found
12

through the literature search. Studies were evaluated based on title, key words,
and abstract by two independent researchers (MC and JS). The screening
process eliminated 1199 articles. Full-text articles were obtained for the
remaining 66 articles. After reviewing full-text articles against inclusion criteria, 54
articles were excluded for reasons of not including statin drug information,
exercise as a part of the intervention or placing a calorie restriction on the
intervention groups. Six researchers were contacted at this step by email to
request data on proportion of subjects taking statin drugs48-54, which resulted in
exclusion of five of these 54 studies. The remaining 12 articles were accepted for
analysis. For the low-fat diet search, 580 articles were found, after removal for
duplicates. The screening process eliminated 543 articles. The remaining 37 fulltext articles were obtained. Upon full-text review, an additional 16 articles were
excluded for reasons of not reporting pre-and post-intervention data, not having a
low-fat diet intervention, and studies with children/adolescents. The remaining 21
articles were accepted for analysis. All systematics reviews and meta-analyses
found in the low-fat diet literature search were also hand-searched for possible
inclusion55-82. One additional article was identified83, for a final count of 22 articles
being accepted for analysis.
Descriptive Statistics
Twelve Mediterranean diet studies, with a total of 9,882 subjects with a
mean age of 61.75±7.82 years, were analyzed. Females accounted for 50.4% of
the subjects. Further, 38.4% of subjects reported taking some type of statin
medication during the trials, and 19.5% were current smokers. A total of 7,720
(78.1%) subjects had hypertension, and 46.2% had dyslipidemia. Trial length
ranged from 8 to 260 weeks. Mean publication year was 2007, with a range of
1993-2016. The average impact factor of the journals of publication was 10.057.
13

Seven of the studies were performed in European countries, and one was
conducted in each the United States, Australia, and Asia. All reports were
published in the English language. Four slight variations of the Mediterranean
diet were observed: Traditional Mediterranean Diet, Indo-Mediterranean Diet,
Mediterranean

Diet

with

subjects

provided

extra-virgin

olive

oil,

and

Mediterranean Diet with subjects provided a mixed variety of nuts. A table of the
Mediterranean diet intervention descriptive statistics can be found in Table 1. No
significant asymmetries were found using the graphical and inferential tests.
Publications bias values are displayed in Table 2. The average methodological
quality score of studies was 13.15 with a range of 8 to 17.
Analysis of the 22 low-fat diet trials revealed a total of 6,793 subjects,
57.7% of which were female. For CVD risk factors, a total of 9.6% of subjects
were smokers, 22.7% carried a diagnosis of hypertension, and 72.6% of subjects
had dyslipidemia. Trials had an average publication year of 1997, with a range of
1990 to 2008. Studies were conducted in various countries, with 9 in the United
States, 9 in European countries, 3 in Asia, 1 in Australia, 1 in Canada, and 1 in
South America. The average impact factor of journals in which the studies were
published was 9.636. Length of intervention ranged from 3 to 208 weeks. The
studies used various forms of a low-fat diet intervention. Types of low-fat diets
used in the interventions included: 10 low-fat diets, 6 American Heart Association
Step 1 diets, 6 American Heart Association Step 2 diets, and 8 other variations,
described as very low-fat, cholesterol-lowering, low saturated fat, lipid-lowering,
and LifeSpring diets. All low-fat diets recommended no more than 30% of
calories from fat, and as low as 17%. Intervention groups of the trials used
various types of statins, including: 12 simvastatin, 8 lovastatin, 3 pravastatin, 3
atorvastatin, 2 fluvastatin, and 1 rosuvastatin intervention. All low-fat descriptive
14

statistics can be viewed in Table 3. There were no significant asymmetries found
in the inferential and graphical tests for publication bias. Publication bias results
for the low-fat diet studies can be found in Table 4. Further, the average
methodological quality score of studies was 12.23 with a range of 5 to 16.
Random Effects Sizes
When individuals adopted a Mediterranean diet, there was a significant
improvement in all outcomes (dTG = -0.45 [-0.79, -0.12, dChol = -0.66 [-0.96, -0.35,
dLDL = -0.52 [-0.76, -0.27],], dHDL = 0.24 [0.01, 0.46]) shown by random effects
model analysis. For heterogeneity, Cochran’s Q ranged from 74.24 to 224.42,
and I2 ranged from 91.84 to 96.89%. A full table of these results can be found in
Table 5. Adopting a low-fat diet resulted in significant reductions for total and
LDL cholesterol (dTG = -0.12 [-0.25, 0.02], dChol = -0.39 [-0.57, -0.20], dLDL = -0.24
[-0.36, -0.11], dHDL = 0.06 [-0.27, 0.16]). Cochran’s Q ranged from 70.92 to
183.94 and I2 from 79.47% to 95.01%. Low-fat diet with statin drug therapy
resulted in significant reductions for all serum lipid outcomes (dTG = -0.43 [-0.57, 0.30], dTChol = -1.68 [-1.90, -1.46], dLDL = -1.75 [-2.01, -1.49]), dHDL = 0.37 [0.29,
0.45]). Cochran’s Q ranged from 299.10 to 723.97, and I2 ranged from 84.32 to
96.75% A table of low-fat diet results, both with and without statin drugs, can be
found in Table 6.
Mediterranean Diet Moderator Analysis
Studies included in the analysis varied in study and intervention
characteristics, such as study region, proportion of female subjects, length of
intervention, and proportion of subjects with cardiovascular disease and
cardiovascular disease risk factors, among others. Analysis of the proportion of
subjects taking statin drugs with a Mediterranean diet intervention did not
account for any heterogeneity across all four serum lipid variables (R2TChol =
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0.00%, p= 0.95; R2TG = 0.00%, p=0.80; R2LDL = 0.00%, p = 0.47; R2HDL = 1.67%, p
= 0.33). A predictive model was used to determine the magnitude of effect statin
drugs carried with various proportions of subjects taking statins. The proportions
analyzed included: 0%, 7% (minimum observed), 10%, 25%, 50%, 75%, and
100% (maximum observed) of subjects. There were no significant associations
observed for proportion of subjects and any of the serum lipid outcomes.
Across the interventions, a significant association was found between
decrease in triglycerides and studies conducted in a European country (R2TG =
32.00%, p=0.02), and with a greater number of follow-up sessions (R2TG =
70.30%, p<.0001). The level of intervention supervision also accounted for
significant heterogeneity for only triglyceride lowering - conducting one-on-one
intervention sessions accounted for 32.00% of heterogeneity (p=0.02), and small
group interventions for 28.16% (p=0.03) of the heterogeneity. Number of
participants lost to follow-up accounted for the highest amount of heterogeneity
for triglycerides (R2TG = 96.47%, p<.0001), but was not significant for any other
outcomes of interest.
Length of intervention (in weeks) had a significant impact on reduction in
total cholesterol levels (R2TChol = 54.74%, p=0.02). A predictive model was used
to determine the magnitude of effect for length of intervention at the minimum
and maximum length (8 and 260 weeks). There was a significant association
found for length of intervention and total cholesterol (BTChol = -0.003, p=0.02) –
longer Mediterranean diet interventions resulted in greater decreases in total
cholesterol. Receiving funding from a government source also was significantly
associated with decrease in total cholesterol (R2TChol = 42.96%, p=0.01), and
increase in HDL-cholesterol (R2LDL = 61.22%, p=0.0005).
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Carrying a diagnosis of dyslipidemia was associated with a significant
beneficial effect on HDL cholesterol with consumption of a Mediterranean diet,
explaining 81.20% (p<.0001) of the variability between studies. Studies reporting
subjects taking hypoglycemic agents, such as insulin or oral hypoglycemic
agents, explained heterogeneity for triglycerides and HDL (R2TG = 78.57%,
p<.0001, R2HDL = 96.47%, p<.0001), but only trending towards significance for
total cholesterol (R2TChol = 31.11%, p=0.10). Studies reporting subjects taking
blood pressure medication during the trial explained some of the heterogeneity
observed for LDL-cholesterol (R2LDL = 14.03%, p=0.03), with no other variables
with adequate reported information explaining heterogeneity for this outcome.
Other cardiovascular disease risk factors (e.g. hypertension, current
smokers, being female, and weight loss) impact per publication (IPP) score of
journal of publication, and methodological quality score were assessed and did
not provide significant results. A full list of the Mediterranean diet moderator
analysis results can be found in Table 7.
Low-Fat Diet Moderator Analysis
Similar moderators evaluated for the Mediterranean diet were considering
for the low-fat diet. Length of intervention was only found to be a significant
moderator for triglycerides, explaining 31.86% (p=0.04) of the heterogeneity
observed. Studies region was evaluated as a moderator, with sufficient data to
evaluate studies conducted in the United States and in Europe. There was no
association found between conducting a study in Europe with the low-fat diet for
any of the four serum lipids; however, studies conducted in the United States
explained 22.71% of the heterogeneity observed for total cholesterol p=0.03).
Sample size also explained significant heterogeneity for total cholesterol
(R2=32.80%, p=0.04). No other study characteristics were found to be significant.
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Cardiovascular disease and risk factors were also assessed. Both
proportion and number of subjects with hypertension explained heterogeneity
among the lipid outcomes. Proportion of subjects explained 59.12% (p=0.0007)
of the variability observed for triglycerides, while number of subjects explained
significant heterogeneity for total and LDL cholesterol (R2TChol =36.21%, p=0.048;
R2LDL=78.06%, p=0.02). Female subjects also significant explained heterogeneity
for total cholesterol (R2=34.79%, p=0.04).
Dietary characteristics were assessed to evaluate the impact of diet in the
relationship between a low-fat diet and the four serum lipids. Macronutrient
distribution was assessed and each macronutrient had significantly explained
some of the heterogeneity for at least one serum lipid. Proportion of fat intake
was significant for total cholesterol and LDL cholesterol (R2TChol =33.73%,
p=0.0008; R2LDL=27.57%, p=0.0049), while proportion of protein intake was
significant for HDL (R2=14.43%, p=0.04) and carbohydrate intake was significant
for triglycerides (R2=65.19%, p=0.01). Dietary cholesterol intake was assessed,
and explained 100% of the heterogeneity observed for HDL cholesterol
(p<.0001). Cholesterol also explained significant heterogeneity for LDL
(R2=35.05%, p=0.03). Dietary fiber intake explained between 13.50 and 43.23%
of the heterogeneity observed for the four outcomes, but was only significant for
change in HDL (R2TG =43.23%, p=0.09; R2TChol=13.50%, p=0.13; R2LDL =18.26%,
p=0.10; R2HDL=15.64%, p=0.04). A table of the moderator analysis results for the
low-fat diet without statins can be found in Table 8.
Low-Fat Diet and Statins Moderator Analysis
All variables with adequate reporting of information from studies were
evaluated to account for heterogeneity of low-fat diet studies as well. Longer
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intervention length yielded significantly more beneficial effects, explaining
19.22% for LDL and 23.64% for total cholesterol.
A predictive model was also used for the low-fat diet studies at the
minimum and maximum lengths of intervention (3 and 104 weeks) to evaluate
the magnitude of effect. Length of intervention was again found to be significant
for both total cholesterol (B = -0.01, p=0.0037) and LDL (B = -0.01, p=0.003),
showing that longer interventions with a low-fat diet with statin drugs produce
greater reductions. Proportion of female was also significant for total and LDL
cholesterol (R2TChol = 20.43%, p=0.0434; R2LDL = 14.76%, p=0.0180), with
predictive models showing greater proportions of female subjects leading to
greater decreases in total (B = 0.78, p=0.0434) and LDL (B = 1.05, p=0.0180)
cholesterol.
Recommended macronutrient distributions and various recommendations
on dietary intake were analyzed as moderators, and predictive models were used
to analyze the proportions if found to be significant. Proportion of fat was
significant for total cholesterol (R2TChol = 9.66%, p=0.0476), with the predictive
model showing the greater proportion of fat intake leading to greater decreases
in total cholesterol levels (B = 0.01, p=0.0476). Recommended proportion of
carbohydrate intake was found to be a significant moderator for total cholesterol
and LDL cholesterol, explaining 26.85% and 11.90% of the heterogeneity,
respectively. For both outcomes, predictive models showed lower carbohydrate
intake producing greater decreases (BTChol = 9.01, p=0.0026, BLDL = 7.26,
p=0.0459). Recommended protein intake was analyzed, and only significant for
HDL-cholesterol, accounting for 12.52% (p = 0.0476) of the variability observed
among the studies. Lower protein intake yielded a greater improvement in HDL
cholesterol levels, according to predictive models (B = -10.60, p=0.0408). Lastly,
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recommended cholesterol intake was found to be significantly associated with
change in HDL (R2HDL = 18.05%, p=0.0173). Minimum and maximum
recommendations were used in the predictive model (31mg and 300mg per day),
and showed greater increases in HDL cholesterol with greater cholesterol intake
(B = -0.0017, p=0.0173).
Intervention characteristics, such as total sample size, intervention group
size, number of intervention groups, level of supervision in the intervention, and
provision of food items were analyzed. Total sample size explained significant
heterogeneity for total cholesterol, LDL, and HDL (R2TChol = 26.51%, p=0.0008;
R2LDL = 28.32%, p=0.0013, R2HDL = 31.07%, p=0.0013). Minimum and maximum
sample sizes (19 and 3390) were used in predictive models, and showed greater
decreases in total cholesterol and LDL cholesterol, and greater increases in HDL
cholesterol with larger sample sizes (BTChol = 0.0003, p=0.0008, BLDL = 0.0003,
p=0.0013, BHDL = 0.0001, p=0.0013).

Intervention group size significantly

explained between 16.58 and 22.16% of the variation among studies for all four
serum lipid outcomes, with larger intervention group sizes providing greater
improvements. Number of intervention groups was a significant moderator for
total cholesterol and HDL (R2TChol = 17.62%, p=0.0120; R2HDL = 35.03%,
p<.0001). Level of intervention specifically having one-on-one intervention
sessions with study participants, explained a small, but still significant amount of
heterogeneity for HDL cholesterol (R2HDL = 3.34%, p=0.0078). Provision of food
intake was analyzed, and only found to be significant for change in total
cholesterol levels (R2TChol = 14.38%, p=0.0191).
Different disease states were used as moderators if significant data were
reported by the studies. Number of subjects with cardiovascular disease
explained significant variation for total cholesterol, LDL, and HDL cholesterol
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(R2TChol = 49.05%, p<.0001; R2LDL = 60.15%, p<.0001, R2HDL = 25.43%,
p=0.0084). Use of predictive models showed greater improvements in these
three serum lipid outcomes with more subjects carrying a diagnosis of
cardiovascular disease. Dyslipidemia was not used as a moderator because all
subjects in the low-fat diet studies who were on statins carried a diagnosis of
dyslipidemia; therefore, the random-effects analysis already included the effects
of a low-fat diet with statins on individuals with dyslipidemia.
Additionally, changes in weight and funding source were assessed as
moderators. Studies only reported enough data on weight maintenance to allow
for analysis. Weight maintenance significantly explained 16.35% and 15.44% of
variation among studies for LDL and HDL cholesterol
Other variables analyzed included study region (United States and
Europe), hypertension, current smokers, and statin dose. None of these variables
were found to be significant. A summary of the low-fat diet with statins moderator
analyses can be found in Table 9. All insignificant moderators tested for all three
dietary interventions can be found in Table 10, and moderators unable to be
analyzed due to lack of reported information in studies in Table 11.
Risk of Bias
For the Mediterranean diet studies, moderator analysis was not significant
for any of the risk of bias parameter. There was a low risk of bias found for 58.3%
of studies for random sequence generation, and 25.0% for allocation of control.
For blinding of participants, low risk of bias was observed for 41.7% of studies,
and high risk of bias for 8.3%. For incomplete outcome data for both short term
and long term reporting, 33.3% of studies had a low risk, and 8.3% had high risk.
There was no reported data on high or low risk of selective outcome reporting.
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For other potential threats of validity, 16.7% of studies had high risk. Figure 31
shows a summary for risk of bias reporting.
For low-fat diet with statin studies, no parameter was significant for risk of
bias when analyzed as a moderator. For random sequence generation, 90.9% of
studies had low risk of bias, and 9.1% had high risk. 59.1% of studies had low
risk of bias and 13.6% with high risk for allocation of control. For blinding of
participants, 27.3% of studies had low risk of bias and 36.4% with high risk.
There were no studies reporting high risk of bias for incomplete outcome data,
and 54.5% had a low risk. Insufficient information was reported for selective
outcome reporting to evaluate studies as low or high risk of bias. 18.2% of
studies had low risk of bias for other potential bias, and 9.1% had a high risk.
Figure 32 shows a summary for risk of bias reporting for the low-fat diet and
statin studies.
Discussion
This meta-analysis of 12 Mediterranean diet studies found the
consumption of a Mediterranean diet yields significant decreases in triglycerides,
total cholesterol, LDL-cholesterol, and HDL-cholesterol in adults who are at highrisk and with existing CVD. The moderator analysis supported our primary
hypothesis that statin drugs did not alter the relationship between the
Mediterranean diet and serum lipids in adults, both at-risk and with existing CVD.
The meta-analysis of 22 low-fat diet studies also reached significance: the low-fat
diet alone significantly improved total cholesterol and LDL cholesterol, and there
were even greater improvements observed in low-fat diet with statins
interventions for all four serum lipid outcomes. When compared to the effects of a
low-fat diet, the Mediterranean diet produced greater effect sizes for all four
serum lipids; therefore the secondary hypothesis was accepted. Our third
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hypothesis stated the Mediterranean diet would be equally effective in improving
serum lipids compared to the traditionally prescribed low-fat diet and statin drug
therapy combination. Results showed the low-fat diet with statins produced
greater outcomes for total, LDL, and HDL cholesterol, resulting in rejecting out
third hypothesis.
This meta-analysis provides new information for achieving improvements
in serum lipids with dietary modification alone and with statin therapy. These
results suggest a low-fat diet with statins remains the best recommendation for
serum lipid lowering in adults at high-risk and with existing CVD; however,
significant improvements observed with the Mediterranean and low-fat diets
support the need for dietary modification in the prevention and treatment of CVD.
The moderator analysis explained significant sources of heterogeneity
among the studies for the Mediterranean diet, low-fat diet, and low-fat diet with
statin interventions. The Mediterranean diet was found to produce significantly
better outcomes for triglycerides when the study was conducted in a European
country. A possible explanation for this is greater access to food components of
the Mediterranean diet when living in a Mediterranean country, as well as
Mediterranean country culture placing a higher value on food and meal
enjoyment than Western culture. Further, the low-fat diet alone showed to be
more beneficial when conducted in the United States. During the mid-1990’s,
low-fat diets increased significantly in popularity in America. Living in an
environment that encourages the prescribed dietary pattern likely increases
adherence, leading to better outcomes.
Longer interventions lead to greater improvements for total, LDL, and
HDL cholesterols in the Mediterranean diet and low-fat diet with statins
interventions, and for triglycerides in the low-fat diet without statin interventions.
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This is consistent with observations in previous studies of greater and longer
adherence to a Mediterranean diet17,84,85. Greater number of follow-up sessions,
and subjects counseled in one-on-one or small group sessions led to greater
improvements in triglycerides, and trend towards greater improvements for total
and LDL cholesterol in the Mediterranean diet, with a possible explanation of
subjects feeling a greater level of support with repeated contact.
For low-fat diet with and without statins, greater proportion of female
subjects had significant or trends towards greater improvements in total, LDL,
and HDL cholesterol. This suggests that female subjects may benefit more from
a low-fat diet. A 2014 meta-analysis by Wu, Ma, Walton-Moss, and He evaluated
a low-fat diet on serum lipids in premenopausal and postmenopausal women.
Their results found significant improvements in total, LDL, and HDL in
premenopausal women, but further studies were needed to evaluate the effects
in postmenopausal women. Therefore, these moderator results are consistent
with observations in other studies86.
Analyzing dietary recommendations provided greater insight to the effects
of diet composition in outcomes. Higher recommendation for proportion of fat
intake was found to yield greater improvements in total cholesterol, and higher
intake of dietary cholesterol lead to greater improvements in HDL cholesterol
levels in low-fat diet with statin interventions. This supports the 2015 Dietary
Guidelines for Americans statement; “Cholesterol is not a nutrient of concern for
overconsumption”

87

. Higher protein intake was inversely associated with

improvement in HDL cholesterol for both low-fat diet interventions. Mediterranean
and low-fat diets tend to have similar recommendations of protein intake of 1020%. The literature shows conflicting evidence of the benefits of higher protein
intake on cardiometabolic risk factors and overall health88,89.
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The mechanisms in which these interventions improve serum lipids differ
and can greatly impact overall health. Beyond inhibiting the HMG-CoA reductase
enzyme, statins decrease cholesterol ester transferase protein (CETP), a protein
that promotes the transfer of cholesterol esters from HDL to more atherogenic
cholesterols, such as IDL, VLDL, and LDL. This contributes to a rise in HDL and
a decrease in LDL cholesterol90. The mechanism of the Mediterranean diet,
however, has not been clearly defined. There have been associations found
between increased satiety from the high fat and fiber content of the diet leading
to weight loss, which is associated with improvement in serum lipids. Individual
components of the diet, such as extra-virgin olive oil, the primary fat source of the
diet, moderate alcohol consumption, and omega-3 intake have also been
associated with improvement in serum lipids and reduced risk of type 2
diabetes91-93. Both mechanisms have shown to be effective.
Use of statins can pose side effects that the Mediterranean diet does not,
which can interfere with reaching cholesterol goals. For studies included in this
analysis, statin dose levels ranged from 5 to 80mg, with those of higher doses
(40 and 80mg) being of shorter duration. In the short duration of these studies of
mostly 4 to 8 weeks, myalgia, rise in liver function tests, epigastric pain, and
diarrhea were the most commonly reported side effects in studies that reported
adverse effects. Though few subjects compared to the entire sample needed to
withdraw treatment due to side effects, the short duration of these studies could
have been motivation for subjects to continue treatment, despite adverse effects.
A retrospective cohort study of Boston-area hospitals analyzed the rate of statin
discontinuation and rate of adverse effects in 107,835 patients. The study found
17.4% of patients experienced adverse effects, with myalgia being the most
commonly reported reason. Of this group experiencing adverse effects, 59.1% of
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them needed to at least temporarily discontinue statin therapy94. Conversely, the
Mediterranean diet does not have side effects, and provides benefits beyond its
lipid-lowering capabilities, including: weight loss, decreased inflammatory
markers, decreased insulin resistance and risk for developing type 2 diabetes,
decreased blood pressure, improvement in endothelial function, and slowed
cognitive decline with aging49,95-98. Further, patients discontinue statin use for
reasons other than adverse effects. Because of the symptomless nature of
dyslipidemia, patients do not have the same motivation to adhere to their
medication regimen that they would with a symptomatic disease. Other possible
reasons for lack of adherence include lack of communication with physician,
medication costs, and complex medication regimens. As a result, 50% or more
patients discontinue statin use within one year after the start of treatment, with
further decrease over time99. Diet, however, is a natural part of day-to-day life
that can be modified with simple nutritional counseling by a registered dietitian.
Further investigation is warranted to provide an answer to which
intervention is more beneficial to patients. This analysis provides a foundation for
future studies to be conducted on the Mediterranean diet and statin drug therapy.
Strengths and Limitations
There are many strengths to this study. These include a comprehensive
coding form with over 330 variables was used to extract data from the studies.
This coding for was thoroughly pilot tested for accuracy. Having many
characteristics coded allows further investigation to explain heterogeneity among
the studies. We used predictive models to evaluate the effects of significant
moderators at multiple levels. A comprehensive literature search was conducted
with the help of a professional university librarian to ensure all relevant studies on
the topic were included on the Mediterranean diet and low-fat diet with statins.
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There are also limitations of this study. First, the literature search for low-fat diet
studies was aimed at low-fat diet with statin drug interventions. The search likely
missed studies with only a low-fat diet intervention due to adding in the analysis
of low-fat diet alone to the Mediterranean diet after the search was conducted.
Exclusion criteria did not address subjects with Liver Disease, another disease
state that is associated with lipodystrophy. None of the included studies stated
subjects with the condition, however they may not have addressed it in their
exclusion criteria. This analysis did not take into account the characteristics, such
as lipophilic versus hydrophilic, generation, or method of metabolism, of different
types of statin drugs, which may have an effect on results. Further, we did not
analysis changes in inflammatory markers, which have a large impact on the
development and progression of cardiovascular disease. The low-fat diet studies
also had a mean publication of ten years earlier than the Mediterranean diet
studies. Due to the high societal presence of Familial Hypercholesterolemia, and
the lack of studies identifying subjects carrying this mutation, we were unable to
evaluate if the effects of the diet are more beneficial for those with genetically or
lifestyle induced dyslipidemias. Uncontrolled or unaccounted level of exercise of
the subjects may cause a change in lipid profile. Subjects of the Mediterranean
diet trials may have been prescribed a statin regimen either before or during the
intervention, but did not inform the principal investigator of their study, causing
subjects to be missed for this analysis. As with all meta-analyses, we were
limited to what studies reported, as the data used in this analysis was mostly
published data. If raw data for all studies were provided for the analysis, it would
allow for an Individual Participant Data (IPD) meta-analysis, which is the gold
standard of meta-analyses. This would ensure greater accuracy of the results.
Further, multiple variables did not have sufficient reported data among studies to
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be analyzed, resulting in significant heterogeneity among the studies that could
not be explained by the moderators analyzed.
Clinical Implications
This preliminary work in the area of Mediterranean diet with statins
suggests combined therapy of Mediterranean diet with statin drug therapy may
be unwarranted. Further research is needed to understand the relationship
between the Mediterranean diet with statins as a recommendation for prevention
and treatment of CVD. In subjects desiring dietary modification without statin
treatment, the Mediterranean diet showed to be more favorable than low-fat diet,
which holds consistent with previous studies (Sofi, 2104; Garcia 2015; Kastorini
2011). The low-fat diet with statin drugs provided greatest improvements in
serum lipids, and therefore is very beneficial for subjects who require more
aggressive lipid-lowering therapy96.
Future Directions
This research supports the need for future trials to be conducted to further
investigate the effects of Mediterranean diet in combination with statin drug
therapy. The question still stands about the accuracy of the cholesterol
hypothesis due to many trials finding substantially greater decreases in morbidity
and mortality with consumption of a Mediterranean diet as opposed to a low-fat
diet with statins. Future analysis should evaluate the outcomes of cardiac death
or cardiac events in individuals who adopt a Mediterranean diet with and without
statin therapy, as well as to those on statin therapy with a low-fat diet to truly test
the accuracy of the hypothesis. Future work can also examine the incidence of
individuals who can lower their lipid levels with diet to a point of being able to
lower dosage or discontinue use of statin drugs. A comparison of individuals with
diet-induced hyperlipidemia versus Familial Hyperlipidemia using Mediterranean
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diet can be performed to assess if the diet with and without statin drugs has a
significant effect on this extremely common genetic defect. This analysis can be
the beginning of a more broad area of research comparing the Mediterranean
diet to various types of drugs for other disease states, such as Type 2 Diabetes
and hypoglycemic agents and Hypertension with antihypertensive medications.

Conclusion
The results of this meta-analysis show the Mediterranean diet can
successfully lower total cholesterol, LDL, and triglycerides, and raise HDL
cholesterol, and statin drugs do not contribute to improvement in serum lipids
when combined with the Mediterranean diet when assessed with moderator
analysis. The Mediterranean diet produces greater improvements in all four
serum lipids than a low-fat diet, and a low-fat diet with statin drugs produces the
greatest improvements among the three interventions. This pilot work supports
the need for the need for clinical trials need to directly evaluate the effects of the
Mediterranean diet with and without statin drug therapy to provide evidence of it’s
effects. This meta-analysis favors both the Mediterranean diet and low-fat diet
with statin drugs as effective lipid-lowering interventions for adults at high-risk
and with existing cardiovascular disease.
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Tables and Figures

Identification

Records screened (n=1,265)
Duplicate screening (MC and JS)

Full-text reports assessed for
eligibility (n=66)

Records excluded by title and
abstract (n=1,199)

Full-text reports excluded, with reasons (n=49)
Did not report statin use (n=37)
Did not report an outcome of interest (n=8)
Did not report pre- and post-data (n=5)
Subjects with HIV-induced lipodystrophy (n=2)
Subjects with Renal Disease (n=1)

Records found through hand-searching metaanalyses and systematic reviews (n=2)

Included

Eligibility

Records identified through electronic database
searches after removing duplicates (n=1,265)
PubMed (n=607)
EMBASE via Scopus (n=343)
Academic Search Premier (n=208)
CINAHL (n=9)
PsycINFO (n=14)
Agricola (n=40)
CAB Direct (n=0)

Screening

Figure 1: PRISMA Diagram for Mediterranean Diet Study Inclusion

Reports included in analysis
(n=12)
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Identification

Records screened (n=580)
Duplicate screening (MC and AS)

Full-text reports assessed for
eligibility (n=66)

Records excluded by title and
abstract (n=543)

Full-text reports excluded, with reasons
(n=16)
Did not report pre- and post-data (n=5)
Did not have a low-fat diet intervention (n=4)
Duplicate publications (n=3)
Child subjects (n=2)
Exercise intervention (n=1)
Non-intervention trial (n=1)

Records found through hand-searching metaanalyses and systematic reviews (n=1)

Included

Eligibility

Records identified through electronic database
searches after removing duplicates (n=580)
PubMed (n=409)
EMBASE via Scopus (n=165)
Academic Search Premier (n=0)
CINAHL (n=6)
PsycINFO (n=0)
Agricola (n=0)
CAB Direct (n=0)

Screening

Figure 2: PRISMA Diagram for Low-Fat Diet Study Inclusion

Reports included in analysis
(n=22)
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Figure 3: Mediterranean Diet and Triglycerides Forest Plot

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
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Figure 4: Mediterranean Diet and Total Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
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Figure 5: Mediterranean Diet and LDL-Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line shows
95% confidence intervals (Cis); dotted line represents the null value of zero; diamond
represents the weighted mean effect size for the outcome.
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Figure 6: Mediterranean Diet and HDL-Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 7: Low-Fat Diet and Triglycerides Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 8: Low-Fat Diet and Total Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 9: Low-Fat Diet and LDL-Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 10: Low-Fat Diet and HDL-Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 11: Low-Fat Diet with Statins and Triglycerides Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 12: Low-Fat Diet with Statins and Total Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 13: Low-Fat Diet with Statins and LDL-Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 14: Low-Fat Diet with Statins and HDL-Cholesterol Forest Plot

Note: Squares represent point estimates for each individual study; extended line
shows 95% confidence intervals (Cis); dotted line represents the null value of
zero; diamond represents the weighted mean effect size for the outcome.
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Figure 15: Mediterranean Diet and Length of Intervention

Note: Number of weeks of the interventions is represented on the x-axis; Outcome of
interest is represented on the y-axis; B is the unstandardized beta and represents the
2
amount of change in the outcome per week of the intervention; R indicates the
percentage of variability accounted for by length of intervention.

Figure 16: Mediterranean Diet and Proportion of Subjects with Dyslipidemia

Note: Proportion of subjects with a diagnosis of dyslipidemia is represented on the x-axis;
Outcome of interest is represented on the y-axis; B is the unstandardized beta and
represents the amount of change in the outcome per percent of subjects with
2
dyslipidemia; R indicates the percentage of variability accounted for by subjects with
dyslipidemia.
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Figure 17: Mediterranean Diet and Number of Follow-Up Sessions

Note: Number of Follow-Up Session throughout the intervention is represented on the xaxis; Outcome of interest is represented on the y-axis; B is the unstandardized beta and
2
represents the amount of change in the outcome per follow-up; R indicates the
percentage of variability accounted for by number of follow-up sessions.

Figure 18: Mediterranean Diet and Number of Subjects Lost to Follow-Up

Note: Number of Subjects Lost to Follow-Up is represented on the x-axis; Outcome of
interest is represented on the y-axis; B is the unstandardized beta and represents the
2
amount of change in the outcome per lost subject; R indicates the percentage of
variability accounted for by number of subjects lost to follow-up.
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Figure 19: Low-Fat Diet with Statins and Length of Intervention

Note: Number of weeks of the interventions is represented on the x-axis; Outcome of
interest is represented on the y-axis; B is the unstandardized beta and represents the
2
amount of change in the outcome per week of the intervention; R indicates the
percentage of variability accounted for by length of intervention.

Figure 20: Low-Fat Diet with Statins and Length of Intervention

Note: Number of weeks of the interventions is represented on the x-axis; Outcome of
interest is represented on the y-axis; B is the unstandardized beta and represents the
2
amount of change in the outcome per week of the intervention; R indicates the
percentage of variability accounted for by length of intervention.
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Figure 21: Low-Fat Diet with Statins and Proportion of Female Subjects

Note: Proportion of females is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per percent increase in female subjects; R indicates the
percentage of variability accounted for by proportion of females.

Figure 22: Low-Fat Diet with Statins and Proportion of Female Subjects

Note: Proportion of females is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per percent increase in female subjects; R indicates the
percentage of variability accounted for by proportion of females.
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Figure 23: Low-Fat Diet with Statins and Recommended Proportion of Fat Intake

Note: Proportion of fat intake is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per percent increase in fat intake recommendation; R indicates
the percentage of variability accounted for by proportion of fat intake.

Figure 24: Low-Fat Diet with Statins and Recommended Proportion of
Carbohydrate Intake

Note: Proportion of carbohydrate intake is represented on the x-axis; Outcome of interest
is represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per percent increase in carbohydrate intake recommendation; R
indicates the percentage of variability accounted for by proportion of carbohydrate intake.
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Figure 25: Low-Fat Diet with Statins and Recommended Proportion of
Carbohydrate Intake

Note: Proportion of carbohydrate intake is represented on the x-axis; Outcome of interest
is represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per percent increase in carbohydrate intake recommendation; R
indicates the percentage of variability accounted for by proportion of carbohydrate intake.

Figure 26: Low-Fat Diet with Statins and Recommended Proportion of Protein
Intake

Note: Proportion of protein intake is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per percent increase protein intake recommendation; R indicates
the percentage of variability accounted for by proportion of protein intake.
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Figure 27: Low-Fat Diet with Statins and Recommended Dietary Cholesterol
Intake

Note: Recommended dietary cholesterol intake is represented on the x-axis; Outcome of
interest is represented on the y-axis; B is the unstandardized beta and represents the
amount of change in the outcome per milligram change in cholesterol intake
2
recommendation; R indicates the percentage of variability accounted for by
recommended dietary cholesterol intake.

Figure 28: Low-Fat Diet with Statins and Sample Size

Note: Sample size is represented on the x-axis; Outcome of interest is represented on
the y-axis; B is the unstandardized beta and represents the amount of change in the
2
outcome per change in number of subjects; R indicates the percentage of variability
accounted for by sample size.
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Figure 29: Low-Fat Diet with Statins and Sample Size

Note: Sample size is represented on the x-axis; Outcome of interest is represented on
the y-axis; B is the unstandardized beta and represents the amount of change in the
2
outcome per change in number of subjects; R indicates the percentage of variability
accounted for by sample size.

Figure 30: Low-Fat Diet with Statins and Sample Size

Note: Sample size is represented on the x-axis; Outcome of interest is represented on
the y-axis; B is the unstandardized beta and represents the amount of change in the
2
outcome per change in number of subjects; R indicates the percentage of variability
accounted for by sample size.
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Figure 31: Low-Fat Diet with Statins and Intervention Group Size

Note: Intervention group size is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per change in number of subjects; R indicates the percentage of
variability accounted for by intervention group size.

Figure 32: Low-Fat Diet with Statins and Intervention Group Size

Note: Intervention group size is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per change in number of subjects; R indicates the percentage of
variability accounted for by intervention group size.
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Figure 33: Low-Fat Diet with Statins and Intervention Group Size

Note: Intervention group size is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per change in number of subjects; R indicates the percentage of
variability accounted for by intervention group size.

Figure 34: Low-Fat Diet with Statins and Intervention Group Size

Note: Intervention group size is represented on the x-axis; Outcome of interest is
represented on the y-axis; B is the unstandardized beta and represents the amount of
2
change in the outcome per change in number of subjects; R indicates the percentage of
variability accounted for by intervention group size.
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Figure 35: Low-Fat Diet with Statins and Subjects with Cardiovascular Disease

Note: Number of subjects with cardiovascular disease is represented on the x-axis;
Outcome of interest is represented on the y-axis; B is the unstandardized beta and
represents the amount of change in the outcome per change in number of subjects with
2
cardiovascular disease; R indicates the percentage of variability accounted for by
number of subjects with cardiovascular disease.

Figure 36: Low-Fat Diet with Statins and Subjects with Cardiovascular Disease

Note: Number of subjects with cardiovascular disease is represented on the x-axis;
Outcome of interest is represented on the y-axis; B is the unstandardized beta and
represents the amount of change in the outcome per change in number of subjects with
2
cardiovascular disease; R indicates the percentage of variability accounted for by
number of subjects with cardiovascular disease.
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Figure 37: Low-Fat Diet with Statins and Subjects with Cardiovascular Disease

Note: Number of subjects with cardiovascular disease is represented on the x-axis;
Outcome of interest is represented on the y-axis; B is the unstandardized beta and
represents the amount of change in the outcome per change in number of subjects with
2
cardiovascular disease; R indicates the percentage of variability accounted for by
number of subjects with cardiovascular disease.
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Figure 38: Mediterranean Diet Risk of Bias
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Figure 39: Low-Fat Diet Risk of Bias
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Tables
Table 1: Description of Included Mediterranean Diet Studies
Study

Country

Babio, et al
102
(2014)

Spain

Casas, et al
48
(2014)
Casas, et al
103
(2016)

N

% F Age

Diseases

Recruitment

5801 58% 67

T2DM,
CVDRF

Physician
Referral

Spain

165 53% 67.7

T2DM,
CVDRF

Physician
Referral

Spain

45 53% 66

T2DM,
CVDRF

Physician
Referral

Dietary
Type of Duration
Assessment
Diet
(weeks)
Individual &
Group
MDN, MDO
250
Unsupervised
Individual &
Group,
MDN, MDO
52
Unsupervised
Individual &
Group,
MDN, MDO
260
Unsupervised

OverWT, Clinical Practice
Individual,
HypoMD,
NIDDM,
of Investigators
Unsupervised low CHO
CVDRF
Referral
CVDRF,
Primary
Individual &
Estruch, et al
Spain
772 56% 68.9
T2DM,
physician
Group,
MDN, MDO
105
(2006)
OverWT/Ob
referral
Unsupervised
IDDM,
Itsiopoulos,
NIDDM,
Individual,
et al
Australia 27 41% 59
Newspaper ad
MD
CVDRF, Ob
Unsupervised
106
(2010)
(59%)
Individual &
Jula, et al
High Chol,
Occupational
Finland 120 0% 48.2
Group,
MD
107
(2016)
High TG
Health Services
Unsupervised
MD
Michalsen, et
Hospital referral,
Group,
immersive
108 Germany 101 23% 59.4 CAD (100%)
al (2005)
advertisement Unsupervised
education
SalasPrimary
Individual &
T2DM,
Salvado, et
Spain 1224 53% 67.4
Physician
Group,
MDO, MDN
CVDRF
109
al (2008)
referral
Unsupervised
Esposito, et
104
al (2009)

Italy

215 51% 52.2

Simoni, et al
110
(1994)

Italy

Singh, et al
111
(2002)

India

Angina, MI,
1000 NR 48.5 T2DM, HTN, Advertisement
CVDRF

Tuttle, et al
112
(2008)

USA

101 36% 58

MI (100%),
T2DM,
CVDRF

12 42% 70

High serum Subsample of an
Unsupervised
lipids, Lp(a) Unnamed Study

Physician
referral

Control

Outcome

LFD

MetS

LFD

CVDRF,
inflam bio,
BG

LFD

IDDM,
CVDRF

208

HypoLFD

IDDM,
CVDRF

12

LFD

CVDRF,
inflam bio,
IR

24

Habitual
Diet

HbA1c, IR,
CVDRF,
inflam bio

12

Habitual
Diet

Serum
lipids, IR,
BG

52
52

MD

8

Individual,
Unsupervised

MDN

104

Individual,
Unsupervised

MD

104

MD written
Inflam bio,
materials
CVDRF
only
LFD

MetS, MS
RF

Serum
lipids,
Lp(a)
Cardiac
NCEP diet events, MI,
CVDRF
Cardiac
events, MI,
LFD
CD,
CVDRF
None

Note. N, number of participants at baseline; F, females; T2DM, Type 2 Diabetes
Mellitus; NR, not reported; MDN, Mediterranean diet with nuts supplemented;
MDO, Mediterranean diet with olive oil supplemented; LFd, low fat; MetS,
Metabolic Syndrome; CVDRF, Cardiovascular Disease risk factors; inflam bio,
inflammatory biomarkers; IDDM, Insulin Dependent Diabetes Mellitus; OverWT,
Overweight; Ob, Obese; IR, Insulin Resistance; NIDDM, Non-insulin Dependent
Diabetes Mellitus; Chol, cholesterol; TG, Triglycerides; BG, Blood Glucose; CAD,
Coronary Artery Disease; Lp(a), lipoprotein-a; MI, Myocardial Infarction; HTN,
Hypertension; NCEP, National Cholesterol Education Program diet; CD, cardiac
death; HypoMD, hypocaloric Mediterranean diet; CHO, carbohydrate; HypoLFD,
hypocaloric low-fat.
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Table 2: Description of Included Low-Fat Diet Studies
Study

Country

N

%F

Andrews, et al
113
(1997)

USA

40

30%

Aquilani, et al
114
(1998)

Italy

126

0%

57.2 CAD, HLD Outpt referral Individual,
VLFD, AHA
Unsupervised Step 1,
AHA Step 2
Statin

24

HypocaloricSerum
Diet Statin lipids

The
215
Netherlands

0%

55.1 HLD

Population- Individual,
AHA Step 1
based
Unsupervised Statin, AHA
Screening
Step 2
Program
Statin

24

AHA Step Serum
1 Placebo, lipids
AHA Step
2 Placebo

14%

51 HLD

Study Centers Individual,
AHA Step 1
Unsupervised Statin

4

AHA Step Serum
1 Placebo lipids

Clinical
Unsupervised AHA Step 1
Centers
Statin
Primary/ Group,
AHA Step
Secondary Unsupervised 1, AHA
Care Referral
Step 2

48

AHA Step Serum
1 Placebo lipids
None Serum
lipids

Lipid Clinic Individual & LFD Statin
Group,
Unsupervised

32

HFD Statin Serum
lipids

Lipid Clinic, Individual,
LFD, LFD
advertisement Unsupervised Statin

20

HFD, HFD Serum
Statin lipids

Bak, et al
115
(1998)

67 CAD, HLD,
DM

BakkerArkema, et al
116
(1996)
Bradford, et al
117
(1993)
Brown, et al
118
(1998)

USA and
Canada

Chisholm, et al
119
(1994)

New
Zealand

19

58%

51 FH, HLD

Clifton, et al
120
(1991)

Australia

19

74%

55 HLD, HTN

Coban, et al
121
(2007)

Turkey

30

43%

48 High MPV,
DYS

Cobb, et al
83
(1991)

USA

29

41%

53 HLD

Brazil

126

55%

56 HLD

Galvan, et al
123
(1996)

Italy

20

35%

Hodis, et al
124
(1996)

USA

188

Hunninghake,
125
et al (1993)

USA

Jenkins, et al
126
(2003)

Canada

Forti (1993)

122

USA
USA

56

Age Diseases Recruitment

3390 100% 58.4 HTN, CAD,
DYS
318 32%
64 ASCVD,
HLD

NR

Dietary
Type of Duration Control Outcome
Assessment
Diet
(weeks)
Individual,
AHA Step 1
24
AHA Step 1Serum
Unsupervised Statin
lipids,
ischemia

54

Primary
Physician
referral

Unsupervised LFD Statin

12

Habitual Serum
Diet
lipids,
MPV

NR

Individual,
LFD, LFD
Unsupervised Statin,
HFD, HFD
Statin

20

LFD
Serum
Placebo, lipids
HFD
Placebo

Physician Individual,
LFD
Referral
Unsupervised
Lipid Clinic Individual,
LFD Statin,
Unsupervised
LFD

12

8%

58 HTN, CAD, MARS study Individual,
LFD Statin,
50%
Unsupervised LCD Statin
stenosis

208

LFD, LCD CAIMT,
Placebo serum
lipids

111

40%

54 HLD

Lipid Clinic, Individual,
AHA Step 2
advertisement Unsupervised statin and
Placebo,
HFD Statin

36

HFD
Serum
Placebo lipids

46

46%

59 DYS

Outpt care Individual,
High PS,
referral, News Unsupervised Soy protein,
Ad
fiber,
almonds

4

44.7 FH

8

None

Serum
lipids, BG
LFD
Serum
Placebo lipids, BG,
IR

LFD w/ WG CRP,CHD
Risk,
Serum
lipids

59

Koh, et al
127
(2001)

South
Korea

13

NR

67 DYS

Canadian Individual,
AHA Step 2
CardiovascularUnsupervised Statin
Society

14

AHA Step 2Serum
lipids,
inflam bio

Koh, et al
128
(2004)

South
Korea

63

41%

62 HTN, DM,
Canadian Individual,
AHA Step 1
CAD
CardiovascularUnsupervised Statin
Society

14

AHA Step 1Inflam bio,
Placebo ICAM-1,
mitrate,
MDA

Mizuno, et al
129
(2004)

Japan

299

23%

58.7 ASCVD,
HLD

Ose, et al
130
(2000)

USA

1105

42%

Ose, et al
131
(1995)

Norway

432

Schafer, et al
132
( (2001)

USA

Ziegler, et al
(1990)133

France

Hospital
Referral

Individual,
LFD Statin
Unsupervised

104

LFD

Serum
lipids,
MOD,
MSD

52.8 HLD

NR

Individual,
AHA Step 1
Unsupervised Statin

48

None

Serum
lipids

47%

52.6 HLD, CHD

NR

Unsupervised LFD Statin

6

47

31%

61 CHD,
OverWt/
Ob, DYS

NR

Individual,
VLFD, LCD
Unsupervised Statin

10

None

Serum
lipids

184

30%

46 HLD

NR

Individual,
Unsupervised

10

None

Serum
lipids

LFD

LFD
Serum
Placebo lipids

Note. N, number of participants at baseline; F, females; CAD, Coronary Artery
Disease; High Chol, High Total and LDL Cholesterol; HLD, Hyperlipidemia; DM,
Diabetes Mellitus; NR, not reported; AHA step 1 or 2, American Heart
Association Step 1 or Step 2 Diet; Chol, Cholesterol; VLFD, Very Low-Fat Diet;
TG, Triglycerides; HTN, Hypertension; ASCVD, Atherosclerotic Cardiovascular
Disease; FH, Familial Hypercholesterolemia; LFD, Low-fat diet; HFD, High-fat
diet; MPV, Mean Platelet Volume; DYS, dyslipidemia; BG, Blood Glucose; IR,
Insulin Resistance; LCD, Low Cholesterol Diet, CAIMT, Carotid Arterial IntimaMedia Thickness; Outpt, Outpatient; PS, Plant Sterols; WG, Whole Grains; CRP,
C-Reactive Protein; CHD Risk, Coronary Heart Disease Risk Percentage; ICAM1, Intracellular adhesion molecule- type 1; MDA, malondialdehyde; MOD,
Minimum Obstruction Diameter; MSD, Mean Segment Diameter; inflam,
inflammation.
Note on Dietary Assessment column:
• Individual: A dietitian performed a dietary assessment, providing
individualized needs for caloric intake and recommendations, for each
participant.
• Group: The study provided general dietary recommendations for the
participants, such as a range of servings of certain food groups, calories
based on gender, as opposed to tailoring diets to individual needs based
on weight and height.
• Supervised: Participants consumed foods in a supervised setting, where
the researchers had control over participant food choices and quantity of
food served.
• Unsupervised: Participants food consumption was unsupervised by
researchers, such as eating at home.
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Table 3: Mediterranean Diet Publication Bias Results
Outcome
Egger’s
Triglycerides
p=0.73
Total Cholesterol
p=0.90
LDL
p=0.61
HDL
p=0.45
Table 4: Low Fat Diet Publication Bias Results
Outcome
Egger’s
Low-Fat Diet without Statins
Triglycerides
p=0.47
Total Cholesterol
p=0.01
LDL
p=0.01
HDL
p=0.36
Low-Fat Diet with Statins
Triglycerides
p=0.39
Total Cholesterol
p=0.07
LDL
p=0.23
HDL
p=0.101
Table 5: Mediterranean Diet Summary of Results
Outcome
K
Fixed-Effects
Random-Effects
Triglycerides
13
-0.45
-0.45
(-0.51, -0.40)
(-0.79, -0.12)
Total
10
-0.67
-0.66
Cholesterol
(-0.74, -0.60)
(-0.96, -0.35)
LDL
12
-0.46
-0.52
(-0.51, -0.40)
(-0.76, -0.27)
HDL
13
0.16
0.24
(0.11, 0.22)
(0.01, 0.46)
Table 6: Low-Fat Diet Summary of Results
Low-Fat Diet Without Statins
Outcome
K
Fixed-Effects
Random-Effects
Triglycerides
16
-0.17
-0.12
(-0.22, -0.12)
(-0.25, 0.02)
Total
17
-0.14
-0.39
Cholesterol
(-0.19, -0.09)
(-0.57, -0.20)
LDL
17
-0.11
-0.24
(-0.16, -0.07)
(-0.36, -0.11)
HDL
19
0.03
-0.06
(-0.01, 0.08)
(-0.27, 0.16)
Low-Fat Diet With Statins
Triglycerides
27
-0.50
-0.43
(-0.54, -0.46)
(-0.57, -0.30)
Total
37
-1.90
-1.68
Cholesterol
(-1.94, -1.86)
(-1.90, -1.46)
LDL
36
-1.92
-1.75
(-1.97, -1.88)
(-2.01, -1.49)
HDL
35
0.45
0.37
(0.42, 0.48)
(0.29, 0.45)

Begg’s
p=0.16
p=1.000
p=0.12
p=0.44
Begg’s
p=0.82
p=0.60
p=0.44
p=0.21
p=0.06
p=0.75
p=0.12
p=0.80
Q
224.42

I2
96.89%

P-value
.0084

73.24

91.84%

<.0001

147.39

93.25%

<.0001

116.74

93.53%

.04

Q
94.24

I2
79.47%

P-value
0.10

183.94

91.12%

<.0001

70.92

79.50%

0.0002

140.08

95.01%

0.62

264.50

86.35%

<.0001

600.61

95.59%

<.0001

723.97

96.75%

<.0001

299.10

84.32%

<.0001
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Table 7: Mediterranean Diet Significant Moderator Analysis Results
Variable
Statins

Outcome
TG

Total
Cholesterol

LDL

HDL

Category
0%

K
13

7% (min)

13

10%

13

25%

13

50%

13

75%

13

100%
(max)
0%

13

7% (min)

10

10%

10

25%

10

50%

10

75%

10

100%

10

0%

12

7% (min)

12

10%

12

25%

12

50%

12

75%

12

100%
(max)
0%

12

7% (min)

13

10%

13

25%

13

50%

13

75%

13

10

13

d+(95%CI)
-0.39
(-1.00, 0.22)
-0.40
(-0.95, 0.15)
-0.40
(-0.93, 0.12)
-0.43
(-0.84, -0.01)
-0.46
(-0.82, -0.10)
-0.50
(-0.99, -0.01)
-0.53
(-1.24, 0.18)
-0.65
(-1.17, -0.14)
-0.65
(-1.12, -0.19)
-0.66
(-1.10, -0.21)
-0.66
(-1.02, -0.30)
-0.66
(-1.02, -0.32)
-0.67
(-1.16, -0.18)
-0.68
(-1.37, 0.02)
-0.38
(-0.86, 0.10)
-0.40
(-0.83, 0.02)
-0.41
(-0.82, -0.01)
-0.46
(-0.78, -0.14)
-0.54
(-0.81, -0.27)
-0.62
(-1.00, -0.25)
-0.70
(-1.25, -0.15)
0.39
(0.01, 0.78)
0.37
(-0.02, 0.72)
0.36
(0.03, 0.69)
0.30
(0.04, 0.57)
0.21
(-0.1, 0.44)
0.12
(-0.19, 0.44)

2

R
0.00%

p-value
0.80

0.00%

0.80

0.00%

0.80

0.00%

0.80

0.00%

0.80

0.00%

0.80

0.00%

0.80

0.00%

0.96

0.00%

0.96

0.00%

0.96

0.00%

0.96

0.00%

0.96

0.00%

0.96

0.00%

0.96

0.00%

0.47

0.00%

0.47

0.00%

0.47

0.00%

0.47

0.00%

0.47

0.00%

0.47

0.00%

0.47

2.08%

0.32

2.08%

0.32

2.08%

0.32

2.08%

0.32

2.08%

0.32

2.08%

0.32
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Dyslipidemia

100%
(max)
15% (min)

13

100%
(max)
15% (min)

10

8

LDL

100%
(max)
15% (min)

9

HDL

100%
(max)
15% (min)

10

TG

100%
(max)
Yes

No

13

Yes

10

No

10

Yes

12

No

12

Yes

13

No

13

Yes

13

No

11

Yes

9

No

9

Yes

10

No

10

Yes

11

No

11

Yes

8

No

8

TG

Total
Cholesterol

Subjects
Taking Blood
Pressure
Medication

Total
Cholesterol
LDL

HDL

Subjects
Taking Aspirin

TG

Total
Cholesterol
LDL

HDL

Subjects
Using Insulin

TG

10

8

9

10

13

0.03
(-0.43, 0.49)
0.75
(-0.26, 1.75)
-0.75
(-0.51, 0.33)
-0.95
(-1.49, -0.42)
-0.68
(-1.13, -0.22)
0.45
(-0.71, 1.61)
-1.25
(-1.95, -0.54)
0.94
(0.61, 1.27)
-0.31
(-0.57, -0.05)
-0.22
(-1.14, 0.70)
-0.49
(-0.87, -0.12)
-1.15
(-2.01, -0.29)
-0.58
(-0.93, -0.23)
-1.26
(-1.97, -0.55)
-0.43
(-0.67, -0.18)
-0.01
(-0.64, 0.61)
0.27
(0.03, 0.51)
-0.57
(-1.54, 0.41)
-0.48
(-0.94, -0.02)
-0.65
(-1.29, -0.01)
-0.58
(-0.91, -0.24)
0.00
(-0.78, 0.78)
-0.47
(-0.71, -0.23)
0.78
(0.30, 1.26)
0.17
(-0.05, 0.38)
-0.99
(-1.23, -0.75)
-0.19
(-0.27, -0.11)

2.08%

0.32

14.36%

0.15

14.36%

0.15

1.40%

0.53

1.40%

0.53

11.07%

0.06

11.07%

0.06

81.20%

<0.0001

81.20%

<0.0001

0.00%

0.59

0.00%

0.59

0.00%

0.23

0.00%

0.23

14.03%

0.03

14.03%

0.03

0.35%

0.40

0.35%

0.40

0.00%

0.87

0.00%

0.87

0.00%

0.83

0.00%

0.83

2.19%

0.24

2.19%

0.24

35.78%

0.02

35.78%

0.02

98.32%

<0.0001

98.32%

<0.0001
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Total
Cholesterol
LDL

Yes

6

No

6

Yes
No

Length
(weeks)

TG

Minimum
(8)
Maximum
(260)
Minimum
(8)
Maximum
(260)
Minimum
(8)
Maximum
(26)
Minimum
(8)
Maximum
(260)
1-on-1

13

Small
group
1-on-1

13

10

LDL

Small
group
1-on-1

12

HDL

Small
group
1-on-1
Minimum
(1)
Maximum
(8)
Minimum
(1)
Maximum
(8)
Minimum
(1)
Maximum
(8)
Minimum
(1)
Maximum
(8)

13

Total
Cholesterol
LDL

HDL

Intervention
level

TG

Total
Cholesterol

Number
Follow Up

TG

Total
Cholesterol
LDL

HDL

13
8
8
12
12
13
13
13

10

12

13

13
10
10
12
12
13
13

-1.24
(-1.99, -0.49)
-0.54
(-0.89, -0.19)
Insufficient
data to
analyze
Insufficient
data to
analyze
-0.30
(-0.75, 0.15)
-0.76
(-1.48, -0.05)
-0.35
(-0.67, -0.04)
-1.04
(-1.45, -0.64)
-0.34
(-0.62, -0.07)
-0.90
(-1.38, -0.43)
0.54
(0.09, 0.99)
0.09
(-0.20, 0.37)
-0.26
(-0.58, 0.06)
-0.97
(-1.51, -0.42)
-0.74
(-1.10, -0.38)
-0.70
(-1.35, -0.04)
-0.54
(-0.85, -0.23)
-0.66
(-1.15, -0.18)
0.30
(0.04, 0.56)
-0.17
(-0.39, 0.06)
-1.40
(-1.88, -0.92)
-0.54
(-0.88, -0.21)
-1.02
(-1.67, -0.36)
-0.45
(-0.73, -0.18)
-0.82
(-1.47, -0.17)
0.21
(-0.07, 0.48)
0.34
(-0.23, 0.91)

31.11%

0.10

31.11%

0.10

0.00%

0.33

0.00%

0.33

54.74%

0.02

54.74%

0.02

32.10%

0.07

32.10%

0.07

13.30%

0.13

13.30%

0.13

32.00%

0.02

28.16%

0.03

0.00%

0.37

0.00%

0.91

0.00%

0.86

0.00%

0.50

0.03%

0.31

70.30%

<0.0001

70.30%

<0.0001

12.75%

0.23

12.75%

0.23

4.17%

0.33

4.17%

0.33

0.00%

0.70

0.00%

0.70
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Participants
Lost F/U

TG

Total
Cholesterol
LDL

HDL

Government
Funding

Minimum
(0)
Maximum
(14)
Minimum
(0)
Maximum
(14)
Minimum
(0)
Maximum
(14)
Minimum
(0)
Maximum
(14)

13
13
10
10
12
12
13
13

TG

11

Total
Cholesterol
LDL

8
10

HDL

11

HDL

Yes

8

No

8

-0.11
(-0.22, 0.003)
-1.56
(-1.83, -1.30)
-0.50
(-0.84, -0.16)
-1.28
(-2.15, -0.40)
-0.46
(-0.75, -0.18)
-0.78
(-1.49, -0.08)
-0.22
(-0.06, 0.51)
0.28
(-0.32, 0.88)
-0.50
(-1.29, 0.30)
-1.52
(-2.28, -0.76)
-0.63
(-1.43, 0.18)
0.84
(0.49, 1.19)
1.12
(0.71, 1.52)
0.19
(0.04, 0.35)

96.47%

<0.0001

96.47%

<0.0001

16.14%

0.14

16.14%

0.14

0.00%

0.43

0.00%

0.43

0.00%

0.88

0.00%

0.88

0.00%

0.89

42.96%

0.01

0.00%

0.65

61.22%

<0.0001

78.57%

<0.0001

78.57%

<0.0001
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Table 8: Low-Fat Diet Significant Moderator Analysis Results
Variable
Age

Outcome
TG

Total
Cholesterol
LDL

HDL

Female

TG

Total
Cholesterol
LDL

HDL

Number with
CVD

TG

Total
Cholesterol
LDL

HDL

Proportion
with
Dyslipidemia

TG

Total

Category
Minimum
(43)
Maximum
(69.5)
Minimum
(43)
Maximum
(69.5)
Minimum
(43)
Maximum
(69.5)
Minimum
(43)
Maximum
(69.5)
Minimum
(0)
Maximum
(1.0)
Minimum
(0)
Maximum
(1.0)
Minimum
(0)
Maximum
(1.0)
Minimum
(0)
Maximum
(1.0)
Minimum
(0)
Maximum
(107)
Minimum
(0)
Maximum
(107)
Minimum
(0)
Maximum
(107)
Minimum
(0)
Maximum
(107)
Minimum
(0)

K
16

Maximum
(1.0)
Minimum

14

16
17
17
17
17
19
19
16
16
17
10
17
17
19
19
6
6
8
8
8
8
9
9
14

16

2

d+(95%CI)
-0.45
(-0.74, -0.16)
0.15
(-0.10, 0.39)
-0.53
(-1.03, -0.02)
-0.27
(-0.71, 0.17)
-0.39
(-0.71, -0.07)
-0.13
(-0.37, 0.11)
0.02
(-0.54, 0.58)
-0.12
(-0.57, 0.34)
-0.44
(-0.71, -0.16)
-0.17
(-0.61, 0.27)
-0.49
(-0.75, -0.22)
-0.17
(-0.62, 0.29)
-0.30
(-0.48, -0.13)
-0.10
(-0.36, 0.17)
0.10
(-0.23, 0.43)
-0.39
(-0.95, 0.18)
-0.40
(-0.79, -0.01)
0.19
(-0.01, 0.39)
-0.99
(-1.75, -0.24)
-0.19
(-0.74, 0.36)
-0.50
(-1.02, 0.02)
-0.17
(-0.51, 0.17)
0.21
(-0.19, 0.62)
0.09
(-0.11, 0.29)
-0.70
(-1.47, 0.07)

R
31.93%

p-value
0.02

31.93%

0.02

0.00%

0.57

0.00%

0.57

0.00%

0.32

0.00%

0.32

0.00%

0.77

0.00%

0.77

0.00%

0.93

0.00%

0.93

18.29%

0.06

18.29%

0.06

34.79%

0.04

34.79%

0.04

0.00%

0.58

0.00%

0.58

0.00%

0.02

0.00%

0.02

4.11%

0.15

4.11%

0.15

0.00%

0.36

0.00%

0.36

0.00%

0.65

0.00%

0.65

0.00%

0.06

-0.05
(-0.22, 0.12)
-0.92

0.00%

0.06

0.00%

0.33
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Cholesterol
LDL

HDL

Proportion
with
Hypertension

TG

Total
Cholesterol
LDL

HDL

Number with
Hypertension

TG

Total
Cholesterol
LDL

HDL

Proportion
Taking ACE
Inhibitors

TG

Total
Cholesterol
LDL

(0)
Maximum
(1.0)
Minimum
(0)
Maximum
(1.0)
Minimum
(0)
Maximum
(1.0)
Minimum
(0.35)
Maximum
(0.946)
Minimum
(0.35)
Maximum
(0.946)
Minimum
(0.35)
Maximum
(0.946)
Minimum
(0.35)
Maximum
(0.946)
Minimum
(0)
Maximum
(328)
Minimum
(0)
Maximum
(328)
Minimum
(0)
Maximum
(328)
Minimum
(0)
Maximum
(328)
Minimum
(0%)
Maximum
(54%)
Minimum
(0%)
Maximum
(54%)
Minimum
(0%)
Maximum

16
16
16
17
17
7
7
8
8
9
9
10
10
7
7
7
7
8
8
9
9
10
10
9
9
11
11

(-2.10, 0.26)
-0.35
(-0.56, -0.13)
-0.35
(-1.10, 0.41)
-0.23
(-0.38, -0.08)
-1.48
(-2.53, -0.44)
-0.08
(-0.13, 0.30)
-0.31
(-0.61, -0.01)

0.00%

0.33

0.00%

0.71

0.00%

0.71

21.94%

0.01

21.94%

0.01

59.12%

0.007

0.24
(-0.11, 0.60)
-0.92
(-2.10, 0.26)
-0.35
(-0.56, -0.13)
-0.16
(-0.42, 0.09)
-0.15
(-0.50, 0.19)
-0.02
(-0.78, 0.74)
-0.23
(-1.21, 0.75)
-0.14
(-0.53, 0.25)
-0.01
(-0.80, 0.79)
-0.66
(-1.07, -0.25)
0.30
(-0.41, 1.01)
-0.39
(-0.58, -0.20)
-0.11
(-0.07, 0.30)
-0.54
(-1.14, 0.07)
-0.37
(-0.67, 1.42)
-0.13
(-0.28, 0.02)

59.12%

0.007

0.00%

0.35

0.00%

0.35

0.00%

0.40

0.00%

0.40

0.00%

0.35

0.00%

0.35

0.00%

0.81

0.00%

0.81

36.21%

0.048

36.21%

0.048

78.06%

0.02

78.06%

0.02

1.03%

0.21

1.03%

0.21

99.99%

0.006

0.19
(0.05, 0.32)
-0.49
(-0.88, -0.11)
-0.45
(-1.70, 0.80)
-0.32
(-0.59, -0.05)
-0.18

99.99%

0.006

0.00%

0.96

0.0%

0.96

0.00%

0.61

0.00%

0.61
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HDL

Number
Taking ACE
Inhibitors

TG

Total
Cholesterol
LDL

HDL

Length
(weeks)

TG

Total
Cholesterol
LDL

HDL

Sample Size

TG

Total
Cholesterol
LDL

HDL

Region

TG

(54%)
Minimum
(0%)
Maximum
(54%)
Minimum
(0)
Maximum
(114)
Minimum
(0)
Maximum
(114)
Minimum
(0)
Maximum
(114)
Minimum
(0)
Maximum
(114)
Minimum
(4)
Maximum
(260)
Minimum
(4)
Maximum
(260)
Minimum
(4)
Maximum
(260)
Minimum
(4)
Maximum
(260)
Minimum
(30)
Maximum
(5850)
Minimum
(30)
Maximum
(5850)
Minimum
(30)
Maximum
(5850)
Minimum
(30)
Maximum
(5850)
United
States

11
11
10
10
9
9
11
11
11
11
16
16
17
17
17
17
19
19
16
16
17
17
17
17
19
19
16

(-0.59, 0.23)
0.11
(-0.09, 0.30)
0.09
(-0.17, 0.35)
-0.09
(-0.21, 0.04)
0.16
(0.04, 0.28)
-0.47
(-0.83, -0.11)
-0.97
(-8.09, 6.15)
-0.33
(-0.55, -0.11)
-0.04
(-0.49, 0.42)
-0.11
(-0.06, 0.28)
-0.07
(-0.24, 0.38)
-0.03
(-0.20, 0.14)
-0.33
(-0.63, -0.02)
-0.37
(-0.63, -0.12)
-0.42
(-0.83, 0.05)
-0.27
(-0.44, -0.11)
-0.13
(-0.50, 0.23)
-0.15
(-0.44, 0.14)
0.21
(-0.36, 0.77)
-0.09
(-0.28, 0.10)
-0.75
(-3.50, 2.00)
-0.46
(-0.65, -0.27)
0.64
(-0.39, 1.68)
-0.29
(-0.42, -0.16)
0.35
(-0.22, 0.93)
-0.09
(-0.34, 0.16)
0.40
(-1.13, 1.93)
-0.16
(-0.32, -0.01)

0.00%

0.92

0.00%

0.92

99.99%

0.006

99.99%

0.006

0.00%

0.89

0.00%

0.89

2.26%

0.28

2.26%

0.28

0.00%

0.83

0.00%

0.83

31.86%

0.04

31.86%

0.04

0.00%

0.70

0.00%

0.70

0.00%

0.55

0.00%

0.55

0.00%

0.35

0.00%

0.35

0.00%

0.65

0.00%

0.65

21.20%

0.0501

21.20%

0.0501

32.80%

0.04

32.80%

0.04

0.00%

0.55

0.00%

0.55

5.54%

0.22
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Total
Cholesterol
LDL

HDL

Fat Intake

TG

Total
Cholesterol
LDL

HDL

Protein Intake

TG

Total
Cholesterol
LDL

HDL

Cholesterol
Intake

TG

Total
Cholesterol
LDL

Europe

16

United
States
Europe

17

United
States
Europe

17

United
States
Europe

19

Minimum
(24.6%)
Maximum
(38.2%)
Minimum
(24.6%)
Maximum
(38.2%)
Minimum
(24.6%)
Maximum
(38.2%)
Minimum
(24.6%)
Maximum
(38.2%)
Minimum
(10%)
Maximum
(22.2%)
Minimum
(10%)
Maximum
(22.2%)
Minimum
(10%)
Maximum
(22.2%)
Minimum
(10%)
Maximum
(22.2%)
Minimum
(28)
Maximum
(300)
Minimum
(28)
Maximum
(300)
Minimum
(28)

11

17

17

19

11
14
14
12
12
14
14
7
7
9
9
9
9
9
9
7
7
9
9
9

-0.02
(-0.23, 0.19)
-0.51
(-0.71, -0.32)
-0.29
(-0.54, -0.04)
-0.30
(-0.46, -0.14)
-0.24
(-0.42, -0.07)
-0.15
(-0.41, 0.11)
-0.03
(-0.34, 0.27)
0.11
(-0.36, 0.58)
-0.59
(-1.60, 0.42)
-0.62
(-1.03, -0.21)
0.43
(-0.50, 1.36)
-0.49
(-0.92, -0.06)
-0.26
(-0.63, 1.14)
-0.15
(-0.43, 0.14)
0.47
(-0.15, 1.10)
-0.07
(-0.45, 0.31)
-0.02
(-0.46, 0.43)
0.16
(-0.45, 0.77)
-0.63
(-1.27, 0.01)
-0.06
(-0.47, 0.35)
-0.55
(-1.07, 0.03)
0.31
(-0.04, 0.66)
-0.45
(-0.89, -0.01)
0.11
(-0.20, 0.41)
-0.05
(-0.21, 0.11)
-0.65
(-1.23, -0.08)
-0.10
(-0.34, 0.14)
-0.84
(-1.39, -0.29)

0.00%

0.96

22.71%

0.03

0.00%

0.45

0.00%

0.54

0.00%

0.38

1.97%

0.16

0.00%

0.73

0.00%

0.72

0.00%

0.72

33.73%

0.008

33.73%

0.008

27.57%

0.049

27.57%

0.049

0.00%

0.69

0.00%

0.69

0.00%

0.89

0.00%

0.89

1.42%

0.19

1.42%

0.19

0.00%

0.26

0.00%

0.26

13.83%

0.04

13.83%

0.04

0.00%

0.44

0.00%

0.44

13.38%

0.11

13.38%

0.11

35.05%

0.03
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HDL

Fiber Intake

TG

Total
Cholesterol
LDL

HDL

Maximum
(300)
Minimum
(28)
Maximum
(300)
Minimum
(23.6)
Maximum
(57)
Minimum
(23.6)
Maximum
(57)
Minimum
(23.6)
Maximum
(57)
Minimum
(23.6)
Maximum
(57)

9
9
9
6
6
8
8
8
8
8
8

-0.12
(-0.34, 0.10)
-0.54
(-0.85, -0.23)
0.19
(0.12, 0.26)
-0.24
(-0.50, 0.0006)
0.40
(-0.21, 1.02)
-0.05
(-0.37, 0.27)
-0.83
(-1.64, -0.03)
-0.07
(-0.39, 0.25)
-0.94
(-1.76, -0.11)
0.20
(-0.10, 0.50)
-0.81
(-1.60, -0.02)

35.05%

0.03

100%

<.0001

100%

<.0001

43.23%

0.09

43.23%

0.09

13.50%

0.13

13.50%

0.13

18.26%

0.10

18.26%

0.10

15.64%

0.04

15.64%

0.04
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Table 9: Low-Fat Diet with Statins Significant Moderator Analysis Results
Variable
Proportion of
Females

Outcome
TG

Category
0% (min)

K
27

100%
(max)
0% (min)

27

37

LDL

100%
(max)
0% (min)

36

HDL

100%
(max)
0% (min)

37

TG

100%
(max)
5 (min)

113 (max)

12

5 (min)

21

113 (max)

21

5 (min)

21

113 (max)

21

5 (min)

21

113 (max)

21

3 (min)

27

208 (max)

27

3 (min)

37

208 (max)

37

3 (min)

36

208 (max)

36

3 (min)

37

208 (max)

37

19 (min)

27

3390
(max)

27

Total
Cholesterol

Number of
Subjects with
Cardiovascular
Disease

Total
Cholesterol
LDL

HDL

Length of
Intervention

TG

Total
Cholesterol
LDL

HDL

Intervention
Group Size

TG

37

36

37

12

d+(95%CI)
-0.44
(-0.71, -0.16)
-0.43
(-0.97, 0.12)
-1.35
(-1.73, -0.96)
-2.13
(-2.62, -1.65)
-1.31
(-1.75, -0.18)
-2.37
(-2.93, -1.80)
0.27
(0.13, 0.41)
0.50
(0.35, 0.66)
-0.34
(-0.80, 0.11)
-0.62
(-1.30, 0.06)
-0.99
(-1.40, -0.59)
-2.55
(-3.02, -2.08)
-0.96
(-1.33, -0.60)
-2.67
(-3.09, -2.25)
0.22
(0.05, 0.38)
0.59
(0.42, 0.76)
-0.45
(-0.65, -0.26)
-0.31
(-1.14, 0.52)
-1.39
(-1.67, -1.11)
-3.71
(-5.09, -2.33)
-1.40
(-1.73, -1.08)
-4.10
(-5.67, -2.53)
0.29
(0.18, 0.41)
0.85
(0.35, 1.35)
-0.34
(-0.49, -0.19)
-0.96
(-1.48, -0.45)

2

R
0.00%

p-value
0.98

0.00%

0.98

10.43%

0.04

10.43%

0.04

14.76%

0.02

14.76%

0.02

16.62%

0.08

16.62%

0.08

0.00%

0.60

0.00%

0.60

49.05%

<.0001

49.05%

<.0001

60.15%

<.0001

60.15%

<.0001

25.43%

0.008

25.43%

0.008

0.00%

0.77

0.00%

0.77

19.22%

0.004

19.22%

0.004

23.64%

0.003

23.64%

0.003

8.93%

0.06

8.93%

0.06

16.73%

0.04

16.73%

0.04
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Total
Cholesterol

Number of
Intervention
Groups

19 (min)

37
37

LDL

3390
(max)
19 (min)

36

HDL

3390
(max)
19 (min)

36

TG

3390
(max)
1 (min)
5 (max)

27

1 (min)

37

5 (max)

37

1 (min)

36

5 (max)

36

1 (min)

36

5 (max)

36

Governme
nt
Private

17

Governme
nt
Private

27

Governme
nt
Private

26

Governme
nt
Private

26

17% (min)

27

30% (max)

27

17% (min)

37

30% (max)

37

17% (min)

36

Total
Cholesterol
LDL

HDL

Funding Source

TG

Total
Cholesterol
LDL

HDL

Proportion of
Recommended
Fat Intake

TG

Total
Cholesterol
LDL

36

36

27

17

27

26

26

-1.46
(-1.71, -1.22)
-2.36
(-2.85, -1.88)
-1.52
(-1.81, -1.23)
-2.45
(-3.02, -1.87)
0.30
(0.20, 0.39)
0.55
(0.39, 0.70)
-0.46
(-0.74, -0.18)

22.16%

0.003

22.16%

0.003

19.23%

0.009

19.23%

0.009

16.58%

0.02

16.58%

0.02

0.00%

0.81

-0.40
(-0.71, -0.09)
-1.17
(1.62, -0.72)
-2.07
(-2.43, -1.71)
-1.29
(-1.83, -0.75)
-2.09
(-2.52, -1.66)
0.12
(-0.03, 0.27)
0.57
(0.45, 0.68)
-0.58
(-0.83, -0.32)
-0.26
(-0.59, 0.08)
-1.76
(-2.08, -1.43)
-1.36
(-1.92, -0.80)
-1.72
(-2.09, -1.36)
-1.46
(-2.09, -0.83)
0.48
(0.38, 0.58)
0.15
(-0.05, 0.34)
-0.36
(-0.64, -0.09)

0.00%

0.81

17.62%

0.01

17.62%

0.01

12.26%

0.06

12.26%

0.06

35.03%

<.0001

35.03%

<.0001

5.64%

0.13

5.64%

0.13

3.94%

0.23

3.94%

0.23

0.00%

0.48

0.00%

0.48

16.44%

0.003

16.44%

0.003

0.00%

0.56

0.00%

0.56

9.66%

0.048

9.66%

0.048

0.00%

0.25

-0.49
(-0.55, -0.31)
-1.43
(-1.94, -0.93)
-1.72
(-1.96, -1.49)
-2.13
(-2.82, -1.44)
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HDL

Proportion of
Recommended
Carbohydrate
Intake

TG

Total
Cholesterol
LDL

HDL

Proportion of
Recommended
Protein Intake

TG

Total
Cholesterol
LDL

HDL

Recommended
Cholesterol
Intake

TG

Total
Cholesterol
LDL

HDL

30% (max)

36

17% (min)

37

30% (max)

37

42.1%
(min)

18

67% (max)

18

42.1%
(min)
67% (max)

28

42.1%
(min)
67% (max)

27

42.1%
(min)
67% (max)

27

15% (min)

18

21% (max)

18

15% (min)

28

21% (max)

28

15% (min)

27

21% (max)

27

15% (min)

27

21% (max)

27

31 (min)

20

300(max)

20

31 (min)

30

300(max)

30

31 (min)

29

300(max)

29

31 (min)

29

28

27

27

-1.70
(-1.97, -1.42)
0.27
(0.07, 0.47)
0.39
(0.31, 0.47)
-0.67
(-1.24, -0.10)

0.00%

0.25

2.47%

0.26

2.47%

0.26

0.00%

0.50

-0.31
(-0.85, 0.23)
-2.88
(-3.67, -2.09)
-0.64
(-1.37, 0.10)
-2.64
(-3.59, -1.68)
-0.83
(-1.72, 0.06)
0.36
(-0.01, 0.73)
0.43
(0.08, 0.79)
-0.53
(-0.73, -0.32)

0.00%

0.50

26.85%

0.003

26.85%

0.003

11.90%

0.046

11.90%

0.046

0.00%

0.84

0.00%

0.84

0.00%

0.35

0.00%

0.35

1.84%

0.30

1.84%

0.30

0.60%

0.42

0.60%

0.42

12.52%

0.04

12.52%

0.04

7.30%

0.10

7.30%

0.10

6.94%

0.11

6.94%

0.11

4.62%

0.19

4.62%

0.19

18.05%

0.02

-0.13
(-0.90, 0.65)
-1.76
(-2.01, -1.51)
-1.23
(-2.16, -0.30)
-1.74
(-2.02, -1.45)
-1.13
(-2.55, 0.29)
0.43
(0.33, 0.52)
-0.21
(-0.80, 0.38)
-0.13
(-0.58, 0.33)
-0.59
(-0.79, -0.38)
-1.17
(-1.90, -0.45)
-1.85
(-2.12, -1.58)
-1.16
(-2.03, -0.29)
-1.82
(-2.12, -1.52)
-0.0062
(-0.34, 0.33)
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300(max)
Reported
Macronutrient
Distribution

TG

Total
Cholesterol
LDL

HDL

Provision of
Food

TG

Total
Cholesterol
LDL

HDL

29

Yes

27

No

27

Yes

37

No

37

Yes

36

No

36

Yes

36

No

36

Yes

27

No

27

Yes

37

No

37

Yes

36

No

36

Yes

36

0.44
(0.35, 0.53)
-0.36
(-0.66, -0.07)

18.05%

0.02

0.00%

0.60

-0.45
(-0.60, -0.30)
-1.82
(-2.42, -1.22)
-0.16
(-0.81, -1.42)
-2.39
(-3.08, -1.70)
-1.65
(-1.92, -1.34)
0.34
(0.13, 0.55)
0.34
(0.29, 0.46)
-0.46
(-0.60, -0.32)
-0.16
(-0.59, 0.27)
-1.75
(-1.96, -1.54)
-0.81
(-1.57, -0.05)
-1.82
(-2.07, -1.56)
-0.92
(-1.81, -0.03)
0.39
(-0.65, 0.07)

0.00%

0.60

0.00%

0.62

0.00%

0.62

5.39%

0.049

5.39%

0.049

0.00%

0.76

0.00%

0.76

2.93%

0.19

2.93%

0.19

14.38%

0.02

14.38%

0.02

9.88%

0.06

9.88%

0.06

5.12%

0.12
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Table 10: Non-Significant Moderators
Mediterranean Diet

Low-Fat Diet

Journal impact factor
Intervention setting
Publication year
Methodological quality
coding score
Subjects recruited by a
hospital
Subject ethnicity
Mean subject age
Proportion with
hypertension
Proportion with Diabetes
Mellitus
Proportion taking ACE
inhibitors
Number taking ACE
inhibitors
Proportion taking statins
Proportion of females
Proportion of current
smokers
Provision of food
Reported macronutrient
distribution
Dietary fat intake
Monitoring dietary
adherence
Weight loss
Number of intervention
groups
Type of control group
Length of weeks between
follow-ups

Impact Per Publication
Score
Methodological Quality
Score
Government Funding
Private Party Funding
Intervention Group Size
Current Smokers
Proportion of Subjects
with Cardiovascular
Disease
Proportion of Subjects
with Type II Diabetes
Mellitus
Number of Subjects with
Type II Diabetes Mellitus
Number of Subjects with
Dyslipidemia
Proportion of Subjects
Using Diuretics
Number of Subjects
Using Diuretics
Subjects Taking Aspirin
Supervision Level – Oneon-One
Supervision Level –
Small Group
Weight Loss
Number of Follow-Ups
Length (in Weeks)
Between Follow-Ups
Monitoring Diet During
Intervention
Assessment of
Compliance
Number of Subjects Lost
to Follow-Up
Recommended
Saturated Fat Intake

Low-Fat Diet with
Statins
Journal impact factor
Intervention setting
Publication year
Methodological quality
coding score
Subjects recruited by a
hospital
Subject ethnicity
Proportion with
hypertension
Proportion with
cardiovascular disease
Proportion of current
smokers
Statin dose (mg)
Recommended sodium
intake
Length of weeks between
follow-up
Number of follow-up
sessions
Number of subjects lost
to follow-up
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Table 11: Moderators Unable to Analyze Due to Lack of Reported Information
Mediterranean Diet

Low-Fat Diet

Proportion with
Cardiovascular Disease
Proportion with Metabolic
Syndrome
Use of beta-blockers
Use of nitrates
Use of diuretics
Use of NSAIDs
Use of fibrates
Recommended protein
intake
Recommended dietary
sodium intake
Recommended dietary
cholesterol intake
Recommended dietary
saturated fat intake
Recommended dietary
fiber intake
Recommended
vegetable servings
Recommended dairy
servings
Recommended meat
servings
Recommended poultry
servings
Recommended fish
servings
Academic/University
funding source
Private funding source

Subject Ethnicity
Method of Recruiting
Subjects
Proportion with
Overweight/Obesity
Number with
Overweight/Obesity
Proportion with Metabolic
Syndrome
Number with Metabolic
Syndrome
Proportion Using BetaBlockers
Number Using BetaBlockers
Proportion Using Nitrates
Number Using Nitrates
Proportion Using Calcium
Channel Blockers
Number Using Calcium
Channel Blockers
Oral Contraceptive or
Hormone Replacement
Therapy
Alcohol Consumption
Weight gain
Weight maintenance
Caloric Intake
Unsaturated Fat Intake
Recommended Sodium
Intake
Servings of Vegetables
Servings of Dairy
Servings of Wine
Servings of Grains
Servings of Fish
Servings of Oil
Servings of Nuts
Servings of Legumes
Servings of Meat
Servings of Poultry
Quality of Life

Low-Fat Diet with
Statins
Proportion with Diabetes
Mellitus
Proportion with Metabolic
Syndrome
Use of ACE inhibitors
Use of beta-blockers
Use of nitrates
Use of diuretics
Use of fibrates
Use of calcium channel
blockers
Adherence to dietary
intervention
Weight loss
Provision of food
Recommended dietary
unsaturated fat intake
Recommended
vegetable servings
Recommended dairy
servings
Recommended meat
servings
Recommended poultry
servings
Recommended fish
servings
Alcohol use
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Appendix
Appendix 1: Comprehensive Literature Search: Mediterranean Diet
PubMed (1940s to present)
Terms were searched in all fields; however, field labels were used to
restrict specific terms/phrases to the Medical Subject Headings [Mesh],
publication type [pt] and journal name [ta] fields.
("Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean dietary" OR
"Mediterranean style diet" OR "Mediterranean style diets" OR "Diet,
Mediterranean"[Mesh]) AND (“Antihyperlipidemic medication”
OR “Antihyperlipidemic medications” OR statin OR statins OR “HMG-CoA
Reductase” OR “cholesterol lowering agents” OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “nicotinic acid”
OR niacin OR “fibric acid derivatives” OR “fibrates” OR “cholesterol absorption
inhibitors” OR “hydroxymethylglutaryl-CoA” OR "hydroxymethylglutaryl-coa
reductase inhibitors"[Pharmacological Action] OR "hydroxymethylglutaryl-coa
reductase inhibitors"[MeSH Terms] OR ("hydroxymethylglutaryl-coa"[All Fields]
AND "reductase"[All Fields] AND "inhibitors"[All Fields]) OR statin* OR "HMGCoA Reductase"[All Fields] OR "HMG-CoA"[All Fields] OR
"hydroxymethylglutaryl-CoA"[All Fields] OR "atorvastatin" OR
"simvastatin"[MeSH Terms] OR "simvastatin" OR "rosuvastatin" OR
"pravastatin"[MeSH Terms] OR "pravastatin" OR "lovastatin"[MeSH Terms] OR
"lovastatin" OR "pitavastatin"[Supplementary Concept] OR "pitavastatin" OR
"fluvastatin"[Supplementary Concept] OR "fluvastatin" OR
"cerivastatin"[Supplementary Concept] OR "cerivastatin" OR
"mevastatin"[Supplementary Concept] OR "mevastatin" OR "cardiovascular
disease" OR "Cardiovascular Diseases"[Mesh] OR "cardiovascular diseases" OR
"heart disease" OR "heart diseases" OR CVD OR CVDs OR
"Hypertension"[Mesh] OR hypertension OR hypertensive* OR "high blood
pressure" OR "Myocardial Infarction"[Mesh] OR "myocardial infarction" OR
"myocardial infarct" OR "MI" OR "heart attack" OR "Stroke"[Mesh] OR stroke OR
"Coronary Artery Disease"[Mesh] OR "coronary artery disease" OR "coronary
arterial disease" OR "coronary heart disease" OR "Cerebrovascular
Disorders"[Mesh] OR "Cerebrovascular Disorders" OR "cerebrovascular disease"
OR "cerebrovascular diseases" OR "Atherosclerosis"[Mesh] OR atherosclerosis
OR "Arteriosclerosis"[Mesh] OR arteriosclerosis OR "Peripheral Vascular
Diseases"[Mesh] OR "peripheral vascular diseases" OR "peripheral vascular
disease" OR "peripheral angiopathy" OR "peripheral angiopathies" OR
"Peripheral Arterial Disease"[Mesh] OR "peripheral arterial disease" OR
"peripheral arterial diseases" OR "peripheral artery disease" OR "peripheral
artery diseases" OR "Venous Thrombosis"[Mesh] OR "venous thrombosis"
OR "venous thromboses" OR "deep vein thrombosis" OR "deep
vein thromboses" OR "Pulmonary Embolism"[Mesh] OR "pulmonary embolism"
OR "pulmonary embolisms" OR "Dyslipidemias"[Mesh] OR dyslipidemia OR
dyslipidemias OR "Hypercholesterolemia"[Mesh] OR hypercholesterolemia
OR hypercholesterolemias OR "Aortic Valve Stenosis"[Mesh] OR "Aortic Valve
Stenosis" OR "aortic stenosis" OR "aortic stenoses" OR "Aneurysm"[Mesh] OR
Aneurysm OR aneurysms OR Aneurism OR regurgitation OR prolapse) AND
(("clinical"[tiab] AND "trial"[tiab]) OR "clinical trials as topic"[mesh] OR "clinical
trial"[pt] OR random*[tiab] OR "random allocation"[mesh] OR "therapeutic
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use"[sh]) NOT ("Case Reports"[pt] OR Comment[pt] OR Editorial[pt] OR Letter[pt]
OR "case control"[ti] OR "case report"[ti] OR "case study"[ti] OR "case series"[ti]
OR "Case-Control Studies"[Mesh] OR "Follow-Up Studies"[Mesh] OR
"observational study"[ti] OR "prospective cohort"[ti] OR "cohort studies"
[Mesh:NoExp] OR "cohort study"[ti] OR "Follow-Up Studies"[mesh] OR
"Retrospective Studies"[mesh] OR "non-randomized"[ti] OR "follow up study"[ti]
OR rat[ti] OR rats[ti] OR mice[ti] OR mouse[ti] OR dog[ti] OR dogs[ti] OR cats[ti]
OR (animals[MH] NOT humans[MH]))
Results: 607
EMBASE (via Scopus) (1823 to present)
Limits: Article, review, conference papers, journals
All terms (unless otherwise noted) were searched in "Article Title,
Abstract, Keywords". Because of character restrictions in Scopus, this
search was run in parts and assembled using the "Search history".
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart
disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein
thrombosis" OR "pulmonary
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: "Clinical Trials" OR "clinical trial" OR random* OR "therapeutic use"
AND NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"
Results: 343
CINAHL (1981-present)
All terms were searched in all fields (unless otherwise noted)
Excluded: MEDLINE Records
Limited: Research Article
Due to database limitations, search was run in parts and assembled using
the search history.
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"
AND
(“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering agents”
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OR “lipid lowering agents” OR “HMG-CoA” OR “bile acid sequestrants”
OR “resins” OR “nicotinic acid” OR niacin OR “fibric acid derivatives”
OR “fibrates” OR “cholesterol absorption inhibitors” OR “hydroxymethylglutarylCoA” OR statin* OR "atorvastatin" OR "simvastatin" OR "simvastatin" OR
"rosuvastatin" OR "pravastatin” OR "lovastatin" OR "pitavastatin" OR
"fluvastatin" OR "cerivastatin" OR "mevastatin" OR "cardiovascular
disease" OR "cardiovascular diseases" OR "heart disease" OR "heart
diseases" OR CVD OR CVDs OR hypertension OR hypertensive* OR "high
blood pressure" OR "myocardial infarction" OR "myocardial
infarct" OR "MI" OR "heart attack" OR stroke OR "coronary artery
disease" OR "coronary arterial disease" OR "coronary heart disease" OR
"Cerebrovascular Disorders" OR "cerebrovascular disease" OR "cerebrovascular
diseases" OR atherosclerosis OR arteriosclerosis OR "peripheral vascular
diseases" OR "peripheral vascular disease" OR
"peripheral angiopathy" OR "peripheral angiopathies" OR "peripheral arterial
disease" OR "peripheral arterial diseases" OR "peripheral artery
disease" OR "peripheral artery diseases" OR "venous thrombosis"
OR "venous thromboses" OR "deep vein thrombosis" OR "deep
vein thromboses" OR "Pulmonary Embolism" OR "pulmonary embolisms" OR
dyslipidemia OR dyslipidemias OR hypercholesterolemia
OR hypercholesterolemias OR "Aortic Valve Stenosis" OR "aortic
stenosis" OR "aortic stenoses" OR Aneurysm OR aneurysms OR Aneurism OR
regurgitation OR prolapse)
AND
Option 1: (clinical AND trial)
OR
Option 2: (MH "Clinical Trials+") OR "clinical trial" OR random* OR (MH "Random
Assignment") OR "therapeutic use"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"
Results : 9
PsycINFO (1872 to present)
Limits: academic journals
Due to database limitations, search was run in parts and assembled using
the search history.
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart
disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart
disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein
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thrombosis" OR "pulmonary
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (DE "Clinical Trials") OR "clinical trial" OR random* OR (DE "Random
Sampling") OR "therapeutic use"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"
Results: 14
Academic Search Premier (1980s to present)
Limit: Scholarly (Peer Reviewed) Journals
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart
disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart
disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein
thrombosis" OR "pulmonary
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (random* OR "therapeutic use")
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"
Results: 208
Agricola (1970-present)
Searched in "All Fields"
Limits: academic journals
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart
disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
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pressure" OR "myocardial infarction" OR "MI" OR "heart
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart
disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein
thrombosis" OR "pulmonary
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (random* OR "therapeutic use")
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"
Results: 40
CAB Direct (1973-present)
Limit to Document Type: Journal article and Evidence based research
articles only
"Mediterranean diet" OR "Mediterranean diets" OR "Mediterranean
dietary" OR "Mediterranean style diet" OR "Mediterranean style diets"
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart
disease" OR "heart
diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart
attack" OR "stroke" OR "coronary artery disease" OR "coronary heart
disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein
thrombosis" OR "pulmonary
embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
Option 1: (clinical AND trial)
OR
Option 2: (random* OR "therapeutic use")
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized"
Results: 0 results
Grand Total 1221
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Appendix 2: Comprehensive Literature Search: Low-Fat Diet
PubMed (1940s to present)
Terms were searched in all fields; however, field labels were used to
restrict specific terms/phrases to the Medical Subject Headings [Mesh],
publication type [pt] and journal name [ta] fields.
(diet[majr] OR diet[ti] OR diets[ti] OR dietary[ti] OR “Dietary Fats” [majr] OR “low
fat”[ti] OR “reduced fat”[ti] OR (“American Heart Association”[tiab] AND
diet) OR (“Therapeutic lifestyle change” AND diet) OR (“therapeutic lifestyle
changes” AND diet) OR “DASH” OR “Dietary Approaches to Stop
Hypertension” OR (“National Cholesterol Education Program” AND diet) OR “fat
restricted”[ti] OR “lower fat”[ti] OR “hypolipidemic”[ti])
AND (“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR
statin OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering agents”
OR “lipid lowering agents” OR “HMG-CoA” OR “bile acid sequestrants”
OR “resins” OR “fibric acid derivatives” OR “fibrates” OR “cholesterol
absorption inhibitors” OR “hydroxymethylglutaryl-CoA” OR
"hydroxymethylglutaryl-coa reductase inhibitors"[Pharmacological Action] OR
"hydroxymethylglutaryl-coa reductase inhibitors"[MeSH Terms] OR
("hydroxymethylglutaryl-coa"[All Fields] AND "reductase"[All Fields] AND
"inhibitors"[All Fields]) OR statin* OR "HMG-CoA Reductase"[All Fields] OR
"HMG-CoA"[All Fields] OR "hydroxymethylglutaryl-CoA"[All Fields] OR
"atorvastatin" OR "simvastatin"[MeSH Terms] OR "simvastatin" OR
"rosuvastatin" OR "pravastatin"[MeSH Terms] OR "pravastatin" OR
"lovastatin"[MeSH Terms] OR "lovastatin" OR "pitavastatin"[Supplementary
Concept] OR "pitavastatin" OR "fluvastatin"[Supplementary Concept] OR
"fluvastatin" OR "cerivastatin"[Supplementary Concept] OR "cerivastatin" OR
"mevastatin"[Supplementary Concept] OR "mevastatin” OR pravachol OR Zocor
OR Lipitor) AND ("cardiovascular disease" OR "Cardiovascular Diseases"[Mesh]
OR "cardiovascular diseases" OR "heart disease" OR "heart diseases" OR CVD
OR CVDs OR "Hypertension"[Mesh] OR hypertension OR hypertensive* OR
"high blood pressure" OR "Myocardial Infarction"[Mesh] OR "myocardial
infarction" OR "myocardial infarct" OR "MI" OR "heart attack" OR "Stroke"[Mesh]
OR stroke OR "Coronary Artery Disease"[Mesh] OR "coronary artery disease"
OR "coronary arterial disease" OR "coronary heart disease" OR
"Cerebrovascular Disorders"[Mesh] OR "Cerebrovascular Disorders" OR
"cerebrovascular disease" OR "cerebrovascular diseases" OR
"Atherosclerosis"[Mesh] OR atherosclerosis OR "Arteriosclerosis"[Mesh] OR
arteriosclerosis OR "Peripheral Vascular Diseases"[Mesh] OR "peripheral
vascular diseases" OR "peripheral vascular disease" OR "peripheral angiopathy"
OR "peripheral angiopathies" OR "Peripheral Arterial Disease"[Mesh] OR
"peripheral arterial disease" OR "peripheral arterial diseases" OR "peripheral
artery disease" OR "peripheral artery diseases" OR "Venous Thrombosis"[Mesh]
OR "venous thrombosis" OR "venous thromboses" OR "deep vein thrombosis"
OR "deep vein thromboses" OR "Pulmonary Embolism"[Mesh] OR "pulmonary
embolism" OR "pulmonary embolisms" OR "Dyslipidemias"[Mesh] OR
dyslipidemia OR dyslipidemias OR "Hypercholesterolemia"[Mesh] OR
hypercholesterolemia OR hypercholesterolemias OR "Aortic Valve
Stenosis"[Mesh] OR "Aortic Valve Stenosis" OR "aortic stenosis" OR
"aortic stenoses" OR "Aneurysm"[Mesh] OR Aneurysm OR aneurysms OR
Aneurism OR regurgitation OR prolapse) AND (("clinical"[tiab] AND "trial"[tiab])
82

OR "clinical trials as topic"[mesh] OR "clinical trial"[pt] OR random*[tiab] OR
"random allocation"[mesh] OR "therapeutic use"[sh]) NOT (review[pt] OR "Case
Reports"[pt] OR Comment[pt] OR Editorial[pt] OR Letter[pt] OR "case
control"[ti] OR polymorphism*[ti] OR allele*[ti] OR "case report"[ti] OR "case
study"[ti] OR "case series"[ti] OR "Case-Control Studies"[Mesh] OR "Follow-Up
Studies"[Mesh] OR "observational study"[ti] OR "prospective cohort"[ti] OR
"cohort studies" [Mesh:NoExp] OR "cohort study"[ti] OR "Follow-Up
Studies"[mesh] OR "Retrospective Studies"[mesh] OR "non-randomized"[ti] OR
"follow up study"[ti] OR rat[ti] OR rats[ti] OR rabbit*[ti] OR mice[ti] OR mouse[ti]
OR dog[ti] OR dogs[ti] OR cats[ti] OR animal*[ti] OR (animals[MH] NOT
humans[MH]) OR "Renal Insufficiency, Chronic"[MeSH] OR renal[ti]
OR renoprotection[ti] OR (("infant"[MeSH Terms] OR "child"[MeSH Terms] OR
"adolescent"[MeSH Terms]) NOT "adult"[MeSH Terms]))
Results: 409
EMBASE (via Scopus) (1823 to present)
Limits: Article, review, conference papers, journals
All terms (unless otherwise noted) were searched in "Article Title,
Abstract, Keywords". Because of character restrictions in Scopus, this
search was run in parts and assembled using the "Search history".
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic
lifestyle changes” OR “DASH” OR “National Cholesterol Education Program” OR
“fat restricted” OR “lower fat” OR “hypolipidemic”
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering
agents” OR Lipitor OR pravachol OR Zocor OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “fibric acid
derivatives” OR “fibrates” OR “cholesterol absorption inhibitors”
OR “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin"
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"
Option 1: (clinical AND trial)
OR
Option 2: "Clinical Trials" OR "clinical trial" OR random* OR "therapeutic use"
AND NOT
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(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*
Results 165
CINAHL (1981-present)
All terms were searched in all fields (unless otherwise noted)
Excluded: MEDLINE Records
Limited: Research Article
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic
lifestyle changes” OR “DASH” OR “National Cholesterol Education Program” OR
“fat restricted” OR “lower fat” OR “hypolipidemic”
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering
agents” OR Lipitor OR pravachol OR Zocor OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “fibric acid
derivatives” OR “fibrates” OR “cholesterol absorption inhibitors”
OR “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin"
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*
Results: 6
PsycINFO (1872 to present)
Limits: peer reviewed journals
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(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic
lifestyle changes” OR “DASH” OR “National Cholesterol Education Program” OR
“fat restricted” OR “lower fat” OR “hypolipidemic”
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering
agents” OR Lipitor OR pravachol OR Zocor OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “fibric acid
derivatives” OR “fibrates” OR “cholesterol absorption inhibitors”
OR “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin"
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*
Results: 0
Academic Search Premier (1980s to present)
Limit: Scholarly (Peer Reviewed) Journals
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic
lifestyle changes” OR “DASH” OR “National Cholesterol Education Program” OR
“fat restricted” OR “lower fat” OR “hypolipidemic”
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
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AND
“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering
agents” OR Lipitor OR pravachol OR Zocor OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “fibric acid
derivatives” OR “fibrates” OR “cholesterol absorption inhibitors”
OR “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin"
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*
Results: 0
Agricola (1970-present)
Limits: journal article
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic
lifestyle changes” OR “DASH” OR “National Cholesterol Education Program” OR
“fat restricted” OR “lower fat” OR “hypolipidemic”
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering
agents” OR Lipitor OR pravachol OR Zocor OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “fibric acid
derivatives” OR “fibrates” OR “cholesterol absorption inhibitors”
OR “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin"
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"
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NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*
Results: 0
CAB Direct (1973-present)
Limit to Document Type: Journal article and Evidence based research
articles only
(in title) diet OR diets OR dietary OR “low fat” OR “reduced fat” OR “therapeutic
lifestyle changes” OR “DASH” OR “National Cholesterol Education Program” OR
“fat restricted” OR “lower fat” OR “hypolipidemic”
AND
"cardiovascular disease" OR "cardiovascular diseases" OR "heart disease" OR
"heart diseases" OR "CVD" OR "CVDs" OR "hypertension" OR "high blood
pressure" OR "myocardial infarction" OR "MI" OR "heart attack" OR "stroke" OR
"coronary artery disease" OR "coronary heart disease" OR "cerebrovascular
disease" OR "atherosclerosis" OR "arteriosclerosis" OR "peripheral vascular
disease" OR "peripheral artery disease" OR "deep vein thrombosis" OR
"pulmonary embolism" OR "dyslipidemia" OR "hypercholesterolemia" OR "aortic
stenosis" OR "Aneurism" OR "regurgitation" OR "prolapse"
AND
“Antihyperlipidemic medication” OR “Antihyperlipidemic medications” OR statin
OR statins OR “HMG-CoA Reductase” OR “cholesterol lowering
agents” OR Lipitor OR pravachol OR Zocor OR “lipid lowering agents”
OR “HMG-CoA” OR “bile acid sequestrants” OR “resins” OR “fibric acid
derivatives” OR “fibrates” OR “cholesterol absorption inhibitors”
OR “hydroxymethylglutaryl-CoA” OR statin* OR "atorvastatin" OR "simvastatin"
OR "simvastatin" OR "rosuvastatin" OR "pravastatin” OR "lovastatin" OR
"pitavastatin" OR "fluvastatin" OR "cerivastatin" OR "mevastatin"
NOT
(in title) rat OR rats OR mice OR mouse OR dog OR dogs OR cats OR "case
report" OR comment OR editorial OR letter OR "case control" OR "case study"
OR "case series" OR "follow-up study" OR "observational study" OR "prospective
cohort" OR "cohort study" OR "retrospective study" OR "non-randomized" OR
allele* OR polymorphism* OR animal* OR review OR renal OR renoprotect*
Results: 0
Total: 580
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Appendix 3: Coding Form
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Appendix 4: Methodological Quality Control Coding Form
•

•

•
•

•

•

•

•

•

MQ1_____ Random assignment
o 0 =Violated randomization and/or
nonequivalence of comparison group
was not addressed
o 1 = Quasi-experimental design;
arbitrary assignment; sequential; how:
_____________________
o 2 = Random assignment of groups of
individuals. What unit:
________________________________
o 3 = Matching individuals on some
variable What variable/s:
______________________________________
o 4 = True randomization (i.e.,
participants had equal chance of
receiving intervention)
MQ2_____ Quality control
0 = No
standardization of treatment is specified
o 1 = Treatment standardized by manual,
specific training, content coding, video
as main intervention strategy, etc
MQ3_____ Pretest post-test design (at least one
measure pre-post)? (0 = No, 1 = Yes)
MQ4_____ Follow-up rate (i.e., largest FU rate at
any delayed post-test, overall)
o 2 = 85-100% completed 1 = 70 – 84%
completed 0 = <70%
MQ5_____ Follow-up length (i.e., final assessment
interval)
o 2 = 6 months or longer 1 = > 3 months
or < 6 months 0 = less than 3 months
MQ6_____ Anonymity attempted (if face-to-face
interviews, mark as ‘0’)
o (0 = No/NR, 1 = Yes)
MQ7_____ Low reactivity of measure completion
(If they do not mention, code “.”)
o 0 = no, intervention and measurement
staff same and face-to-face interviews
used
o 1 = yes, used different personnel for
intervention and measurement (face-toface) or measurement technique not
highly reactive (written rather than oral
questions, even if given by same person
as intervention)
MQ8_____ Collateral verification of self-report
o 0 = No collateral verification, not
reported
o 1 = At least some collaterals
interviewed; if known, _________%
MQ9_____ Used objective measures (at FUP, not
just baseline or for inclusion criteria)

•

•

•

•

•

•

MQ10_____ Withdrawal/Drop-outs (**This
category applies to cases that withdrew after
randomization)
o 0 = Not reported or all non-completers
were excluded from analyses
o 1 = Enumerated and/or compared with
completed cases (e.g., intent-to-treat;
baseline differences)
MQ11_____Attrition (**This category applies to
cases lost to follow-up after treatment) 0 =
Cases lost to follow-up are not considered in
outcome reporting
o 1 = Enumerated and considered in
outcome reporting (e.g., included in all
possible analyses, imputed the mean for
lost cases, compared with non-attrition
at baseline)
MQ12_____ Independent/Double-blinding
o 0 = Follow-up non-blind, unspecified, or
questionnaire only
o 1 = Follow-up assessment completed by
independent interviewer blind to group
assignment
MQ13_____Analyses
o 0 = No inferential statistical analysis;
inappropriate, or unspecified
o 1 = Appropriate statistical analyses of
group or time points differences (e.g.,
comparing two groups/measures using
at least a t or F test but did not control
for other characteristics). Code this
category as well if they mention that
groups were comparable but do not
report any statistical information about
them at baseline or they do not mention
any statistical test they used to
demonstrate they did it.(i.e. test to
compare group at FUP)
o 2 = Controlled for baseline and/or other
characteristics in appropriate statistical
analyses of group differences (e.g.,
compared two groups using at least a t
or F test) (i.e. test to compare groups at
FUP that controls for baseline, or no
baseline differences found through test
and thus no need to control for post
comparison)
MQ14_____Pilot testing 0 = None previous pilot
testing of the intervention.
o 1 = There was a previous pilot testing of
the intervention.
MQ15_____Intervention content matched to
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o
o

0 = No objective measure used or
unspecified (i.e., self-report only)
1 = Objective measures used in more
than 50% of the cases

•
•

sample (0 = No/NR, 1 = Yes)
MQ16_____Incentives Offered (0 = No, 1 = Yes)
MQ17_____Total Methodological Quality Score
(out of 22 pts)

Appendix 5: SAS Code
proc means data=mdstatin n sum mean max min range std;
run;
proc freq data=mdstatin;
run;
proc means data=LFDstatin n sum mean max min range std;
run;
proc freq data=LFDstatin;
run;
Appendix 6: R Code for Mediterranean Diet
Fixed- and Random-Effects Models
> model1<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1),
data=MedDietStatins, method="FE")
> model1
> model2<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==1),
data=MedDietStatins, method="REML")
> model2
>model3<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2),
data=MedDietStatins, method="FE")
> model3
> model4<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==2),
data=MedDietStatins, method="REML")
> model4
> model5<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3),
data=MedDietStatins, method="FE")
> model5
>model6<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==3),
data=MedDietStatins, method="REML")
> model6
> model7<-rma(d.ex.,var_d.ex.,subset=(Diet==1&Outcome==4),
data=MedDietStatins, method="FE")
> model7
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> model8<-rma(d.ex.,var_d.ex.,subset=(Diet ==1&Outcome==4),
data=MedDietStatins, method="REML")
> model8
Forest Plots
forest(model2, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,15.5, "Triglycerides") #the first number indicates where the title starts and
the second number how high in the plot
text(c(-4,4),14.5,c("Favors Intervention", "Favors Baseline"))
text(-10,14.5, "Author(s) and Year", pos=4)
text(8,14.5, "d[95%CI]", pos=4)
par(op)
forest(model4, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=0.85, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,12.5, "Total Cholesterol")
text(c(-4,4),11.5,c("Favors Intervention", "Favors Baseline"))
text(-10,11.5, "Author(s) and Year", pos=4)
text(8,11.5, "d[95%CI]", pos=4)
par(op)
forest(model6, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=0.85, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,14.5, "LDL-Cholesterol")
text(c(-4,4),13.5,c("Favors Intervention", "Favors Baseline"))
text(-10,13.5, "Author(s) and Year", pos=4)
text(8,13.5, "d[95%CI]", pos=4)
par(op)
forest(model8, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=0.85, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,15.5, "HDL-Cholesterol")
text(c(-4,4),14.5,c("Favors Baseline", "Favors Intervention"))
text(-10,14.5, "Author(s) and Year", pos=4)
text(8,14.5, "d[95%CI]", pos=4)
par(op)
Publication Bias
#Egger’s
> regtest(model1, model="lm", data=MedDietStatins)
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> regtest(model3, model="lm", data= MedDietStatins)
> regtest(model5, model="lm", data= MedDietStatins)
> regtest(model7, model="lm", data= MedDietStatins)
#Begg’s
> ranktest(model1, data= MedDietStatins)
> ranktest(model3, data= MedDietStatins)
> ranktest(model5, data= MedDietStatins)
> ranktest(model7, data= MedDietStatins)
#Trim-and-Fill with Funnel Plots
> MTGtrim=trimfill(model1, data= MedDietStatins)
> funnel(MTGtrim)
> MTCtrim=trimfill(model3, data= MedDietStatins)
> funnel(MTCtrim)
>MLDLtrim=trimfill(model5, data= MedDietStatins)
>funnel(MLDLtrim)
> MHDLtrim=trimfill(model7, data= MedDietStatins)
>funnel(MHDLtrim)
Risk of Bias
RanSeq
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(RanSeq), data=Quality, method=”REML”)
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(RanSeq), data=Quality, method=”REML”)
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(RanSeq), data=Quality, method=”REML”)
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(AllCon)-1, data=Quality, method=”REML”)
> Summary(MHDLbias)
RanSeq-1
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1&Outcome==1), mods= ~
factor(RanSeq)-1, data=Quality, method="REML")
> Summary(MTGbias)
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>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(RanSeq)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(RanSeq)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(RanSeq)-1, data=Quality, method="REML")
> Summary(MHDLbias)
AllCon
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(AllCon), data=Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(AllCon), data=Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(AllCon), data=Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(AllCon), data=Quality, method="REML")
> Summary(MHDLbias)
AllCon-1
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(AllCon)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(AllCon)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(AllCon)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(AllCon)-1, data=Quality, method="REML")
> Summary(MHDLbias)
Blinding
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(Blinding), data= Quality, method="REML")
> Summary(MTGbias)
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>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(Blinding), data= Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(Blinding), data= Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(Blinding), data=Quality, method="REML")
> Summary(MHDLbias)
Blinding-1
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(Blinding)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(Blinding)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(Blinding)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(Blinding)-1, data= Quality, method="REML")
> Summary(MHDLbias)
Incomp
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(Incomp), data= Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(Incomp), data= Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(Incomp), data= Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(Incomp), data= Quality, method="REML")
> Summary(MHDLbias)
Incomp-1
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(Incomp)-1, data=Quality, method="REML")
> Summary(MTGbias)
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>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(Incomp)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(Incomp)-1, data= Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(Incomp)-1, data= Quality, method="REML")
> Summary(MHDLbias)
Select
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(Select), data= Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(Select), data= Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(Select), data= Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(Select), data= Quality, method="REML")
> Summary(MHDLbias)
Select-1
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(Select)-1, data= Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(Select)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(Select)-1, data=Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(Select)-1, data= Quality, method="REML")
> Summary(MHDLbias)
OtherBias
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(OtherBias), data= Quality, method="REML")
> Summary(MTGbias)
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>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(OtherBias), data= Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(OtherBias), data= Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(OtherBias), data= Quality, method="REML")
> Summary(MHDLbias)
OtherBias-1
> MTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==1),
mods=~factor(OtherBias)-1, data= Quality, method="REML")
> Summary(MTGbias)
>MCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==2),
mods=~factor(OtherBias)-1, data= Quality, method="REML")
> Summary(MTGbias)
>MLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==3),
mods=~factor(OtherBias)-1, data= Quality, method="REML")
> Summary(MTGbias)
>MHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==1 & Outcome==4),
mods=~factor(OtherBias)-1, data= Quality, method="REML")
> Summary(MHDLbias)
Moderator Analysis
#Statins
> model9<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Prop_Statins, data= MedDietStatins, method="REML")
> model9
> model10<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Prop_Statins, data= MedDietStatins, method="REML")
> model10
> model11<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Prop_Statins, data= MedDietStatins, method="REML")
>model11
> model12<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Prop_Statins, data= MedDietStatins, method="REML")
> model12
# Length of Intervention
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> MTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Weeks, data= MedDietStatins, method="REML")
> MTGwks
> MCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Weeks, data= MedDietStatins, method="REML")
> MCholwks
> MLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Weeks, data= MedDietStatins, method="REML")
> MLDLwks
> MHDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Weeks, data= MedDietStatins, method="REML")
> MHDLwks
# Proportion of Females
> MTGfem<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Female, data= MedDietStatins, method="REML")
> MTGfem
> MCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Female, data= MedDietStatins, method="REML")
> MCholfem
> MLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Female, data= MedDietStatins, method="REML")
> MLDLfem
> MHDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Female, data= MedDietStatins, method="REML")
> MHDLfem
# Region (Europe)
> MTGregion<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Region==2), data= MedDietStatins, method="REML")
> MTGregion
> MCholregion<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Region==2), data= MedDietStatins, method="REML")
> MCholregion
> MLDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
(Region==2), data= MedDietStatins, method="REML")
> MLDLregion
> MHDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Region==2), data= MedDietStatins, method="REML")
> MHDLregion
# Hypertension
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> MTGHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods= HTN,
data= MedDietStatins, method="REML")
> MTGHTN
> MCholHTN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
HTN, data= MedDietStatins, method="REML")
> MCholHTN
> MLDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
HTN, data= MedDietStatins, method="REML")
> MLDLHTN
> MHDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
HTN, data= MedDietStatins, method="REML")
> MHDLHTN
# Dyslipidemia
> MTGdys<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Dys,
data= MedDietStatins, method="REML")
> MTGdys
> MCholdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= Dys,
data= MedDietStatins, method="REML")
> MCholdys
> MLDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Dys,
data= MedDietStatins, method="REML")
> MLDLdys
#Med Diet and HDL-Cholesterol
> MHDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= Dys,
data= MedDietStatins, method="REML")
> MHDLdys
# Current Smokers
> MTGSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Smoke, data= MedDietStatins, method="REML")
> MTGSmoke
> MCholSmoke <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Smoke, data= MedDietStatins, method="REML")
> MCholSmoke
> MLDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Smoke, data= MedDietStatins, method="REML")
> MLDLSmoke
> MHDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Smoke, data= MedDietStatins, method="REML")
> MHDLSmoke
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# Impact Factor
> MTGIPP<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=IPP,
data= MedDietStatins, method="REML")
> MTGIPP
> MCholIPP <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
IPP, data= MedDietStatins, method="REML")
> MCholIPP
> MLDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= IPP,
data= MedDietStatins, method="REML")
> MLDLIPP
> MHDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= IPP,
data= MedDietStatins, method="REML")
> MHDLIPP
#Mean Age
> MTGage<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Age,
data= MedDietStatins, method="REML")
> MTGage
> MCholage <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Age, data= MedDietStatins, method="REML")
> MCholage
> MLDLage<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Age,
data= MedDietStatins, method="REML")
> MLDLage
> MHDLage <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Age, data= MedDietStatins, method="REML")
> MHDLage
#Proportion Fat Intake
> MTGfat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Fat,
data= MedDietStatins, method="REML")
> MTGfat
> MCholfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods= Fat,
data= MedDietStatins, method="REML")
> MCholfat
> MLDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Fat,
data= MedDietStatins, method="REML")
> MLDLfat
> MHDLfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= Fat,
data= MedDietStatins, method="REML")
> MHDLfat
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# Length Between Follow-Up
> MTGfu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=
FollowUp, data= MedDietStatins, method="REML")
> MTGfu
> MCholfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
FollowUp, data= MedDietStatins, method="REML")
> MCholfu
> MLDLfu<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
FollowUp, data= MedDietStatins, method="REML")
> MLDLfu
> MHDLfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
FollowUp, data= MedDietStatins, method="REML")
> MHDLfu
# Number of Follow-Ups
> MTGnofu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=NoFollowUp, data= MedDietStatins, method="REML")
> MTGnofu
> MCholnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
NoFollowUp, data= MedDietStatins, method="REML")
> MCholnofu
> MLDLnofu<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
NoFollowUp, data= MedDietStatins, method="REML")
> MLDLnofu
> MHDLnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
NoFollowUp, data= MedDietStatins, method="REML")
> MHDLnofu
# Provision of Food
> MTGProv<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Provision, data= MedDietStatins, method="REML")
> MTGProv
> MCholProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Provision, data= MedDietStatins, method="REML")
> MCholProv
> MLDLProv<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Provision, data= MedDietStatins, method="REML")
> MLDLProv
> MHDLProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Provision, data= MedDietStatins, method="REML")
> MHDLProv
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#Level of Supervision in Intervention
> MTGInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Interlvl, data= MedDietStatins, method="REML")
> MTGInterlvl
> MCholInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Interlvl, data= MedDietStatins, method="REML")
> MCholInterlvl
> MLDLInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Interlvl, data= MedDietStatins, method="REML")
> MLDLInterlvl
> MHDLInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Interlvl, data= MedDietStatins, method="REML")
> MHDLInterlvl
# Level of Supervision (One-on-one)
> MTGInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Interlvl==1), data= MedDietStatins, method="REML")
> MTGInterlvl1
> MCholInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
(Interlvl==1), data= MedDietStatins, method="REML")
> MCholInterlvl1
> MLDLInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
(Interlvl==1), data= MedDietStatins, method="REML")
> MLDLInterlvl1
> MHDLInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
(Interlvl==1), data= MedDietStatins, method="REML")
> MHDLInterlvl1
#Level of Supervision (Small Group)
> MTGInterlvl2<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Interlvl==2), data= MedDietStatins, method="REML")
> MTGInterlvl2
> MCholInterlvl2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
(Interlvl==2), data= MedDietStatins, method="REML")
> MCholInterlvl2
> MLDLInterlvl2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
(Interlvl==2), data= MedDietStatins, method="REML")
> MLDLInterlvl2
> MHDLInterlvl2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
(Interlvl==2), data= MedDietStatins, method="REML")
> MHDLInterlvl2
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# Methodological Quality Score
> MTGMQ<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=MQ,
data= MedDietStatins, method="REML")
> MTGMQ
> MCholMQ <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
MQ, data= MedDietStatins, method="REML")
> MCholMQ
> MLDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= MQ,
data= MedDietStatins, method="REML")
> MLDLMQ
> MHDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= MQ,
data= MedDietStatins, method="REML")
> MHDLMQ
# Reported Use of Blood Pressure Medication
> MTGBPMed<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=BPMed, data= MedDietStatins, method="REML")
> MTGBPMed
> MCholBPMed <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
BPMed, data= MedDietStatins, method="REML")
> MCholBPMed
> MLDLBPMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
BPMed, data= MedDietStatins, method="REML")
> MLDLBPMed
> MHDLBPMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
BPMed, data= MedDietStatins, method="REML")
> MHDLBPMed
#No Blood Pressure Medication
> MTGBPMed0<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
(mods=BPMed==0), data= MedDietStatins, method="REML")
>MTGBPMed0
> MCholBPMed0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(BPMed==0), data= MedDietStatins, method="REML")
> MCholBPMed0
> MLDLBPMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(BPMed==0), data= MedDietStatins, method="REML")
> MLDLBPMed0
> MHDLBPMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(BPMed==0), data= MedDietStatins, method="REML")
>MHDLBPMed0

106

# Reported Use of Other Medications
> MTGOMed<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=OtherMed, data= MedDietStatins, method="REML")
> MTGOMed
#Total Cholesterol
> MCholOMed <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
OtherMed, data= MedDietStatins, method="REML")
> MCholOMed
> MLDLOMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
OtherMed, data= MedDietStatins, method="REML")
> MLDLOMed
> MHDLOMed<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
OtherMed, data= MedDietStatins, method="REML")
> MHDLOMed
#No Other Medications
> MTGOMed0<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(OtherMed==0), data= MedDietStatins, method="REML")
> MTGOMed0
> MCholOMed0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(OtherMed==0), data= MedDietStatins, method="REML")
> MCholOMed0
> MLDLOMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(OtherMed==0), data= MedDietStatins, method="REML")
> MLDLOMed0
> MHDLOMed0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(OtherMed==0), data= MedDietStatins, method="REML")
> MHDLOMed0
# Diabetes Mellitus
> MTGDM<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=DM,
data= MedDietStatins, method="REML")
> MTGDM
> MCholDM <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
DM, data= MedDietStatins, method="REML")
> MCholDM
> MLDLDM<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= DM,
data= MedDietStatins, method="REML")
> MLDLDM
> MHDLDM<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= DM,
data= MedDietStatins, method="REML")
> MHDLDM
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# Intervention Sample Size
> MTGIntN<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=
n_post, data= MedDietStatins, method="REML")
> MTGIntN
> MCholIntN <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
n_post, data= MedDietStatins, method="REML")
> MCholIntN
> MLDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
n_post, data= MedDietStatins, method="REML")
> MLDLIntN
> MHDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
n_post, data= MedDietStatins, method="REML")
> MHDLIntN
# Total Sample Size
> MTGN<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Ntotal,
data= MedDietStatins, method="REML")
> MTGN
> MCholN <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Ntotal, data= MedDietStatins, method="REML")
> MCholN
> MLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods= Ntotal,
data= MedDietStatins, method="REML")
> MLDLN
> MHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods= Ntotal,
data= MedDietStatins, method="REML")
> MHDLN
# Participants Lost to Follow-Up
> MTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Part_lost, data= MedDietStatins, method="REML")
> MTGlost
> MChollost <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Part_lost, data= MedDietStatins, method="REML")
> MChollost
> MLDLDlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Part_lost, data= MedDietStatins, method="REML")
> MLDLlost
# HDL-Cholesterol
> MHDLlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Part_lost, data= MedDietStatins, method="REML")
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> MHDLlost
# Non-Diet Control + 3 interventions
> MTGctrl3<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Controlgrp==3), data= MedDietStatins, method="REML")
> MTGctrl3
> MCholctrl3 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Controlgrp==3), data= MedDietStatins, method="REML")
> MCholctrl3
> MLDLctrl3<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Controlgrp==3), data= MedDietStatins, method="REML")
> MLDLctrl3
> MHDLctrl3<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Controlgrp==3), data= MedDietStatins, method="REML")
> MHDLctrl3
# Non-Diet Control Group
> MTGctrl4<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Controlgrp==4), data= MedDietStatins, method="REML")
> MTGctrl4
> MCholctrl4 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Controlgrp==4), data= MedDietStatins, method="REML")
> MCholctrl4
> MLDLDctrl4<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Controlgrp==4), data= MedDietStatins, method="REML")
> MLDLctrl4
> MHDLctrl4<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Controlgrp==4), data= MedDietStatins, method="REML")
> MHDLctrl4
# Experimental Conditions: Diet Control Plus 1 Intervention
> MTGexp<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Experiment==4), data= MedDietStatins, method="REML")
> MTGexp
> MCholexp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Experiment==4), data= MedDietStatins, method="REML")
> MCholexp
> MLDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Experiment==4), data= MedDietStatins, method="REML")
> MLDLexp
> MHDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Experiment==4), data= MedDietStatins, method="REML")
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> MHDLexp
# Experimental Conditions: Diet Control Plus 2 Interventions
# Triglycerides
> MTGexp2<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Experiment==5), data= MedDietStatins, method="REML")
> MTGexp2
> MCholexp2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Experiment==5), data= MedDietStatins, method="REML")
> MCholexp2
> MLDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Experiment==5), data= MedDietStatins, method="REML")
> MLDLexp2
> MHDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Experiment==5), data= MedDietStatins, method="REML")
> MHDLexp2
#Experimental Setting (Hospital)
> MTGset<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(exp_setting==1), data= MedDietStatins, method="REML")
> MTGset
> MCholset <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(exp_setting==1), data= MedDietStatins, method="REML")
> MCholset
> MLDLset<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(exp_setting==1), data= MedDietStatins, method="REML")
> MLDLset
> MHDLset<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(exp_setting==1), data= MedDietStatins, method="REML")
> MHDLset
# Experimental Setting (Clinic)
> MTGset2<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(exp_setting==2), data= MedDietStatins, method="REML")
> MTGset2
> MCholset2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(exp_setting==2), data= MedDietStatins, method="REML")
> MCholset2
> MLDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(exp_setting==2), data= MedDietStatins, method="REML")
> MLDLset2
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> MHDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(exp_setting==2), data= MedDietStatins, method="REML")
> MHDLset2
# Diet Adherence Monitored
> MTGMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Monitor==1), data= MedDietStatins, method="REML")
> MTGMonitor
> MCholMonitor <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Monitor==1), data= MedDietStatins, method="REML")
> MCholMonitor
> MLDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Monitor==1), data= MedDietStatins, method="REML")
> MLDLMonitor
> MHDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Monitor==1), data= MedDietStatins, method="REML")
> MHDLMonitor
#Weight Loss
> MTGwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=(
WtGainLoss ==1), data= MedDietStatins, method="REML")
> MTGwtloss
> MCholwtloss <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=(
WtGainLoss ==1), data= MedDietStatins, method="REML")
> MCholwtloss
> MLDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=(
WtGainLoss ==1), data= MedDietStatins, method="REML")
> MLDLwtloss
> MHDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(WtGainLoss==1), data= MedDietStatins, method="REML")
> MHDLwtloss
#Proportion of Subjects Using ACE Inhibitors
> MTGace<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=ACEProp, data= MedDietStatins, method="REML")
> MTGace
> MCholace <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=ACEProp, data= MedDietStatins, method="REML")
> MCholace
> MLDLace<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
ACEProp, data= MedDietStatins, method="REML")
> MLDLace
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> MHDLace<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(WtGainLoss==1), data= MedDietStatins, method="REML")
> MHDLace
#Number of Subjects Using ACE Inhibitors
> MTGaceno<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=ACENo, data= MedDietStatins, method="REML")
> MTGaceno
> MCholaceno <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=ACENo, data= MedDietStatins, method="REML")
> MCholaceno
> MLDLaceno <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=ACENo, data= MedDietStatins, method="REML")
> MLDLaceno
> MHDLaceno<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=ACENo, data= MedDietStatins, method="REML")
> MHDLaceno
#Subjects Taking Aspirin
> MTGaspirin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Aspirin==1), data= MedDietStatins, method="REML")
> MTGaspirin
> MCholaspirin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Aspirin==1), data= MedDietStatins, method="REML")
> MCholaspirin
> MLDLaspirin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Aspirin==1), data= MedDietStatins, method="REML")
> MLDLaspirin
> MHDLaspirin<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Aspirin==1), data= MedDietStatins, method="REML")
> MHDLaspirin
#No Subjects Taking Aspirin
> MTGasp<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Aspirin==0), data= MedDietStatins, method="REML")
> MTGasp
> MCholasp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Aspirin==0), data= MedDietStatins, method="REML")
> MCholasp
> MLDLasp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Aspirin==0), data= MedDietStatins, method="REML")
> MLDLasp
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> MHDLasp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Aspirin==0), data= MedDietStatins, method="REML")
> MHDLasp
#Funding Source (Government)
> MTGfund<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Funding==1), data= MedDietStatins, method="REML")
> MTGfund
> MCholfund <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Funding==1), data= MedDietStatins, method="REML")
> MCholfund
> MLDLfund <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Funding==1), data= MedDietStatins, method="REML")
> MLDLfund
> MHDLfund<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Funding==1), data= MedDietStatins, method="REML")
> MHDLfund
#Recruitment (Clinical/Hospital)
> MTGrecruit<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=(Recruit==3), data= MedDietStatins, method="REML")
> MTGrecruit
> MCholrecruit <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2),
mods=(Recruit==3), data= MedDietStatins, method="REML")
> MCholrecruit
> MLDLrecruit <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(Recruit==3), data= MedDietStatins, method="REML")
> MLDLrecruit
> MHDLrecruit<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4),
mods=(Recruit==3), data= MedDietStatins, method="REML")
> MHDLrecruit
#Number of Intervention Groups
> MTGIntgrp<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=NoIntGrps, data= MedDietStatins, method="REML")
> MTGIntgrp
> MCholIntgrp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
NoIntGrps, data= MedDietStatins, method="REML")
> MCholIntgrp
> MLDLIntgrp <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
NoIntGrps, data= MedDietStatins, method="REML")
> MLDLIntgrp
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> MHDLIntgrp<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
NoIntGrps, data= MedDietStatins, method="REML")
> MHDLIntgrp
#Subjects Using Insulin or Oral Hypoglycemic Agents
> MTGinsulin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Insulin/OHA, data= MedDietStatins, method="REML")
> MTGinsulin
> MCholinsulin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Insulin/OHA, data= MedDietStatins, method="REML")
> MCholinsulin
> MLDLinsulin <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=Insulin/OHA, data= MedDietStatins, method="REML")
> MLDLinsulin
> MHDLinsulin<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Insulin/OHA, data= MedDietStatins, method="REML")
> MHDLinsulin
#No Subjects Using Insulin or Oral Hypoglycemic Agents
> MTGinsulin0<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
(mods=InsulinOHA==0), data= MedDietStatins, method="REML")
> MTGinsulin0
> MCholinsulin0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
(InsulinOHA==0), data= MedDietStatins, method="REML")
> MCholinsulin0
> MLDLinsulin0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=(InsulinOHA==0), data= MedDietStatins, method="REML")
> MLDLinsulin0
> MHDLinsulin0<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
(InsulinOHA==0), data= MedDietStatins, method="REML")
> MHDLinsulin0
#Alcohol Intake Recommended
> MTGETOH<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=ETOH, data= MedDietStatins, method="REML")
> MTGETOH
> MCholETOH <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
ETOH, data= MedDietStatins, method="REML")
> MCholETOH
> MLDLETOH <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3),
mods=ETOH, data= MedDietStatins, method="REML")
> MLDLETOH
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> MHDLETOH<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
ETOH, data= MedDietStatins, method="REML")
> MHDLETOH
#Reported Macronutrient Distribution
> MTGmacro<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=MacroDis, data= MedDietStatins, method="REML")
> MTGmacro
> MCholmacro <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
MacroDis, data= MedDietStatins, method="REML")
> MCholmacro
> MLDLmacro <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
MacroDis, data= MedDietStatins, method="REML")
> MLDLmacro
> MHDLmacro<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
MacroDis, data= MedDietStatins, method="REML")
> MHDLmacro
#Publication Year
> MTGyear<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods= Year,
data= MedDietStatins, method="REML")
> MTGyear
> MCholyear <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==2), mods=
Year, data= MedDietStatins, method="REML")
> MCholyear
> MLDLyear <-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==3), mods=
Year, data= MedDietStatins, method="REML")
> MLDLyear
> MHDLyear<-rma(d.ex.,var_d.ex.,subset=(Diet ==1 & Outcome==4), mods=
Year, data= MedDietStatins, method="REML")
> MHDLyear
#Proportion Taking Statins Min 7%, Max 100%, plus 0%, 10%, 25%, 50%, and
75%
> maxstatins = 1-MedDietStatins$Prop_Statins
> maxstatins
> minstatins=MedDietStatins$Prop_Statins - 0.07
> minstatins
> threefourthsstatin= MedDietStatins$Prop_Statins - 0.75
> threefourthsstatin
> halfonstatins= MedDietStatins$Prop_Statins - 0.5
> halfonstatins
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> quarterstat = MedDietStatins$Prop_Statins - 0.25
> quarterstat
> tenstat= MedDietStatins$Prop_Statins - 0.1
> tenstat
> nostat = maxstatins - 1
> nostat
> MTGStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTGStat
> MTG75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab=
paste(Author, Prop_Statins, sep =","))
> MTG75Stat
> MTG50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=halfonstatins, data=MedDietStatins, method="REML", slab= paste(Author,
Prop_Statins, sep =","))
> MTG50Stat
> MTG25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=quarterstat, data=MedDietStatins, method="REML", slab= paste(Author,
Prop_Statins, sep =","))
> MTG25stat
> MTG10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Author,
Prop_Statins, sep =","))
>MTG10stat
> TGminstat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minstatins, data=MedDietStatins, method="REML", slab= paste(Author,
Prop_Statins, sep =","))
> TGminstat
> MTGNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> MTGNoStat
Maximum, 100% on Statins
> MTCholMaxStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=maxstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTCholMaxStat
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> MTChol75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTChol75Stat
> MTChol50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=halfonstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTChol50Stat
> MTChol25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=quarterstat, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTChol25stat
> MTChol10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> MTChol10stat
> MTCholMinStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTCholMinStat
> MTCholNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> MTCholNoStat
> MLDLMaxStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=maxstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MLDLMaxStat
> MLDL75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MLDL75Stat
> MLDL50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=halfonstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MLDL50Stat
> MLDL25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=quarterstat, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MLDL25stat
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> MLDL10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> MLDL10stat
> MLDLMinStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MLDLMinStat
> MLDLNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> MLDLNoStat
> MHDLMaxStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=maxstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MHDLMaxStat
> MHDL75Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=threefourthsstatin, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MHDL75Stat
> MHDL50Stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=halfonstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MHDL50Stat
> MHDL25stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=quarterstat, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MHDL25stat
> MHDL10stat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=tenstat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> HDL10stat
> MHDLMinStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minstatins, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MHDLMinStat
> MHDLNoStat<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=nostat, data=MedDietStatins, method="REML", slab= paste(Reference,
Prop_Statins, sep =","))
> HDLNoStat
# Min Max for Hypertension
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> maxHTN = 0.94-MedDietStatins$HTN
> maxHTN
> minHTN=MedDietStatins$HTN - 0.39
> minHTN
> MTGHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MTGHTNmax
> MTGHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MTGHTNmin
> MTCholHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MTCholHTNmax
> MTCholHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MTCholHTNmin
> MLDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MLDLHTNmax
> MLDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MLDLHTNmin
> MHDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=maxHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MHDLHTNmax
> MHDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minHTN, data=MedDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> MHDLHTNmin
# Min Max for Proportion of Females
maxFemales = 0.60 -MedDietStatins$Female
> maxFemales
> minFemale = MedDietStatins$Female - 0.0
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> minFemale
> MTGFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxFemales, data=MedDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> MTGFemmax
> MTGFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minFemale, data=MedDietStatins, method="REML", slab=
paste(Reference, Prop_Statins, sep =","))
> MTGFemmin
> MCholFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods=
maxFemales, data=MedDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
> MCholHTNmax
> MTCholFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minFemale, data=MedDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> MTCholFemmin
> MLDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=
maxFemales, data=MedDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
>MLDLFemmax
> MLDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minFemale, data=MedDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> MLDLFemmin
> HDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=
maxFemales, data=MedDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
> HDLFemmax
> MHDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minFemale, data=MedDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> MHDLFemmin
#Min Max for Dyslipidemia
> maxDys = 0.72-MedDietStatins$Dys
> maxDys
> minDys=MedDietStatins$Dys - 0.327
> minDysS
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> MTGDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxDys, data=MedDietStatins, method="REML", slab= paste(Reference,
Dys, sep =","))
> MTGDysmax
> MTGDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference,
Dys, sep =","))
> MTGDysmin
> MCholDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods=
maxDys, data=MedDietStatins, method="REML", slab= paste(Reference, Dys,
sep =","))
> MCholDysmax
> MTCholDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference,
Dys, sep =","))
> MTCholDysmin
> MLDLDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=
maxDys, data=MedDietStatins, method="REML", slab= paste(Reference, Dys,
sep =","))
> MLDLDysmax
> MLDLDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference,
Dys, sep =","))
> MLDLDysmin
> MHDLDysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=
maxDys, data=MedDietStatins, method="REML", slab= paste(Reference, Dys,
sep =","))
> MHDLDysmax
> MHDLDysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minDys, data=MedDietStatins, method="REML", slab= paste(Reference,
Dys, sep =","))
> MHDLDysmin
# Min Max for Length of Intervention
> maxWeeks = 260-MedDietStatins$Weeks
> maxWeeks
> minWeeks=MedDietStatins$Weeks - 8
> minWeeks
> MTGWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxWeeks, data=MedDietStatins, method="REML", slab=
paste(Reference, Weeks, sep =","))
> MTGWksmax
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> MTGWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minWeeks, data=MedDietStatins, method="REML", slab=
paste(Reference, Weeks, sep =","))
> MTGWksmin
> MCholWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods=
maxWeeks, data=MedDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> MCholWksmax
> MCholWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minWeeks, data=MedDietStatins, method="REML", slab=
paste(Reference, Weeks, sep =","))
> MCholWksmin
> MLDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=
maxWeeks, data=MedDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> MLDLWksmax
> MLDLWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minWeeks, data=MedDietStatins, method="REML", slab=
paste(Reference, Weeks, sep =","))
> MLDLWksmin
> MHDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=
maxWeeks, data=MedDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> MHDLWksmax
> HDLWeeksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minWeeks, data=MedDietStatins, method="REML", slab=
paste(Reference, Weeks, sep =","))
> HDLWeeksmin
# Min Max for Current Smokers
> maxSmoke = 0.51-MedDietStatins$Smoke
> maxSmoke
> minSmoke=MedDietStatins$Smoke - 0
> minSmoke
> MTGSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MTGSmokemax
> MTGSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
122

> MTGSmokemin
> MCholSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=maxSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MCholSmokemax
> MCholSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MCholSmokemin
> MLDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods= maxSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MLDLSmokemax
> MLDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MLDLSmokemin
> MHDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods= maxSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MHDLSmokemax
> MHDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minSmoke, data=MedDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> MHDLSmokemin
#Min Max for Methodological Quality Score
> maxMQ = 17 -MedDietStatins$MQ
> maxMQ
> minMQ=MedDietStatins$MQ - 8
> minMQ
> MTGMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxMQ, data=MedDietStatins, method="REML", slab= paste(Reference,
MQ, sep =","))
> MTGMQmax
> MTGMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference,
MQ, sep =","))
> MTGMQmin
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> MCholMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=maxMQ, data=MedDietStatins, method="REML", slab= paste(Reference,
MQ, sep =","))
> MCholMQmax
> MCholMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference,
MQ, sep =","))
> MCholMQmin
> MLDLMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=
maxMQ, data=MedDietStatins, method="REML", slab= paste(Reference, MQ,
sep =","))
> MLDLMQmax
> MLDLMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference,
MQ, sep =","))
> MLDLMQmin
> MHDLMQmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=
maxMQ, data=MedDietStatins, method="REML", slab= paste(Reference, MQ,
sep =","))
> MHDLMQmax
> MHDLMQmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minMQ, data=MedDietStatins, method="REML", slab= paste(Reference,
MQ, sep =","))
> MHDLMQmin
# Min Max for Number of Follow-Ups
> maxfu = 10 -MedDietStatins$NoFollowUp
> maxfu
> minfu=MedDietStatins$NoFollowUp - 1
> minfu
> MTGfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MTGfumax
> MTGfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MTGfumin
> MCholfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MCholfumax
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> MCholfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MCholfumin
> MLDLfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MLDLfumax
> MLDLfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MLDLfumin
> MHDLfumax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=maxfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MHDLfumax
> MHDLfumin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minfu, data=MedDietStatins, method="REML", slab= paste(Reference,
NoFollowUp, sep =","))
> MHDLfumin
# Min Max for Participants Lost to Follow-Up
> maxlost = 14 -MedDietStatins$Part_lost
> maxlost
> minlost=MedDietStatins$ Part_lost - 0
> minlost
> MTGlostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MTGlostmax
> MTGlostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MTGlostmin
> MChollostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MChollostmax
> MChollostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
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> MChollostmin
> MLDLlostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MLDLlostmax
> MLDLlostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3),
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MLDLlostmin
> MHDLlostmax<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=maxlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MHDLlostmax
> MHDLlostmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4),
mods=minlost, data=MedDietStatins, method="REML", slab= paste(Reference,
Part_lost, sep =","))
> MHDLlostmin
Meta-Regressions Plots
#Length of intervention
MTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods=Weeks,
data=MedDietStatins, method="REML", slab= paste(Author, Weeks, sep =","))
MTGwkspred <- predict(MTGwks, newmods=cbind(seq(0, 260,.1)))
wi = MedDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietTG= subset(MedDietStatins, Diet==1 & Outcome==1)
plot(dietTG$Weeks,dietTG$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Number of Weeks",
ylab = "Triglycerides Effect Size (d)", xlim=c(0,260), ylim=c(-2, 0.5))
lines(seq(0,260,.1), MTGwkspred$pred, col = "dark red")
lines(seq(0,260,.1), MTGwkspred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,260,.1), MTGwkspred$ci.ub, lty = "dashed", col="dark red")
MTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods = Weeks,
data=MedDietStatins, method="REML", slab= paste(Author, Year, sep =","))
MTGwkspred <- predict(MTGwks, newmods=cbind(seq(0,260,.1)))
MTGwks
MCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=Weeks,
data=MedDietStatins, method="REML", slab= paste(Author, Weeks, sep =","))
MCholwkspred <- predict(MCholwks, newmods=cbind(seq(0,260,.1)))
wi = MedDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
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size= 1.0 + 0.5 * (wi - min)/(max - min)
dietTChol= subset(MedDietStatins,Diet==1 & Outcome==2)
plot(dietTChol$Weeks,dietTChol$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Number of Weeks", #Plotting here the observed values of the subsample
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 260), ylim=c(-2, 0.5))
lines(seq(0,260,.1), MCholwkspred$pred, col = "dark red")
lines(seq(0,260,.1), MCholwkspred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,260,.1), MCholwkspred$ci.ub, lty = "dashed", col="dark red")
MCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2), mods =
Weeks,
data=MedDietStatins, method="REML", slab= paste(Author, Year, sep =","))
MCholwkspred <- predict(MCholwks, newmods=cbind(seq(0,260,.1)))
MCholwks
MLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods=Weeks,
data=MedDietStatins, method="REML", slab= paste(Author, Weeks, sep =","))
MLDLwkspred <- predict(MLDLwks, newmods=cbind(seq(0,260,.1)))
wi = MedDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(MedDietStatins,Diet==1 & Outcome==3)
plot(dietLDL$Weeks,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Number of Weeks", #Plotting here the observed values of the subsample
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 260), ylim=c(-2, 0.5))
lines(seq(0,260,.1), MLDLwkspred$pred, col = "dark red")
lines(seq(0,260,.1), MLDLwkspred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,260,.1), MLDLwkspred$ci.ub, lty = "dashed", col="dark red")
MLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==3), mods =
Weeks, data=MedDietStatins, method="REML", slab= paste(Author, Year, sep
=","))
MLDLwkspred <- predict(MLDLwks, newmods=cbind(seq(0,260,.1)))
MLDLwks
#Dyslipidemia
MHDLDys<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods=Dys,
data=MedDietStatins, method="REML", slab= paste(Author, Dys, sep =","))
MHDLDyspred <- predict(MHDLDys, newmods=cbind(seq(0,1.0,.1)))
wi = MedDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietHDL= subset(MedDietStatins,Diet==1 & Outcome==4)
plot(dietHDL$Dys,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Proportion of Dyslipidemia",
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 1.0), ylim=c(-1, 1.5))
lines(seq(0,1.0,.1), MHDLDyspred$pred, col = "dark red")
lines(seq(0,1.0,.1), MHDLDyspred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), MHDLDyspred$ci.ub, lty = "dashed", col="dark red")
MHDLDys<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==4), mods = Dys,
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data=MedDietStatins, method="REML", slab= paste(Author, Year, sep =","))
MHDLDyspred <- predict(MHDLDys, newmods=cbind(seq(0,1.0,.1)))
MHDLDys
#Number of follow-ups
MTGNofu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=NoFollowUp,
data=MedDietStatins, method="REML", slab= paste(Author, NoFollowUp, sep
=","))
MTGNofupred <- predict(MTGNofu, newmods=cbind(seq(0,8.0,1)))
wi = MedDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietTG= subset(MedDietStatins,Diet==1 & Outcome==1)
plot(dietTG$NoFollowUp,dietTG$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Number of Follow-Up Sessions",
ylab = "Triglycerides Effect Size (d)", xlim=c(0, 8.0), ylim=c(-3, 0.5))
lines(seq(0,8.00,1), MTGNofupred$pred, col = "dark red")
lines(seq(0,8.00,1), MTGNofupred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,8.00,1), MTGNofupred$ci.ub, lty = "dashed", col="dark red")
MTGNofu<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods =
NoFollowUp,
data=MedDietStatins, method="REML", slab= paste(Author, NoFollowUp, sep
=","))
MTGpred <- predict(MTGNofu, newmods=cbind(seq(0,8.00,1)))
MTGNofu
#Number of Subjects Lost to Follow-up
MTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1),
mods=Part_lost,
data=MedDietStatins, method="REML", slab= paste(Author, Part_lost, sep =","))
MTGlostpred <- predict(MTGlost, newmods=cbind(seq(0,14,0.1)))
wi = MedDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietTG= subset(MedDietStatins,Diet==1 & Outcome==1)
plot(dietTG$Part_lost,dietTG$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Number of Subjects Lost to Follow-Up",
ylab = "Triglycerides Effect Size (d)", xlim=c(0, 15.0), ylim=c(-2, 0.5))
lines(seq(0,14.0,.1), MTGlostpred$pred, col = "dark red")
lines(seq(0,14.0,.1), MTGlostpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,14.0,.1), MTGlostpred$ci.ub, lty = "dashed", col="dark red")
MTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==1), mods =
Part_lost,
data=MedDietStatins, method="REML", slab= paste(Author, Part_lost, sep =","))
MTGpred <- predict(MTGlost, newmods=cbind(seq(0,14.0,0.1)))
MTGlost
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Appendix 7: R Code for Low-Fat Diet
Random-Effect and Fixed-Effect Sizes
#Low Fat Diet without Statins
> model01<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==1),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model01
> model02<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==1),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model02
> model03<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==2),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model03
> model04<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==2),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model04
> model05<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==3),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model05
> model06<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==3),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model06
> model07<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==4),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model07
> model08<-rma(d.ex.,var_d.ex.,subset=(Diet ==4&Outcome==4),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model08
#Low Fat Diet with Statins
> model13<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==1),
data=LFDietStatins, method="FE")
> model13
> model14<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==1),
data=LFDietStatins, method="REML")
> model14
> model15<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==2),
data=LFDietStatins, method="FE")
> model15
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> model16<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==2),
data=LFDietStatins, method="REML")
> model16
> model17<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==3),
data=LFDietStatins, method="FE")
> model17
> model18<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==3),
data=LFDietStatins, method="REML")
> model18
> model19<-rma(d.ex.,var_d.ex.,subset=(Diet==5&Outcome==4),
data=LFDietStatins, method="FE")
> model19
> model20<-rma(d.ex.,var_d.ex.,subset=(Diet ==5&Outcome==4),
data=LFDietStatins, method="REML")
> model20
> model01<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==1),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model01
> model02<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==1),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model02
> model03<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==2),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model03
> model04<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==2),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model04
> model05<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==3),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model05
> model06<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==3),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model06
> model07<-rma(d.ex.,var_d.ex.,subset=(Diet==4&Outcome==4),
data=LFDalone, method="FE", slab= paste(Author, Year, sep =", "))
> model07
> model08<-rma(d.ex.,var_d.ex.,subset=(Diet ==4&Outcome==4),
data=LFDalone, method="REML", slab= paste(Author, Year, sep =", "))
> model08
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Forest Plots
forest(model02, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,19, "Triglycerides")
text(c(-3,2.5),17.5,c("Favors Intervention", "Favors Baseline"))
text(-10,17.5, "Author(s) and Year", pos=4)
text(7.5,17.5, "d[95%CI]", pos=4)
par(op)
forest(model04, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,20, "Total Cholesterol")
text(c(-3.5,3.5),18.5,c("Favors Intervention", "Favors Baseline"))
text(-10,18.5, "Author(s) and Year", pos=4)
text(8,18.5, "d[95%CI]", pos=4)
par(op)
forest(model06, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,20, "LDL Cholesterol")
text(c(-3.5,3.5),18.5,c("Favors Intervention", "Favors Baseline"))
text(-10,18.5, "Author(s) and Year", pos=4)
text(8,18.5, "d[95%CI]", pos=4)
par(op)
forest(model08, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,22, "HDL Cholesterol")
text(c(-3.5,3.5),20.5,c("Favors Baseline", "Favors Intervention"))
text(-10,20.5, "Author(s) and Year", pos=4)
text(8,20.5, "d[95%CI]", pos=4)
par(op)
forest(model14, xlim=c(-8,8), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black”)
op<-par(cex=0.85, font=2, col="dark red")
text (0,30, "Triglycerides")
text(c(-3,2.5),29,c("Favors Intervention", "Favors Baseline"))
text(-8,29, "Author(s) and Year", pos=4)
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text(6.25,29, "d[95%CI]", pos=4)
par(op)
forest(model16, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,40, "Total Cholesterol")
text(c(-4,3.5),39,c("Favors Intervention", "Favors Baseline"))
text(-10,39, "Author(s) and Year", pos=4)
text(8,39, "d[95%CI]", pos=4)
par(op)
forest(model18, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,39, "LDL Cholesterol")
text(c(-4,3.5),38,c("Favors Intervention", "Favors Baseline"))
text(-10,38, "Author(s) and Year", pos=4)
text(8,38, "d[95%CI]", pos=4)
par(op)
forest(model20, xlim=c(-10,10), xlab="Standardized Mean Difference", cex=0.8,
efac=2, col="dark red", border="black")
op<-par(cex=1.00, font=2, col="black")
op<-par(cex=0.85, font=2, col="dark red")
text (0,39, "HDL Cholesterol")
text(c(-4,3.5),38,c("Favors Baseline", "Favors Intervention"))
text(-10,38, "Author(s) and Year", pos=4)
text(8,38, "d[95%CI]", pos=4)
par(op)
Publication Bias
#Egger’s
> regtest(model13, model="lm", data=LFDietStatins)
> regtest(model15, model="lm", data= LFDietStatins)
> regtest(model17, model="lm", data= LFDietStatins)
> regtest(model19, model="lm", data= LFDietStatins)
> regtest(model01, model="lm", data=LFDalone)
> regtest(model03, model="lm", data= LFDalone)
> regtest(model05, model="lm", data= LFDalone)
> regtest(model07, model="lm", data= LFDalone)
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#Begg’s
> ranktest(model13, data= LFDietStatins)
> ranktest(model15, data= LFDietStatins)
> ranktest(model17, data= LFDietStatins)
> ranktest(model19, data= LFDietStatins)
> ranktest(model01, data= LFDalone)
> ranktest(model03, data= LFDalone)
> ranktest(model05, data= LFDalone)
> ranktest(model07, data= LFDalone)
#Trim-and-Fill with Funnel Plots
>LFTGtrim=trimfill(model13, data= LFDietStatins)
>funnel(LFTGtrim)
>LFTCtrim=trimfill(model15, data= LFDietStatins)
>funnel(LFTCtrim)
>LFLDLtrim=trimfill(model17, data= LFDietStatins)
>funnel(LFLDLtrim)
>LFHDLtrim=trimfill(model19, data= LFDietStatins)
>funnel(LFHDLtrim)
>LFTGtrim=trimfill(model01, data= LFDalone)
>funnel(LFTGtrim)
>LFTCtrim=trimfill(model03, data= LFDalone)
>funnel(LFTCtrim)
>LFLDLtrim=trimfill(model05, data= LFDalone)
>funnel(LFLDLtrim)
>LFHDLtrim=trimfill(model07, data= LFDalone)
>funnel(LFHDLtrim)
Risk of Bias
RanSeq-1
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(RanSeq)-1, data=LQuality, method="REML")
> Summary(LTGbias)
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>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(RanSeq)-1, data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(RanSeq)-1, data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(RanSeq)-1, data= LQuality, method="REML")
> Summary(LHDLbias)
RanSeq
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(RanSeq), data= LQuality, method="REML")
> Summary(LTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(RanSeq), data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(RanSeq), data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(RanSeq), data= LQuality, method="REML")
> Summary(LHDLbias)
AllCon-1
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(AllCon)-1, data= LQuality, method="REML")
> Summary(LTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(AllCon)-1, data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(AllCon)-1, data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(AllCon)-1, data= LQuality, method="REML")
> Summary(LHDLbias)
AllCon
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(AllCon), data= LQuality, method="REML")
> Summary(LTGbias)
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>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(AllCon), data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(AllCon), data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(AllCon), data= LQuality, method="REML")
> Summary(LHDLbias)
Blinding-1
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(Blinding)-1, data= LQuality, method="REML")
> Summary(MTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(Blinding)-1, data= LQuality, method="REML")
> Summary(MTGbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(Blinding)-1, data= LQuality, method="REML")
> Summary(MTGbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(Blinding)-1, data= LQuality, method="REML")
> Summary(MHDLbias)
Blinding
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(Blinding), data= LQuality, method="REML")
> Summary(LTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(Blinding), data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(Blinding), data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(Blinding), data= LQuality, method="REML")
> Summary(LHDLbias)
Incomp-1
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(Incomp)-1, data= LQuality, method="REML")
> Summary(LTGbias)
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>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(Incomp)-1, data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(Incomp)-1, data= LQuality, method="REML")
> Summary(LTGbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(Incomp)-1, data= LQuality, method="REML")
> Summary(LHDLbias)
Incomp
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(Incomp), data= LQuality, method="REML")
> Summary(LTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(Incomp), data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(Incomp), data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(Incomp), data= LQuality, method="REML")
> Summary(LHDLbias)
Select-1
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(Select)-1, data= LQuality, method="REML")
> Summary(LTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(Select)-1, data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(Select)-1, data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(Select)-1, data= LQuality, method="REML")
> Summary(LHDLbias)
Select
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(Select), data= LQuality, method="REML")
> Summary(LTGbias)
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>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(Select), data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(Select), data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(Select), data= LQuality, method="REML")
> Summary(LHDLbias)
OtherBias-1
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(OtherBias)-1, data= LQuality, method="REML")
> Summary(LTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(OtherBias)-1, data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(OtherBias)-1, data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(OtherBias)-1, data= LQuality, method="REML")
> Summary(LHDLbias)
OtherBias
> LTGbias <-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1),
mods=~factor(OtherBias), data= LQuality, method="REML")
> Summary(MTGbias)
>LCholbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==2),
mods=~factor(OtherBias), data= LQuality, method="REML")
> Summary(LCholbias)
>LLDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==3),
mods=~factor(OtherBias), data= LQuality, method="REML")
> Summary(LLDLbias)
>LHDLbias<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==4),
mods=~factor(OtherBias), data= LQuality, method="REML")
> Summary(LHDLbias)
Moderator Analysis Low Fat Diet Without Statins
# Length of Intervention
> lfdTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1),
mods=Weeks, data= LFDalone, method="REML")
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> lfdTGwks
> lfdCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2),
mods=Weeks, data= LFDalone, method="REML")
> lfdCholwks
> lfdLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=Weeks, data= LFDalone, method="REML")
> lfdLDLwks
> lfdHDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=Weeks, data= LFDalone, method="REML")
> lfdHDLwks
# Proprtion of Females
> lfdTGfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1),
mods=Female, data= LFDalone, method="REML")
> lfdTGfem
> lfdCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2),
mods=Female, data= LFDalone, method="REML")
> lfdCholfem
> lfdLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=Female, data= LFDalone, method="REML")
> lfdLDLfem
> lfdHDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=Female, data= LFDalone, method="REML")
> lfdfHDLem
# Region (USA)
> lfdTGusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1),
mods=(Region==1), data= LFDalone, method="REML")
> lfdTGusa
> lfdCholusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2),
mods=(Region==1), data= LFDalone, method="REML")
> lfdCholusa
> lfdLDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=(Region==1), data= LFDalone, method="REML")
> lfdLDLusa
> lfdHDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=(Region==1), data= LFDalone, method="REML")
> lfdHDLusa
# Region (Europe)
> lfdTGregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1),
mods=(Region==2), data= LFDalone, method="REML")
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> lfdTGregion
> lfdCholregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2),
mods=(Region==2), data= LFDalone, method="REML")
> lfdCholregion
> lfdLDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=(Region==2), data= LFDalone, method="REML")
> lfdLDLregion
> lfdHDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=(Region==2), data= LFDalone, method="REML")
> lfdHDLregion
# Intervention Sample Size
> LTGIntN<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
n_post, data= LFDalone, method="REML")
> LTGIntN
> LCholIntN <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods=
n_post, data= LFDalone, method="REML")
> LCholIntN
> LLDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods=
n_post, data= LFDalone, method="REML")
> LLDLIntN
> LHDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods=
n_post, data= LFDalone, method="REML")
> LHDLIntN
# Total Sample Size
> LTGN<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=Ntotal,
data= LFDalone, method="REML")
> LTGN
> LCholN <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods=
Ntotal, data= LFDalone, method="REML")
> LCholN
> LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= Ntotal,
data= LFDalone, method="REML")
> LLDLN
> LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= Ntotal,
data= LFDalone, method="REML")
> LHDLN
# Proportion of Subjects with Dyslipidemia
> lfdTGdys<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=Dys,
data= LFDalone, method="REML")
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> lfdTGdys
> lfdCholdys <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods=
Dys, data= LFDalone, method="REML")
> MCholdys
> lfdLDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= Dys,
data= LFDalone, method="REML")
> lfdLDLdys
> lfdHDLdys<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods=
Dys, data= LFDalone, method="REML")
> lfdHDLdys
#Proportion of Subjects with HTN
> LTGhtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=HTN,
data= LFDalone, method="REML")
> LTGhtn
> LCholhtn <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods=
HTN, data= LFDalone, method="REML")
> LCholhtn
> LLDLhtn<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods= HTN,
data= LFDalone, method="REML")
> LLDLhtn
> LHDLhtn<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods= HTN,
data= LFDalone, method="REML")
> LHDLhtn
# Mean Age
> LTGage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= Age,
data= LFDalone, method="REML")
> LTGage
> LCholage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=Age,
data= LFDalone, method="REML")
> LCholage
> LLDLage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= Age,
data= LFDalone, method="REML")
> LLDLage
> LHDLage<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= Age,
data= LFDalone, method="REML")
> LHDLage
# Carbohydrate intake
> LTGcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Carbs, data= LFDalone, method="REML")
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> LTGcarb
> LCholcarb <-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==2), mods=
Carbs, data= LFDalone, method="REML")
> LCholcarb
> LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==3), mods=
Carbs, data= LFDalone, method="REML")
> LLDLcarb
> LHDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet ==4 & Outcome==4), mods=
Carbs, data= LFDalone, method="REML")
> LHDLcarb
# Fat intake
> LTGfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= Fat,
data= LFDalone, method="REML")
> LTGfat
> LCholfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods= Fat,
data= LFDalone, method="REML")
> LCholfat
> LLDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods= Fat,
data= LFDalone, method="REML")
> LLDLfat
> LHDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods= Fat,
data= LFDalone, method="REML")
> LHDLfat
# Protein intake
> LTGpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Protein, data= LFDalone, method="REML")
> LTGpro
> LCholpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Protein, data= LFDalone, method="REML")
> LCholpro
> LLDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
Protein, data= LFDalone, method="REML")
> LLDLpro
> LHDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Protein, data= LFDalone, method="REML")
> LHDLpro
# Proportion of Subjects Taking ACE Inhibitors
> LTGACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
PropACE, data= LFDalone, method="REML")
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> LTGACE
> LCholACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
PropACE, data= LFDalone, method="REML")
> LCholACE
> LLDLACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
PropACE, data= LFDalone, method="REML")
> LLDLACE
> LHDLACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
PropACE, data= LFDalone, method="REML")
> LHDLACE
# Number of Subjects Taking ACE Inhibitors
> LTGnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
NoACE, data= LFDalone, method="REML")
> LTGnoACE
> LCholnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
NoACE, data= LFDalone, method="REML")
> LCholnoACE
> LLDLnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
NoACE, data= LFDalone, method="REML")
> LLDLnoACE
> LHDLnoACE<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
NoACE, data= LFDalone, method="REML")
> LHDLnoACE
# Number Subjects with HTN
> LTGnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
NoHTN, data= LFDalone, method="REML")
> LTGnohtn
> LCholnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
NoHTN, data= LFDalone, method="REML")
> LCholnohtn
> LLDLnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
NoHTN, data= LFDalone, method="REML")
> LLDLnohtn
> LHDLnohtn<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
NoHTN, data= LFDalone, method="REML")
> LHDLnohtn
# Number Subjects with CVD
> LTGnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
NoCVD, data= LFDalone, method="REML")
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> LTGnocvd
> LCholnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
NoCVD, data= LFDalone, method="REML")
> LCholnocvd
> LLDLnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
NoCVD, data= LFDalone, method="REML")
> LLDLnocvd
> LHDLnocvd<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
NoCVD, data= LFDalone, method="REML")
> LHDLnocvd
# Cholesterol Intake
> LTGchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Cholesterol, data= LFDalone, method="REML")
> LTGchol
> LCholchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Cholesterol, data= LFDalone, method="REML")
> LCholchol
> LLDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
Cholesterol, data= LFDalone, method="REML")
> LLDLchol
> LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Cholesterol, data= LFDalone, method="REML")
> LHDLchol
# Fiber Intake
> LTGFiber <-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Fiber, data= LFDalone, method="REML")
> LTGFiber
> LCholFiber <-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Fiber, data= LFDalone, method="REML")
> LCholFiber
> LLDLFiber<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
Fiber, data= LFDalone, method="REML")
> LLDLFiber
> LHDLFiber<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Fiber, data= LFDalone, method="REML")
> LHDLFiber
#Moving Constant Technique
# Length of Intervention (Weeks)
> wksmax = 260 -LFDalone$Weeks
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> wksmax
> wksmin =LFDalone$Weeks - 4
> wksmin
> LTGwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
wksmax, data= LFDalone, method="REML")
> LTGwksmax
> LTGwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
wksmin, data=LFDalone, method="REML")
> LTGwksmin
> LCholwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
wksmax, data=LFDalone, method="REML")
> LCholwksmax
> LCholwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
wksmin, data=LFDalone, method="REML")
> LCholwksmin
> LLDLwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
wksmax, data=LFDalone, method="REML")
> LLDLwksmax
> LLDLwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=wksmin, data=LFDalone, method="REML")
> LLDLwksmin
> LHDLwksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
wksmax, data=LFDalone, method="REML")
> LHDLwksmax
> LHDLwksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
wksmin, data=LFDalone, method="REML")
> LHDLwksmin
# Female
> femmax = 1.0 - LFDalone$Female
> femmax
> femmin =LFDalone$Female - 0
> femmin
> LTGfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
femmax, data= LFDalone, method="REML")
> LTGfemmax
> LTGfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
femmin, data=LFDalone, method="REML")
> LTGfemmin
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> LCholfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
femmax, data=LFDalone, method="REML")
> LCholfemmax
> LCholfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
femmin, data=LFDalone, method="REML")
> LCholfemmin
> LLDLfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
femmax, data=LFDalone, method="REML")
> LLDLfemmax
> LLDLfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=femmin, data=LFDalone, method="REML")
> LLDLfemmin
> LHDLfemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
femmax, data=LFDalone, method="REML")
> LHDLfemmax
> LHDLfemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
femmin, data=LFDalone, method="REML")
> LHDLfemmin
# Total Sample Size
> lNmax = 5850 -LFDalone$Ntotal
> lNmax
> lNmin =LFDalone$Ntotal - 30
> lNmin
> LTGNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
lNmax, data= LFDalone, method="REML")
> LTGNmax
> LTGNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
lNmin, data=LFDalone, method="REML")
> LTGNmin
> LCholNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
lNmax, data=LFDalone, method="REML")
> LCholNmax
> LCholNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
lNmin, data=LFDalone, method="REML")
> LCholNmin
> LLDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
lNmax, data=LFDalone, method="REML")
> LLDLNmax
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> LLDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=lNmin, data=LFDalone, method="REML")
> LLDLNmin
> LHDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
lNmax, data=LFDalone, method="REML")
> LHDLNmax
> LHDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
lNmin, data=LFDalone, method="REML")
> LHDLNmin
# Age
> agemax = 69.5 -LFDalone$Age
> agemax
> agemin =LFDalone$Age - 43
> agemin
> LTGagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
agemax, data= LFDalone, method="REML")
> LTGagemax
> LTGagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
agemin, data=LFDalone, method="REML")
> LTGagemin
> LCholagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
agemax, data=LFDalone, method="REML")
> LCholagemax
> LCholagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
agemin, data=LFDalone, method="REML")
> LCholagemin
> LLDLagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
agemax, data=LFDalone, method="REML")
> LLDLagemax
> LLDLagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=agemin, data=LFDalone, method="REML")
> LLDLagemin
> LHDLagemax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
agemax, data=LFDalone, method="REML")
> LHDLagemax
> LHDLagemin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
agemin, data=LFDalone, method="REML")
> LHDLagemin
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# Proportion of Subjects with Dyslipidemia
> Dysmax = 1 -LFDalone$Dys
> Dysmax
> Dysmin =LFDalone$Dys - 0
> Dysmin
> LTGdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Dysmax, data= LFDalone, method="REML")
> LTGdysmax
> LTGdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Dysmin, data=LFDalone, method="REML")
> LTGdysmin
> LCholdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Dysmax, data=LFDalone, method="REML")
> LCholdysmax
> LCholdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Dysmin, data=LFDalone, method="REML")
> LCholdysmin
> LLDLdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
Dysmax, data=LFDalone, method="REML")
> LLDLdysmax
> LLDLdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=Dysmin, data=LFDalone, method="REML")
> LLDLdysmin
> LHDLdysmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Dysmax, data=LFDalone, method="REML")
> LHDLdysmax
> LHDLdysmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Dysmin, data=LFDalone, method="REML")
> LHDLdysmin
# Proportion of Subjects with Hypertension
> HTNmax = .946 -LFDalone$HTN
> HTNmax
> HTNmin =LFDalone$HTN - .35
> HTNmin
> LTGHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
HTNmax, data= LFDalone, method="REML")
> LTGHTNmax
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> LTGHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
HTNmin, data=LFDalone, method="REML")
> LTGHTNmin
> LCholHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
HTNmax, data=LFDalone, method="REML")
> LCholHTNmax
> LCholHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
HTNmin, data=LFDalone, method="REML")
> LCholHTNmin
> LLDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
HTNmax, data=LFDalone, method="REML")
> LLDLHTNmax
> LLDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=HTNmin, data=LFDalone, method="REML")
> LLDLHTNmin
> LHDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
HTNmax, data=LFDalone, method="REML")
> LHDLHTNmax
> LHDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
HTNmin, data=LFDalone, method="REML")
> LHDLHTNmin
#Number of Subjects with Hypertension
> NHTNmax = 328 -LFDalone$NoHTN
> NHTNmax
> NHTNmin =LFDalone$NoHTN - 0
> NHTNmin
> LTGNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
NHTNmax, data= LFDalone, method="REML")
> LTGNHTNmax
> LTGNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
NHTNmin, data=LFDalone, method="REML")
> LTGNHTNmin
> LCholNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2),
mods= NHTNmax, data=LFDalone, method="REML")
> LCholNHTNmax
> LCholNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
NHTNmin, data=LFDalone, method="REML")
> LCholNHTNmin
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> LLDLNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods= NHTNmax, data=LFDalone, method="REML")
> LLDLNHTNmax
> LLDLNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=NHTNmin, data=LFDalone, method="REML")
> LLDLNHTNmin
> LHDLNHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods= NHTNmax, data=LFDalone, method="REML")
> LHDLNHTNmax
> LHDLNHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
NHTNmin, data=LFDalone, method="REML")
> LHDLNHTNmin
# Fat Intake
> fatmax = .382 -LFDalone$Fat
> fatmax
> fatmin =LFDalone$Fat - .246
> fatmin
> LTGfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
fatmax, data= LFDalone, method="REML")
> LTGHfatmax
> LTGHfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
fatmin, data=LFDalone, method="REML")
> LTGfatmin
> LCholfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
fatmax, data=LFDalone, method="REML")
> LCholfatmax
> LCholfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
fatmin, data=LFDalone, method="REML")
> LCholfatmin
> LLDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
fatmax, data=LFDalone, method="REML")
> LLDLfatmax
> LLDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=fatmin, data=LFDalone, method="REML")
> LLDLfatmin
> LHDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=fatmax, data=LFDalone, method="REML")
> LHDLfatmax
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> LHDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
fatmin, data=LFDalone, method="REML")
> LHDLfatmin
# Protein Intake
> promax = .222 -LFDalone$Protein
> promax
> promin =LFDalone$Protein - .1
> promin
> LTGpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
promax, data= LFDalone, method="REML")
> LTGHpromax
> LTGpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
promin, data=LFDalone, method="REML")
> LTGpromin
> LCholpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
promax, data=LFDalone, method="REML")
> LCholpromax
> LCholpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
promin, data=LFDalone, method="REML")
> LCholpromin
> LLDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
promax, data=LFDalone, method="REML")
> LLDLpromax
> LLDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=promin, data=LFDalone, method="REML")
> LLDLpromin
> LHDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=promax, data=LFDalone, method="REML")
> LHDLpromax
> LHDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
promin, data=LFDalone, method="REML")
> LHDLpromin
# Proportion of Subjects Taking ACE inhibitors
> ACEmax = .54 - LFDalone$PropACE
> ACEmax
> ACEmin =LFDalone$PropACE - 0
> ACEmin
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> LTGACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
ACEmax, data= LFDalone, method="REML")
> LTGHACEmax
> LTGHACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
ACEmin, data=LFDalone, method="REML")
> LTGACEmin
> LCholACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
ACEmax, data=LFDalone, method="REML")
> LCholACEmax
> LCholACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
ACEmin, data=LFDalone, method="REML")
> LCholACEmin
> LLDLACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
ACEmax, data=LFDalone, method="REML")
> LLDLACEmax
> LLDLACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=ACEmin, data=LFDalone, method="REML")
> LLDLACEmin
> LHDLACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=ACEmax, data=LFDalone, method="REML")
> LHDLACEmax
> LHDLACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
ACEmin, data=LFDalone, method="REML")
> LHDLACEmin
# Number of Subjects Taking ACE inhibitors
> NACEmax = 114 - LFDalone$NoACE
> NACEmax
> NACEmin =LFDalone$NoACE - 0
> NACEmin
> LTGNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
NACEmax, data= LFDalone, method="REML")
> LTGHNACEmax
> LTGHNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1),
mods= NACEmin, data=LFDalone, method="REML")
> LTGNACEmin
> LCholNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2),
mods= NACEmax, data=LFDalone, method="REML")
> LCholNACEmax

151

> LCholNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
NACEmin, data=LFDalone, method="REML")
> LCholNACEmin
> LLDLNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods= NACEmax, data=LFDalone, method="REML")
> LLDLNACEmax
> LLDLNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=NACEmin, data=LFDalone, method="REML")
> LLDLNACEmin
> LHDLNACEmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4),
mods=NACEmax, data=LFDalone, method="REML")
> LHDLNACEmax
> LHDLNACEmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
NACEmin, data=LFDalone, method="REML")
> LHDLNACEmin
# Number of Subjects with Cardiovascular Disease
> CVDmax = 107 - LFDalone$NoCVD
> CVDmax
> CVDmin =LFDalone$NoCVD - 0
> CVDmin
> LTGCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
CVDmax, data= LFDalone, method="REML")
> LTGCVDmax
> LTGCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
CVDmin, data=LFDalone, method="REML")
> LTGCVDmin
> LCholCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
CVDmax, data=LFDalone, method="REML")
> LCholCVDmax
> LCholCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
CVDmin, data=LFDalone, method="REML")
> LCholCVDmin
> LLDLCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
CVDmax, data=LFDalone, method="REML")
> LLDLCVDmax
> LLDLCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=CVDmin, data=LFDalone, method="REML")
> LLDLCVDmin
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> LHDLCVDmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
CVDmax, data=LFDalone, method="REML")
> LHDLCVDmax
> LHDLCVDmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
CVDmin, data=LFDalone, method="REML")
> LHDLCVDmin
# Cholesterol Intake
> Cmax = 300 - LFDalone$Cholesterol
> Cmax
> Cmin =LFDalone$Cholesterol - 28
> Cmin
> LTGCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Cmax, data= LFDalone, method="REML")
> LTGCmax
> LTGCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Cmin, data=LFDalone, method="REML")
> LTGCmin
> LCholCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Cmax, data=LFDalone, method="REML")
> LCholCmax
> LCholCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Cmin, data=LFDalone, method="REML")
> LCholCmin
> LLDLCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
Cmax, data=LFDalone, method="REML")
> LLDLCmax
> LLDLCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=Cmin, data=LFDalone, method="REML")
> LLDLCmin
> LHDLCmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Cmax, data=LFDalone, method="REML")
> LHDLCmax
> LHDLCmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Cmin, data=LFDalone, method="REML")
> LHDLCmin
# Fiber Intake
> Fmax = 57 - LFDalone$Fiber
> Fmax
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> Fmin =LFDalone$Fiber – 23.6
> Fmin
> LTGFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
Fmax, data= LFDalone, method="REML")
> LTGFmax
> LTGFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods= Fmin,
data=LFDalone, method="REML")
> LTGFmin
> LCholFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Fmax, data=LFDalone, method="REML")
> LCholFmax
> LCholFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
Fmin, data=LFDalone, method="REML")
> LCholFmin
> LLDLFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
Fmax, data=LFDalone, method="REML")
> LLDLFmax
> LLDLFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3),
mods=Fmin, data=LFDalone, method="REML")
> LLDLFmin
> LHDLFmax<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Fmax, data=LFDalone, method="REML")
> LHDLFmax
> LHDLFmin<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
Fmin, data=LFDalone, method="REML")
> LHDLFmin
#Region Study Conducted
> LTGUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
(Region==1), data= LFDalone, method="REML")
> LTGUSA
> LCholUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
(Region==1), data=LFDalone, method="REML")
> LCholUSA
> LLDLUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
(Region==1), data=LFDalone, method="REML")
> LLDLUSA
> LHDLUSA<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
(Region==1), data=LFDalone, method="REML")
> LHDLUSA
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> LTGeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==1), mods=
(Region==4), data= LFDalone, method="REML")
> LTGeuro
> LCholeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==2), mods=
(Region==4), data=LFDalone, method="REML")
> LCholeuro
> LLDLeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==3), mods=
(Region==4), data=LFDalone, method="REML")
> LLDLeuro
> LHDLeuro<-rma(d.ex.,var_d.ex.,subset=(Diet==4 & Outcome==4), mods=
(Region==4), data=LFDalone, method="REML")
> LHDLeuro
Moderator Analysis Low Fat Diet with Statins
# Length of Intervention
> lfdTGwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=Weeks, data= LFDietStatins, method="REML")
> lfdTGwks
> lfdCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=Weeks, data= LFDietStatins, method="REML")
> lfdCholwks
> lfdLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=Weeks, data= LFDietStatins, method="REML")
> lfdLDLwks
> lfdHDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=Weeks, data= LFDietStatins, method="REML")
> lfdHDLwks
# Proprtion of Females
> lfdTGfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=Female, data= LFDietStatins, method="REML")
> lfdTGfem
> lfdCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=Female, data= LFDietStatins, method="REML")
> lfdCholfem
> lfdLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=Female, data= LFDietStatins, method="REML")
> lfdLDLfem
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> lfdHDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=Female, data= LFDietStatins, method="REML")
> lfdfHDLem
# Region (USA)
> lfdTGusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Region==1), data= LFDietStatins, method="REML")
> lfdTGusa
> lfdCholusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=(Region==1), data= LFDietStatins, method="REML")
> lfdCholusa
> lfdLDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=(Region==1), data= LFDietStatins, method="REML")
> lfdLDLusa
> lfdHDLusa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=(Region==1), data= LFDietStatins, method="REML")
> lfdHDLusa
# Region (Europe)
> lfdTGregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Region==2), data= LFDietStatins, method="REML")
> lfdTGregion
> lfdCholregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=(Region==2), data= LFDietStatins, method="REML")
> lfdCholregion
> lfdLDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=(Region==2), data= LFDietStatins, method="REML")
> lfdLDLregion
> lfdHDLregion<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=(Region==2), data= LFDietStatins, method="REML")
> lfdHDLregion
# Hypertension
> lfdTGHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=HTN,
data= LFDietStatins, method="REML")
> lfdTGHTN
> lfdColHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=HTN,
data= LFDietStatins, method="REML")
> lfdColHTN
> lfdLDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=HTN, data= LFDietStatins, method="REML")
> lfdLDLHTN
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> lfdHDLHTN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=HTN, data= LFDietStatins, method="REML")
> lfdHDLHTN
# Current Smokers
> lfdTGSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
Smoke, data= LFDietStatins, method="REML")
> lfdTGSmoke
> lfdCholSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=Smoke, data= LFDietStatins, method="REML")
> lfdCholSmoke
> lfdLDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
Smoke, data= LFDietStatins, method="REML")
> lfdLDLSmoke
> lfdHDLSmoke<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
Smoke, data= LFDietStatins, method="REML")
> lfdHDLSmoke
# Impact Factor
> lfdTGIPP<-rma(d.ex.,var_d.ex., subset=(Diet==5 & Outcome==1), mods=IPP,
data= LFDietStatins, method="REML")
> lfdTGIPP
> lfdCholIPP <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
IPP, data= LFDietStatins, method="REML")
> lfdCholIPP
> lfdLDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= IPP,
data= LFDietStatins, method="REML")
> lfdLDLIPP
> lfdHDLIPP<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
IPP, data= LFDietStatins, method="REML")
> lfdHDLIPP
# Statin Dose
> lfdTGdose<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=Dose, data= LFDietStatins, method="REML")
> lfdTGdose
> lfdCholdose <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Dose, data= LFDietStatins, method="REML")
> lfdCholdose
> lfdLDLdose<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Dose, data= LFDietStatins, method="REML")
> lfdLDLdose
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> lfdHDLdose<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Dose, data= LFDietStatins, method="REML")
> lfdHDLdose
# Methodological Quality Score
> lfdTGMQ<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=MQ,
data= LFDietStatins, method="REML")
> lfdTGMQ
> lfdCholMQ <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
MQ, data= LFDietStatins, method="REML")
> MCholMQ
# LDL-Cholesterol
> lfdLDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= MQ,
data= LFDietStatins, method="REML")
> lfdLDLMQ
> lfdHDLMQ<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
MQ, data= LFDietStatins, method="REML")
> lfdHDLMQ
# Mean Age
> LTGage<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Age,
data= LFDietStatins, method="REML")
> LTGage
> LCholage <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Age, data= LFDietStatins, method="REML")
> LCholage
> LLDLage<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= Age,
data= LFDietStatins, method="REML")
> LLDLage
> LHDLage <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Age, data= LFDietStatins, method="REML")
> LHDLage
#Fat Intake
> LTGfat<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Fat,
data= LFDietStatins, method="REML")
> LTGfat
> LCholfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods= Fat,
data= LFDietStatins, method="REML")
> LCholfat
> LLDLfat<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= Fat,
data= LFDietStatins, method="REML")
> LLDLfat
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> LHDLfat <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= Fat,
data= LFDietStatins, method="REML")
> LHDLfat
#Carb Intake
> LTGcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Carbs,
data= LFDietStatins, method="REML")
> LTGcarb
> LCholcarb <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Carbs, data= LFDietStatins, method="REML")
> LCholcarb
> LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Carbs, data= LFDietStatins, method="REML")
> LLDLcarb
> LHDLcarb <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Carbs, data= LFDietStatins, method="REML")
> LHDLcarb
#Protein Intake
> LTGpro<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
Protein, data= LFDietStatins, method="REML")
> LTGpro
> LCholpro <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Protein, data= LFDietStatins, method="REML")
> LCholpro
> LLDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Protein, data= LFDietStatins, method="REML")
> LLDLpro
> LHDLpro <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Protein, data= LFDietStatins, method="REML")
> LHDLpro
# Length Follow-Up
> LTGfu<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
FollowUp, data= LFDietStatins, method="REML")
> LTGfu
> LCholfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
FollowUp, data= LFDietStatins, method="REML")
> LCholfu
> LLDLfu<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
FollowUp, data= LFDietStatins, method="REML")
> LLDLfu
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> LHDLfu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
FollowUp, data= LFDietStatins, method="REML")
> LHDLfu
# Number of Follow-Ups
> LTGnofu<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=NoFollowUp, data= LFDietStatins, method="REML")
> LTGnofu
> LCholnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
NoFollowUp, data= LFDietStatins, method="REML")
> LCholnofu
> LLDLnofu<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
NoFollowUp, data= LFDietStatins, method="REML")
> LLDLnofu
> LHDLnofu <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
NoFollowUp, data= LFDietStatins, method="REML")
> LHDLnofu
# Provision of Food
> LTGProv<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=Provision, data= LFDietStatins, method="REML")
> LTGProv
> LCholProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Provision, data= LFDietStatins, method="REML")
> LCholProv
> LLDLProv<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Provision, data= LFDietStatins, method="REML")
> LLDLProv
> LHDLProv <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Provision, data= LFDietStatins, method="REML")
> LHDLProv
# Intervention Level
> LTGInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=Interlvl, data= LFDietStatins, method="REML")
> LTGInterlvl
> LCholInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Interlvl, data= LFDietStatins, method="REML")
> LCholInterlvl
> LLDLInterlvl<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Interlvl, data= LFDietStatins, method="REML")
> LLDLInterlvl
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> LHDLInterlvl <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Interlvl, data= LFDietStatins, method="REML")
> LHDLInterlvl
# Intervention Level, One-on-One
> LTGInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Interlvl==1), data= LFDietStatins, method="REML")
> LTGInterlvl1
> LCholInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
(Interlvl==1), data= LFDietStatins, method="REML")
> LCholInterlvl1
> LLDLInterlvl1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
(Interlvl==1), data= LFDietStatins, method="REML")
> LLDLInterlvl1
> LHDLInterlvl1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
(Interlvl==1), data= LFDietStatins, method="REML")
> LHDLInterlvl1
# Intervention Sample Size
> LTGIntN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
n_post, data= LFDietStatins, method="REML")
> LTGIntN
> LCholIntN <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
n_post, data= LFDietStatins, method="REML")
> LCholIntN
> LLDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
n_post, data= LFDietStatins, method="REML")
> LLDLIntN
> LHDLIntN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
n_post, data= LFDietStatins, method="REML")
> LHDLIntN
# Total Sample Size
> LTGN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Ntotal,
data= LFDietStatins, method="REML")
> LTGN
> LCholN <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Ntotal, data= LFDietStatins, method="REML")
> LCholN
> LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods= Ntotal,
data= LFDietStatins, method="REML")
> LLDLN
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> LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods= Ntotal,
data= LFDietStatins, method="REML")
> LHDLN
# Participants Lost
> LTGlost<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=Part_lost, data= LFDietStatins, method="REML")
> LTGlost
> LChollost <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=
Part_lost, data= LFDietStatins, method="REML")
> LChollost
> LLDLDlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Part_lost, data= LFDietStatins, method="REML")
> LLDLDlost
> LHDLlost<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Part_lost, data= LFDietStatins, method="REML")
> LHDLlost
# Experimental Conditions: Diet control plus 1 intervention
> LTGexp<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Experiment==4), data= LFDietStatins, method="REML")
> LTGexp
> LCholexp <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(Experiment==4), data= LFDietStatins, method="REML")
> LCholexp
> LLDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Experiment==4), data= LFDietStatins, method="REML")
> LLDLexp
> LHDLexp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Experiment==4), data= LFDietStatins, method="REML")
> LHDLexp
# Experimental Conditions: Diet control plus 3 interventions
> LTGexp2<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Experiment==6), data= LFDietStatins, method="REML")
> LTGexp2
> LCholexp2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(Experiment==6), data= LFDietStatins, method="REML")
> LCholexp2
> LLDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Experiment==6), data= LFDietStatins, method="REML")
> LLDLexp2
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> LHDLexp2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Experiment==6), data= LFDietStatins, method="REML")
> LHDLexp2
# Experimental Setting - Clinic
> LTGset2<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(exp_setting==2), data= LFDietStatins, method="REML")
> LTGset2
> LCholset2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(exp_setting==2), data= LFDietStatins, method="REML")
> LCholset2
> LLDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(exp_setting==2), data= LFDietStatins, method="REML")
> LLDLset2
> LHDLset2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(exp_setting==2), data= LFDietStatins, method="REML")
> LHDLset2
# Diet Adherence Monitored (yes)
> LTGMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Monitor==1), data= LFDietStatins, method="REML")
> LTGMonitor
> LCholMonitor <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(Monitor==1), data= LFDietStatins, method="REML")
> LCholMonitor
> LLDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Monitor==1), data= LFDietStatins, method="REML")
> LLDLMonitor
> LHDLMonitor<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Monitor==1), data= LFDietStatins, method="REML")
> LHDLMonitor
# Weight Loss
> LTGwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=(
WtGainLoss ==1), data= LFDietStatins, method="REML")
> LTGwtloss
> LCholwtloss <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(WtGainLoss==1), data= LFDietStatins, method="REML")
> LCholwtloss
> LLDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(WtGainLoss==1), data= LFDietStatins, method="REML")
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> LLDLwtloss
> LHDLwtloss<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(WtGainLoss==1), data= LFDietStatins, method="REML")
> LHDLwtloss
# Weight Maintenance
> LTGwtmain<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(WtGainLoss==3), data= LFDietStatins, method="REML")
> LTGwtmain
> LCholwtmain <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(WtGainLoss==3), data= LFDietStatins, method="REML")
> LCholwtmain
> LLDLwtmain<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(WtGainLoss==3), data= LFDietStatins, method="REML")
> LLDLwtmain
> LHDLwtmain<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(WtGainLoss==3), data= LFDietStatins, method="REML")
> LHDLwtmain
# Weight Change Not Reported
> LTGwtNR<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=(
WtGainLoss ==4), data= LFDietStatins, method="REML")
> LTGwtNR
> LCholwtNR <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mods=(
WtGainLoss ==4), data= LFDietStatins, method="REML")
> LCholwtNR
> LLDLwtNR<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=(
WtGainLoss ==4), data= LFDietStatins, method="REML")
> LLDLwtNR
> LHDLwtNR<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(WtGainLoss==4), data= LFDietStatins, method="REML")
> LHDLwtNR
#Publication Year
> LTGYear<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=Year,
data= LFDietStatins, method="REML")
> LTGYear
> LCholYear <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=Year, data= LFDietStatins, method="REML")
> LCholYear
> LLDLYear<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=Year, data= LFDietStatins, method="REML")
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> LLDLYear
> LHDLYear<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=Year, data= LFDietStatins, method="REML")
> LHDLYear
#Funding Source - Government
> LTGfund<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Funding==1), data= LFDietStatins, method="REML")
> LTGfund
> LCholfund <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mod=(Funding==1), data= LFDietStatins, method="REML")
> LCholfund
> LLDLfund<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Funding==1), data= LFDietStatins, method="REML")
> LLDLfund
> LHDLfund<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Funding==1), data= LFDietStatins, method="REML")
> LHDLfund
#Funding Source – Private Funder
> LTGfund2<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Funding==3), data= LFDietStatins, method="REML")
> LTGfund2
> LCholfund2 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mod=(Funding==3), data= LFDietStatins, method="REML")
> LCholfund2
> LLDLfund2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Funding==3), data= LFDietStatins, method="REML")
> LLDLfund2
> LHDLfund2<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Funding==3), data= LFDietStatins, method="REML")
> LHDLfund2
#Number of Intervention Groups
> LTGnointgrp<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=NoIntGrps, data= LFDietStatins, method="REML")
> LTGnointgrp
> LCholnointgrp <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
NoIntGrps, data= LFDietStatins, method="REML")
> LCholnointgrp
> LLDLnointgrp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
NoIntGrps, data= LFDietStatins, method="REML")
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> LLDLnointgrp
> LHDLnointgrp<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
NoIntGrps, data= LFDietStatins, method="REML")
> LHDLnointgrp
#Proportion of Subjects with Cardiovascular Disease
> LTGcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=CVDProp, data= LFDietStatins, method="REML")
> LTGcvdprop
> LCholcvdprop <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
CVDProp, data= LFDietStatins, method="REML")
> LCholcvdprop
> LLDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
CVDProp, data= LFDietStatins, method="REML")
> LLDLcvdprop
> LHDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
CVDProp, data= LFDietStatins, method="REML")
> LHDLcvdprop
#Number of Subjects with Cardiovascular Disease
> LTGcvdno<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=CVDNo, data= LFDietStatins, method="REML")
> LTGcvdno
> LCholcvdno <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
CVDNo, data= LFDietStatins, method="REML")
> LCholcvdno
> LLDLcvdno<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
CVDNo, data= LFDietStatins, method="REML")
> LLDLcvdno
> LHDLcvdno<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
CVDNo, data= LFDietStatins, method="REML")
> LHDLcvdno
# Subjects Taking Oral Contraceptives or on Hormone Replacement Therapy
> LTGcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=OC_HRT, data= LFDietStatins, method="REML")
> LTGcvdprop
> LCholcvdprop <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
OC_HRT, data= LFDietStatins, method="REML")
> LCholcvdprop
> LLDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
OC_HRT, data= LFDietStatins, method="REML")
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> LLDLcvdprop
> LHDLcvdprop<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
OC_HRT, data= LFDietStatins, method="REML")
> LHDLcvdprop
# Recommended Sodium Intake
> LTGNa<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
Sodium, data= LFDietStatins, method="REML")
> LTGNa
> LCholNa <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
Sodium, data= LFDietStatins, method="REML")
> LCholNa
> LLDLNa<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Sodium, data= LFDietStatins, method="REML")
> LLDLNa
> LHDLNa<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Sodium, data= LFDietStatins, method="REML")
> LHDLNa
# Recommended Cholesterol Intake
> LTGchol<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
Cholesterol, data= LFDietStatins, method="REML")
> LTGchol
> LCholchol <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
Cholesterol, data= LFDietStatins, method="REML")
> LCholchol
> LLDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=Cholesterol, data= LFDietStatins, method="REML")
> LLDLchol
> LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Cholesterol, data= LFDietStatins, method="REML")
> LHDLchol
# Recommended Fiber Intake
> LTGfiber<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods= Fiber,
data= LFDietStatins, method="REML")
> LTGfiber
> LCholfiber <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
Fiber, data= LFDietStatins, method="REML")
> LCholfiber
> LLDLfiber<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
Fiber, data= LFDietStatins, method="REML")
167

> LLDLfiber
> LHDLfiber<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
Fiber, data= LFDietStatins, method="REML")
> LHDLfiber
# Reported Macronutrient Distribution
> LTGmacro<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
MacroDis, data= LFDietStatins, method="REML")
> LTGmacro
> LCholmacro <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
MacroDis, data= LFDietStatins, method="REML")
> LCholmacro
> LLDLmacro<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3), mods=
MacroDis, data= LFDietStatins, method="REML")
> LLDLmacro
> LHDLmacro<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4), mods=
MacroDis, data= LFDietStatins, method="REML")
> LHDLmacro
#No Reported Macronutrient Distribution
> LTGmacro1<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
(MacroDis==0), data= LFDietStatins, method="REML")
> LCholmacro1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2), mod=
(MacroDis==0), data= LFDietStatins, method="REML")
> LLDLmacro1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(MacroDis==0), data= LFDietStatins, method="REML")
> LHDLmacro1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(MacroDis==0), data= LFDietStatins, method="REML")
#Min Max for Statin Dosage
> maxdose = 80 -LFDietStatins$Dose
> maxdose
> mindose = LFDietStatins$Dose - 5
> mindose
> LTGdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=maxdose, data=LFDietStatins, method="REML", slab= paste(Reference,
Dose, sep =","))
> LTGdosemax
> LTGdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference,
Dose, sep =","))
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> LTGdosemin
> LCholdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
maxdose, data=LFDietStatins, method="REML", slab= paste(Reference, Dose,
sep =","))
> LCholDosemax
> LCholdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference,
Dose, sep =","))
> LCholdosemin
> LLDLdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
maxdose, data=LFDietStatins, method="REML", slab= paste(Reference, Dose,
sep =","))
> LLDLdosemax
> LLDLdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference,
Dose, sep =","))
> LLDLdosemin
> LHDLdosemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
maxdose, data=LFDietStatins, method="REML", slab= paste(Reference, Dose,
sep =","))
> LHDLdosemax
> LHDLdosemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=mindose, data=LFDietStatins, method="REML", slab= paste(Reference,
Dose, sep =","))
> LHDLdosemin
#Min Max for Hypertension
> lmaxHTN = .72 -LFDietStatins$HTN
> lmaxHTN
> lminHTN=LFDietStatins$HTN - 0.215
> lminHTN
> LTGHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LTGHTNmax
> LTGHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LTGHTNmin
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> LCholHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LCholHTNmax
> LCholHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==1 & Outcome==2),
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LCholHTNmin
> LLDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LLDLHTNmax
> LLDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LLDLHTNmin
> LHDLHTNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lmaxHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LHDLHTNmax
> LHDLHTNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lminHTN, data=LFDietStatins, method="REML", slab= paste(Reference,
HTN, sep =","))
> LHDLHTNmin
#Min Max for Females
>lmaxFemale = 1 - LFDietStatins$Female
> lmaxFemale
> lminFemale = LFDietStatins$Female - 0.0
> lminFemale
> LTGFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
> LTGFemmax
> LTGFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lminFemale, data=LFDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> LTGFemmin
> LCholFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
> LCholFemmax
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> LCholFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=lminFemale, data=LFDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> LCholFemmin
> LDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
> LDLFemmax
> LDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lminFemale, data=LFDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> LDLFemmin
> LHDLFemmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxFemale, data=LFDietStatins, method="REML", slab= paste(Reference,
Female, sep =","))
> LHDLFemmax
> LHDLFemmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lminFemale, data=LFDietStatins, method="REML", slab=
paste(Reference, Female, sep =","))
> LHDLFemmin
#Min Max for Length of Intervention
> lmaxWeeks = 208-LFDietStatins$Weeks
> lmaxWeeks
> lminWeeks=LFDietStatins$Weeks - 3
> lminWeeks
> LTGWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lmaxWeeks, data=LFDietStatins, method="REML", slab=
paste(Reference, Weeks, sep =","))
> LTGWksmax
> LTGWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> LTGWksmin
> LCholWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> LCholWksmax
> LCholWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
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> LCholWksmin
> LLDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> LLDLWksmax
> LLDLWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> LLDLWksmin
> LHDLWksmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> LHDLWksmax
> LHDLWksmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lminWeeks, data=LFDietStatins, method="REML", slab= paste(Reference,
Weeks, sep =","))
> LHDLWksmin
#Min Max for Smokers
> lmaxSmoke = 0.50-LFDietStatins$Smoke
> lmaxSmoke
> lminSmoke=LFDietStatins$Smoke - 0
> lminSmoke
> LTGSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lmaxSmoke, data=LFDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> LTGSmokemax
> LTGSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference,
Smoke, sep =","))
> MTGSmokemin
> LCholSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=lmaxSmoke, data=LFDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> LCholSmokemax
> LCholSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference,
Smoke, sep =","))
> LCholSmokemin
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> LLDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods= lmaxSmoke, data=LFDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> LLDLSmokemax
> LLDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference,
Smoke, sep =","))
> LLDLSmokemin
> LHDLSmokemax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods= lmaxSmoke, data=LFDietStatins, method="REML", slab=
paste(Reference, Smoke, sep =","))
> LHDLSmokemax
> LHDLSmokemin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lminSmoke, data=LFDietStatins, method="REML", slab= paste(Reference,
Smoke, sep =","))
> LHDLSmokemin
#Min Max for Fat Intake
> lmaxfat = .30 -LFDietStatins$Fat
> lmaxfat
> lminfat=LFDietStatins$Fat - .17
> lminfat
> LTGfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep
=","))
> LTGfatmax
> LTGfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lminfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep
=","))
> LTGfatmin
> LCholfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep
=","))
> LCholfatmax
> LCholfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lminfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep
=","))
> LCholfatmin
> LLDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep
=","))
> LLDLfatmax
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> LLDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lminfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat,
sep =","))
> LLDLfatmin
> LHDLfatmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep
=","))
> LHDLfatmax
> LHDLfatmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lminfat, data=LFDietStatins, method="REML", slab= paste(Reference, Fat,
sep =","))
> LHDLfatmin
#Min Max for Carbohydrate Intake
> lmaxcarb = .67 -LFDietStatins$Carbs
> lmaxcarb
> lmincarb=LFDietStatins$Carbs - .421
> lmincarb
> LTGcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxcarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LTGcarbmax
> LTGcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmincarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LTGcarbmin
> LCholcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxcarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LCholcarbmax
> LCholcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmincarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LCholcarbmin
> LLDLcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxcarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LLDLcarbmax
> LLDLcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lmincarb, data=LFDietStatins, method="REML", slab= paste(Reference,
Carbs, sep =","))
> LLDLcarbmin
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> LHDLcarbmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxcarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LHDLcarbmax
> LHDLcarbmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmincarb, data=LFDietStatins, method="REML", slab= paste(Reference, Carbs,
sep =","))
> LHDLcarbmin
#Min Max for Protein Intake
> lmaxpro = .21 -LFDietStatins$Protein
> lmaxpro
> lminpro=LFDietStatins$Protein - .15
> lminpro
> LTGpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxpro, data=LFDietStatins, method="REML", slab= paste(Reference, Protein,
sep =","))
> LTGpromax
> LTGpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference,
Protein, sep =","))
> LTGpromin
> LCholpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxpro, data=LFDietStatins, method="REML", slab= paste(Reference, Protein,
sep =","))
> LCholpromax
> LCholpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference,
Protein, sep =","))
> LCholpromin
> LLDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxpro, data=LFDietStatins, method="REML", slab= paste(Reference, Protein,
sep =","))
> LLDLpromax
> LLDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference,
Protein, sep =","))
> LLDLpromin
> LHDLpromax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxpro, data=LFDietStatins, method="REML", slab= paste(Reference, Protein,
sep =","))
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> LHDLpromax
> LHDLpromin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=lminpro, data=LFDietStatins, method="REML", slab= paste(Reference,
Protein, sep =","))
> LHDLpromin
#Min Max for Intervention Group Size
> lintgrpmax = 753 -LFDietStatins$n_post
> lintgrpmax
> lintgrpmin =LFDietStatins$n_post - 12
> lintgrpmin
> LTGintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference,
n_post, sep =","))
> LTGintgrpmax
> LTGintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lintgrpmin, data=LFDietStatins, method="REML", slab= paste(Reference, n_post,
sep =","))
> LTGintgrpmin
> LCholintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference,
n_post, sep =","))
> LCholintgrpmax
> LCholintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lintgrpmin, data=LFDietStatins, method="REML", slab= paste(Reference, n_post,
sep =","))
> LCholintgrpmin
> LLDLintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference,
n_post, sep =","))
> LLDLintgrpmax
> LLDLintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lintgrpmin, data=LFDietStatins, method="REML", slab= paste(Reference,
n_post, sep =","))
> LLDLintgrpmin
> LHDLintgrpmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lintgrpmax, data=LFDietStatins, method="REML", slab= paste(Reference,
n_post, sep =","))
> LHDLintgrpmax
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> LHDLintgrpmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lintgrpmin, data=LFDietStatins, method="REML", slab= paste(Reference, n_post,
sep =","))
> LHDLintgrpmin
#Min Max for Total Sample Size
> lNmax = 3390 -LFDietStatins$Ntotal
> lNmax
> lNmin =LFDietStatins$Ntotal - 19
> lNmin
> LTGNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lNmax, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LTGNmax
> LTGNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lNmin, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LTGNmin
> LCholNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lNmax, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LCholNmax
> LCholNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lNmin, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LCholNmin
> LLDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lNmax, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LLDLNmax
> LLDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3),
mods=lNmin, data=LFDietStatins, method="REML", slab= paste(Reference,
Ntotal, sep =","))
> LLDLNmin
> LHDLNmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lNmax, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LHDLNmax
> LHDLNmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lNmin, data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep
=","))
> LHDLNmin
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#Min Max for Number of Intervention Groups
>lmaxintgrp = 5 - LFDietStatins$NoIntGrps
> lmaxintgrp
> lminintgrp = LFDietStatins$NoIntGrps - 1
> lminintgrp
> LTGintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LTGintgrp1max
> LTGintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LTGintgrp1min
> LCholintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods= lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LCholintgrp1max
> LCholintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2),
mods= lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LCholintgrp1min
> LDLintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LDLintgrp1max
> LDLintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LDLintgrp1min
> LHDLintgrp1max<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods= lmaxintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LHDLintgrp1max
> LHDLintgrp1min<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods= lminintgrp, data=LFDietStatins, method="REML", slab= paste(Reference,
NoIntGrps, sep =","))
> LHDLintgrp1min
#Min Max for Number of Subjects with Cardiovascular Disease
>lmaxcvd = 113 - LFDietStatins$CVDNo
> lmaxcvd
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> lmincvd = LFDietStatins$CVDNo - 5
> lmincvd
> LTGcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxcvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LTGcvdmax
> LTGcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmincvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LTGcvdmin
> LCholcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxcvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LCholcvdmax
> LCholcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmincvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LCholcvdmin
> LDLcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxcvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LDLcvdmax
> LDLcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmincvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LDLcvdmin
> LHDLcvdmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxcvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LHDLcvdmax
> LHDLcvdmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmincvd, data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo,
sep =","))
> LHDLcvdmin
#Min Max for Cholesterol Intake
>lmaxchol = 300 - LFDietStatins$Cholesterol
> lmaxchol
> lminchol = LFDietStatins$Cholesterol - 31
> lminchol
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> LTGcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LTGcholmax
> LTGcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LTGcholmin
> LCholcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LCholcholmax
> LCholcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LCholcholmin
> LDLcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LDLcholmax
> LDLcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LDLcholmin
> LHDLcholmax<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lmaxchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LHDLcholmax
> LHDLcholmin<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=
lminchol, data=LFDietStatins, method="REML", slab= paste(Reference,
Cholesterol, sep =","))
> LHDLcholmin
#Provision of Food
> LTGProv1<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Provision==1), data= LFDietStatins, method="REML",
slab=paste(Reference, Provision, sep “,”))
> LTGProv1
> LCholProv1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(Provision==1), data= LFDietStatins, method="REML",
slab=paste(Reference, Provision, sep “,”))
> LCholProv1
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> LLDLProv1<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Provision==1), data= LFDietStatins, method="REML",
slab=paste(Reference, Provision, sep “,”))
> LLDLProv1
> LHDLProv1 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Provision==1), data= LFDietStatins, method="REML",
slab=paste(Reference, Provision, sep “,”))
> LHDLProv1
#No Provision of Food
> LTGProv0<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1),
mods=(Provision==0), data= LFDietStatins, method="REML"
slab=paste(Reference, Provision, sep “,”))
> LTGProv0
> LCholProv0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==2),
mods=(Provision==0), data= LFDietStatins, method="REML"
slab=paste(Reference, Provision, sep “,”))
> LCholProv0
> LLDLProv0<-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==3),
mods=(Provision==0), data= LFDietStatins, method="REML",
slab=paste(Reference, Provision, sep “,”))
> LLDLProv0
> LHDLProv0 <-rma(d.ex.,var_d.ex.,subset=(Diet ==5 & Outcome==4),
mods=(Provision==0), data= LFDietStatins, method="REML",
slab=paste(Reference, Provision, sep “,”))
> LHDLProv0
Meta-Regression Plots
#Length of Intervention
LCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Weeks,
data=LFDietStatins, method="REML", slab= paste(Reference, Weeks, sep =","))
LCholwkspred <- predict(LCholwks, newmods=cbind(seq(0,104,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietTChol= subset(LFDietStatins,Diet==5 & Outcome==2) #Here we have to
create the
subsample we are working on to just plot the observed values of that below
plot(dietTChol$Weeks,dietTChol$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Number of Weeks", #Plotting here the observed values of the subsample
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 104), ylim=c(-3, 0.5))
lines(seq(0,104,.1), LCholwkspred$pred, col = "dark red")
lines(seq(0,104,.1), LCholwkspred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,104,.1), LCholwkspred$ci.ub, lty = "dashed", col="dark red")
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LCholwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods =
Weeks,
data=LFDietStatins, method="REML", slab= paste(Author, Year, sep =","))
LCholwkspred <- predict(LCholwks, newmods=cbind(seq(0,104,.1)))
LCholwks
LLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Weeks,
data=LFDietStatins, method="REML", slab= paste(Reference, Weeks, sep =","))
LLDLwkspred <- predict(LLDLwks, newmods=cbind(seq(0,104,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3)
plot(dietLDL$Weeks,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Number of Weeks", #Plotting here the observed values of the subsample
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 104), ylim=c(-3, 0.5))
lines(seq(0,104,.1), LLDLwkspred$pred, col = "dark red")
lines(seq(0,104,.1), LLDLwkspred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,104,.1), LLDLwkspred$ci.ub, lty = "dashed", col="dark red")
LLDLwks<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods =
Weeks,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LLDLwkspred <- predict(LLDLwks, newmods=cbind(seq(0,104,.1)))
LLDLwks
#Proportion of Females
LCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Female,
data=LFDietStatins, method="REML", slab= paste(Reference, Female, sep =","))
LCholfempred <- predict(LCholfem, newmods=cbind(seq(0,1.0,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2)
plot(dietChol$Female,dietChol$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Proportion of Female", #Plotting here the observed values of the
subsample
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 1.0), ylim=c(-3, 0.5))
lines(seq(0,1.0,.1), LCholfempred$pred, col = "dark red")
lines(seq(0,1.0,.1), LCholfempred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), LCholfempred$ci.ub, lty = "dashed", col="dark red")
LCholfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods =
Female,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LCholfempred <- predict(LCholfem, newmods=cbind(seq(0,1.0,.1)))
LCholfem
LLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Female,
data=LFDietStatins, method="REML", slab= paste(Reference, Female, sep =","))
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LLDLfempred <- predict(LLDLfem, newmods=cbind(seq(0,1.0,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3)
plot(dietLDL$Female,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Proportion of Female", #Plotting here the observed values of the
subsample
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 1.0), ylim=c(-3, 0.5))
lines(seq(0,1.0,.1), LLDLfempred$pred, col = "dark red")
lines(seq(0,1.0,.1), LLDLfempred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), LLDLfempred$ci.ub, lty = "dashed", col="dark red")
LLDLfem<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods =
Female,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LLDLfempred <- predict(LLDLfem, newmods=cbind(seq(0,1.0,.1)))
LLDLfem
#Recommended Proportion of Fat Intake
LCholfat<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Fat,
data=LFDietStatins, method="REML", slab= paste(Reference, Fat, sep =","))
LCholfatpred <- predict(LCholfat, newmods=cbind(seq(0,1.0,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2)
plot(dietChol$Fat,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Proportion of Fat Intake", #Plotting here the observed values of the
subsample
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0.1, 0.35), ylim=c(-3.5, 0.5))
lines(seq(0,1.0,.1), LCholfatpred$pred, col = "dark red")
lines(seq(0,1.0,.1), LCholfatpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), LCholfatpred$ci.ub, lty = "dashed", col="dark red")
LCholfat<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = Fat,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LCholfatpred <- predict(LCholfat, newmods=cbind(seq(0,1.0,.1)))
LCholfat
#Proportion of Carbohydrate Intake
LCholcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Carbs,
data=LFDietStatins, method="REML", slab= paste(Reference, Carbs, sep =","))
LCholcarbpred <- predict(LCholcarb, newmods=cbind(seq(0,1.0,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2)
plot(dietChol$Carbs,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Proportion of Carbohydrate Intake",
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ylab = "Total Cholesterol Effect Size (d)", xlim=c(0.1, 0.7), ylim=c(-3, 0.5))
lines(seq(0,1.0,.1), LCholcarbpred$pred, col = "dark red")
lines(seq(0,1.0,.1), LCholcarbpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), LCholcarbpred$ci.ub, lty = "dashed", col="dark red")
LCholcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods =
Carbs,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LCholcarbpred <- predict(LCholcarb, newmods=cbind(seq(0,1.0,.1)))
LCholcarb
LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Carbs,
data=LFDietStatins, method="REML", slab= paste(Reference, Carbs, sep =","))
LLDLcarbpred <- predict(LLDLcarb, newmods=cbind(seq(0,1.0,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3)
plot(dietLDL$Carbs,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Proportion of Carbohydrate Intake",
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0.25, 0.7), ylim=c(-3, 0.5))
lines(seq(0,1.0,.1), LLDLcarbpred$pred, col = "dark red")
lines(seq(0,1.0,.1), LLDLcarbpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), LLDLcarbpred$ci.ub, lty = "dashed", col="dark red")
LLDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = Carbs,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LLDLcarbpred <- predict(LLDLcarb, newmods=cbind(seq(0,1.0,.1)))
LLDLcarb
#Recommended Proportion of Protein Intake
LHDLpro<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=Protein,
data=LFDietStatins, method="REML", slab= paste(Reference, Protein, sep =","))
LHDLpropred <- predict(LHDLpro, newmods=cbind(seq(0,1.0,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4)
plot(dietHDL$Protein,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Proportion of Protein Intake",
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0.10, 0.30), ylim=c(-1, 1.5))
lines(seq(0,1.0,.1), LHDLpropred$pred, col = "dark red")
lines(seq(0,1.0,.1), LHDLpropred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,1.0,.1), LHDLpropred$ci.ub, lty = "dashed", col="dark red")
LHDLcarb<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods =
Protein,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LHDLpropred <- predict(LHDLpro, newmods=cbind(seq(0,1.0,.1)))
LHDLpro
#Intervention Group Size
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LTGint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods=n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =","))
LTGintpred <- predict(LTGint, newmods=cbind(seq(0,753,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietTG= subset(LFDietStatins,Diet==5 & Outcome==1)
plot(dietTG$n_post,dietTG$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Intervention Group Size",
ylab = "Triglycerides Effect Size (d)", xlim=c(0, 760), ylim=c(-3.5, 0.5))
lines(seq(0,753,1), LTGintpred$pred, col = "dark red")
lines(seq(0,753,1), LTGintpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,753,1), LTGintpred$ci.ub, lty = "dashed", col="dark red")
LTGint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==1), mods = n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LTGintpred <- predict(LTGint, newmods=cbind(seq(0,753,.1)))
LTGint
LCholint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =","))
LCholintpred <- predict(LCholint, newmods=cbind(seq(0,753,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2)
plot(dietChol$n_post,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Intervention Group Size",
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 760), ylim=c(-3.5, 0.5))
lines(seq(0,753,1), LCholintpred$pred, col = "dark red")
lines(seq(0,753,1), LCholintpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,753,1), LCholintpred$ci.ub, lty = "dashed", col="dark red")
LCholint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LCholintpred <- predict(LCholint, newmods=cbind(seq(0,753,1)))
LCholint
LLDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =","))
LLDLintpred <- predict(LLDLint, newmods=cbind(seq(0,753,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3)
plot(dietLDL$n_post,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Intervention Group Size",
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 800), ylim=c(-3.5, 0.5))
lines(seq(0,753,1), LLDLintpred$pred, col = "dark red")
lines(seq(0,753,1), LLDLintpred$ci.lb, lty = "dashed", col="dark red")
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lines(seq(0,753,1), LLDLintpred$ci.ub, lty = "dashed", col="dark red")
LLDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LLDLintpred <- predict(LLDLint, newmods=cbind(seq(0,753,1)))
LLDLint
LHDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, n_post, sep =","))
LHDLintpred <- predict(LHDLint, newmods=cbind(seq(0,753,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4)
plot(dietHDL$n_post,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Intervention Group Size",
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 800), ylim=c(-1, 1.5))
lines(seq(0,753,1), LHDLintpred$pred, col = "dark red")
lines(seq(0,753,1), LHDLintpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,753,1), LHDLintpred$ci.ub, lty = "dashed", col="dark red")
LHDLint<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = n_post,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LHDLintpred <- predict(LHDLint, newmods=cbind(seq(0,753,.1)))
LHDLint
#Number with Cardiovascular Disease
LCholcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=CVDNo,
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =","))
LCholcvdpred <- predict(LCholcvd, newmods=cbind(seq(0,113,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2)
plot(dietChol$CVDNo,dietChol$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Number of Subjects with Cardiovascular Disease",
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 115), ylim=c(-4, 0.5))
lines(seq(0,113,.1), LCholcvdpred$pred, col = "dark red")
lines(seq(0,113,.1), LCholcvdpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,113,.1), LCholcvdpred$ci.ub, lty = "dashed", col="dark red")
LCholcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods =
CVDNo,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LCholcvdpred <- predict(LCholcvd, newmods=cbind(seq(0,113,.1)))
LCholcvd
LLDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=CVDNo,
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =","))
LLDLcvdpred <- predict(LLDLint, newmods=cbind(seq(0,113,1)))
wi = LFDietStatins$w_d.ex.
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min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3)
plot(dietLDL$CVDNo,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Number of Subjects with Cardiovascular Disease",
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 115), ylim=c(-4, 0.5))
lines(seq(0,113,.1), LLDLcvdpred$pred, col = "dark red")
lines(seq(0,113,.1), LLDLcvdpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,113,.1), LLDLcvdpred$ci.ub, lty = "dashed", col="dark red")
LLDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods =
CVDNo,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LLDLcvdpred <- predict(LLDLcvd, newmods=cbind(seq(0,1.0,.1)))
LLDLcvd
LHDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=CVDNo,
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =","))
LHDLcvdpred <- predict(LHDLcvd, newmods=cbind(seq(0,113,.1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4)
plot(dietHDL$CVDNo,dietHDL$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Number of Subjects with Cardiovascular Disease",
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 115), ylim=c(-1, 1.5))
lines(seq(0,113,.1), LHDLcvdpred$pred, col = "dark red")
lines(seq(0,113,.1), LHDLcvdpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,113,.1), LHDLcvdpred$ci.ub, lty = "dashed", col="dark red")
LHDLcvd<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods =
CVDNo,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LHDLcvdpred <- predict(LHDLcvd, newmods=cbind(seq(0,1.0,.1)))
LHDLcvd
#Total Sample Size
LCholN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods=Ntotal,
data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep =","))
LCholNpred <- predict(LCholN, newmods=cbind(seq(0,3390,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietChol= subset(LFDietStatins,Diet==5 & Outcome==2)
plot(dietChol$Ntotal,dietChol$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Sample Size",
ylab = "Total Cholesterol Effect Size (d)", xlim=c(0, 3400), ylim=c(-4, 0.5))
lines(seq(0,3390,1), LCholNpred$pred, col = "dark red")
lines(seq(0,3390,1), LCholNpred$ci.lb, lty = "dashed", col="dark red")
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lines(seq(0,3390,1), LCholNpred$ci.ub, lty = "dashed", col="dark red")
LCholN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==2), mods = Ntotal,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LCholNpred <- predict(LCholN, newmods=cbind(seq(0,3390,.1)))
LCholN
LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods=Ntotal,
data=LFDietStatins, method="REML", slab= paste(Reference, Ntotal, sep =","))
LLDLNpred <- predict(LLDLN, newmods=cbind(seq(0,3390,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietLDL= subset(LFDietStatins,Diet==5 & Outcome==3)
plot(dietLDL$Ntotal,dietLDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Sample Size",
ylab = "LDL Cholesterol Effect Size (d)", xlim=c(0, 3400), ylim=c(-4, 0.5))
lines(seq(0,3390,1), LLDLNpred$pred, col = "dark red")
lines(seq(0,3390,1), LLDLNpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,3390,1), LLDLNpred$ci.ub, lty = "dashed", col="dark red")
LLDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==3), mods = Ntotal,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LLDLNpred <- predict(LLDLN, newmods=cbind(seq(0,3390,.1)))
LLDLN
LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods=Ntotal,
data=LFDietStatins, method="REML", slab= paste(Reference, CVDNo, sep =","))
LHDLNpred <- predict(LHDLN, newmods=cbind(seq(0,3390,1)))
wi = LFDietStatins$w_d.ex.
min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4)
plot(dietHDL$Ntotal,dietHDL$d.ex.,pch= 20, col="black", bg = "black", cex=size,
xlab = "Sample Size",
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 3400), ylim=c(-1, 1.5))
lines(seq(0,3390,1), LHDLNpred$pred, col = "dark red")
lines(seq(0,3390,1), LHDLNpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,3390,1), LHDLNpred$ci.ub, lty = "dashed", col="dark red")
LHDLN<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods = Ntotal,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LHDLNpred <- predict(LHDLN, newmods=cbind(seq(0,3390,.1)))
LHDLN
#Recommended Dietary Cholesterol Intake
LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4),
mods=Cholesterol,
data=LFDietStatins, method="REML", slab= paste(Reference, Cholesterol, sep
=","))
LHDLcholpred <- predict(LHDLchol, newmods=cbind(seq(0,300,1)))
wi = LFDietStatins$w_d.ex.
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min= min(wi,na.rm=TRUE)
max= max(wi,na.rm=TRUE)
size= 1.0 + 0.5 * (wi - min)/(max - min)
dietHDL= subset(LFDietStatins,Diet==5 & Outcome==4)
plot(dietHDL$Cholesterol,dietHDL$d.ex.,pch= 20, col="black", bg = "black",
cex=size,
xlab = "Dietary Cholesterol Intake (mg)",
ylab = "HDL Cholesterol Effect Size (d)", xlim=c(0, 300), ylim=c(-1, 1.5))
lines(seq(0,300,.1), LHDLcholpred$pred, col = "dark red")
lines(seq(0,300,.1), LHDLcholpred$ci.lb, lty = "dashed", col="dark red")
lines(seq(0,300,.1), LHDLcholpred$ci.ub, lty = "dashed", col="dark red")
LHDLchol<-rma(d.ex.,var_d.ex.,subset=(Diet==5 & Outcome==4), mods =
Cholesterol,
data=LFDietStatins, method="REML", slab= paste(Reference, Year, sep =","))
LHDLcholpred <- predict(LHDLchol, newmods=cbind(seq(0,300,.1)))
LHDLchol
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